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Abstract 
 
 
Background: The central nervous system is frequently affected in children with inherited 
metabolic disorders (IMD). The causes of the brain insult are incompletely understood, and 
novel methods are required for disease diagnosis and monitoring response to novel therapies. 
 
Aims & Methods: The study aimed to improve understanding of the pathogenesis of IMD-
related neurodegeneration, and to identify potential disease biomarkers in specific IMD, by 
directly investigating alterations in brain tissue metabolite profiles using non-invasive in vivo 
magnetic resonance spectroscopy (MRS) in conjunction with conventional MRI brain scans. 
 
Results: MRI/MRS studies were performed on over 300 children. Normal brain metabolite 
profiles were established from a standard comparator cohort. A detailed quality analysis 
enabled combination of data from different scanner systems. Non-standard brain metabolites 
were detected in 2.3% of children. Metabolite-based methods of disease progression 
monitoring were evaluated in Hunter Syndrome. Mechanisms leading to strokes in patients 
with propionic acidaemia and to learning difficulties and epilepsy in argininosuccinic aciduria 
were explored using brain tissue metabolite profiling. 
 
Conclusions: Non-invasive in vivo brain tissue metabolite profiling is achievable using 
quantitative magnetic resonance spectroscopy in the routine clinical paediatric setting, and has 
utility in disease diagnostics, in monitoring disease progression and in investigating disease 
pathogenesis. 
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Chapter One 
 
1. An Introduction to Childhood Metabolic 
Neurodegenerative Disease 
 
The developing and maturing brain is vulnerable to damage from a wide range of causes and 
this damage frequently manifests as developmental delay. Where there is an ongoing active 
process causing injury to the brain, there can be progressive loss of developmental skills, i.e. 
developmental regression. Developmental delay is a common paediatric clinical problem, 
affecting up to 3-5% of the UK paediatric population [1]. In a substantial number of these 
children there is a genetic or inherited basis for the disease causing the brain insult, including 
the inherited metabolic disorders [2]. Children with inherited metabolic disorders are 
vulnerable to chronic brain degeneration, developmental delay/regression, epilepsy and also 
sudden acute episodes of brain damage including strokes. Understanding of the mechanisms 
underlying the processes causing brain damage in the metabolic diseases is far from complete, 
and in a substantial number of children with presumed metabolic neurodegenerative disease 
no specific diagnosis is reached. Although clinically invaluable, current neuroimaging 
techniques are limited to detecting visible structural changes in the brain late in the disease 
process, and are inadequate for diagnosing and monitoring these conditions. In this work a 
novel functional imaging technique for probing brain metabolism directly is investigated. 
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In this chapter a brief introduction is given to the inherited metabolic disorders, with a 
particular focus on their direct and secondary effects on the central nervous system. Potential 
methods for investigating brain pathological processes are outlined, and functional 
neuroimaging techniques are introduced. The aims and objectives of this thesis are then 
described. 
 
1.1. Inherited metabolic disorders 
The inherited metabolic disorders (IMD) are a heterogeneous group of monogenic diseases 
caused by defects in diverse metabolic pathways. Sir Archibald Garrod is widely held as the 
father of the study of metabolic disorders, describing in a lecture to the Royal College of 
Physicians in 1908 several diseases that  
 
 “…apparently result from failure of some step or other in the series of chemical 
 changes which constitute metabolism” [3]. 
 
Each step of a metabolic pathway is facilitated by an enzyme, a protein capable of catalysing 
a specific chemical conversion [4]. In general terms, a single defective or deficient enzyme 
step in a pathway results in disease by one of several mechanisms: accumulation of a 
proximal metabolite that is in someway deleterious (e.g. phenylalanine in phenylketonuria; 
dermatan and heparan sulfates in Hunter Syndrome); deficiency of a required product of the 
pathway (e.g. adenosine triphosphate (ATP) in mitochondrial respiratory chain defects); 
accumulation of an alternative and toxic metabolite (e.g. galactitol in galactosaemia; 
methylcitrate in propionic acidaemia); or various secondary metabolic effects (e.g. 
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hyperammonaemia in methylmalonic and propionic acidaemia due to secondary urea cycle 
inhibition) [3]. 
 
IMDs variably affect all organ systems and many result in multi-organ system dysfunction, 
commonly including hepatic, endocrine, renal, cardiac, muscular or neurologic systems. 
Involvement of the central nervous system (CNS) can be particularly devastating and is a 
feature of many IMD [5], either in isolation or conjunction with other organ system 
involvement, and either as an acute or chronic process. The “neurologic syndrome” is a 
common mode of initial presentation of the IMDs, often in the neonatal period but potentially 
at any stage during childhood or even adult life [5]. 
 
Although individually rare, inherited metabolic disorders together constitute an important 
disease group. One recent retrospective study in the West Midlands found an overall birth 
prevalence of 1 in 784 live births [6], generating by extrapolation around 800 new cases 
annually in the United Kingdom. The expanding newborn screening programme is testament 
to the clinical importance of these disorders [7]. 
 
1.1.1. Classification of inherited metabolic diseases 
In clinical practice, a classification system of the numerous IMD based on clinical presenting 
features assists in the recognition and diagnosis of these disorders. A taxonomy based on 
pathophysiological characteristics is useful, however, in providing an overview of the wide 
range of metabolic pathways that may be affected by an IMD. One such pathophysiological 
classification divides the IMDs into three broad categories: firstly disorders involving 
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metabolic intoxication, secondly disorders of energy metabolism, and thirdly disorders of 
complex molecules [8].   
 
The intoxicating disorders are due to abnormalities of intermediary metabolism, whereby the 
pathology arises due to accumulation of a metabolite proximal to the metabolic block. Diverse 
metabolic pathways can be affected, including amino acid metabolism (e.g. tyrosinaemia, 
phenylketonuria), organic acid catabolism (e.g. propionic acidaemia), the urea cycle (e.g. 
citrullinaemia), sugar metabolism and neurotransmitter metabolism [3, 8]. Jean-Marie 
Saudubray highlights some of the key characteristics of this group, including the protection of 
the foetus in utero afforded by placental “dialysis”, and the classical symptom-free interval 
after birth, followed by either an acute or progressive intoxication phenotype [8]. 
 
The disorders of energy metabolism manifest signs and symptoms due to failure in energy 
production or utilisation, with prominent features seen in the organs and tissues with high 
metabolic energy demands such as cardiac and skeletal muscle and brain. These may be 
subdivided into mitochondrial disorders including the congenital lactic acidaemias due to 
pyruvate metabolism or Krebs cycle defects, disorders of the electron transport chain, 
disorders of fatty acid oxidation or ketone body metabolism, and defects of cytoplasmic 
energy production including disorders of glycolysis, glycogen metabolism and creatine 
metabolism [8].  
 
The third category of IMD, i.e. those involving complex molecules, arise due to the disrupted 
synthesis or catabolism of complex molecules, often due to dysfunction in the various 
subcellular organelles including the endoplasmic reticulum and lysosomal system [9]. This 
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group includes the diverse lysosomal storage disorders (e.g. the mucopolysaccharidoses, 
neuronal ceroid lipofuscinoses and sphingolipidoses), disorders of peroxisomal function, and 
other disorders of intracellular trafficking. These disorders usually present with chronic 
insidious symptoms rather than an acute or fluctuating phenotype. 
 
1.2. The neurology of inherited metabolic disease 
As already noted, the CNS is frequently affected in IMDs, and neurologic features are found 
in IMDs from each of the three pathophysiological categories described [3]. The nature of the 
CNS involvement, however, covers a wide spectrum from acute encephalopathy and acute 
stroke or stroke-like episodes to a chronic neurodegenerative phenotype (chronic 
encephalopathy). Encephalopathy is a clinical description of global brain dysfunction, and 
may be an acute phenomenon such as that seen due to hyperammonaemia in the urea cycle 
defects, or a chronic process as seen in many of the lysosomal storage disorders. 
 
The differential diagnosis for a child presenting with an acute encephalopathy includes 
trauma, CNS infection, and exogenous intoxication, as well as metabolic causes. Metabolic 
causes of acute encephalopathy include secondary features of diabetic ketoacidosis or 
multiorgan dysfunction, as well as the specific IMDs. Such acute CNS dysfunction is a 
feature of the metabolic crises seen in many IMDs, resulting from intoxication with 
accumulating metabolites including ammonia, and organic or amino acids. 
 
Stroke and stroke-like phenomena are seen in many IMDs, including Fabry disease. Acute 
basal ganglia infarction or dysfunction is seen in the organic acidaemias, in particular 
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propionic acidaemia [10] and glutaric aciduria [11] as well as in the mitochondrial disorders 
[12]. 
 
Chronic encephalopathy is a feature of many IMDs that result in neurodegeneration, i.e. the 
progressive structural and/or functional loss of CNS neuronal and glial cells. The clinical 
hallmarks of neurodegenerative disorders include developmental delay and regression, 
namely the failure to acquire, or loss of previously acquired, developmental milestones or 
skills. The clinical features depend on which brain areas are predominantly affected. 
Disorders predominantly affecting gray matter (poliodystrophies) manifest with seizures, 
psychomotor retardation and progressive dementia, and impairment of the special senses 
notably visual dysfunction. Clarke notes that the cognitive impairment seen in many IMDs is 
often global, i.e. affecting all domains of development, and is frequently associated with 
severe irritability or aggressiveness as seen, for example in Krabbe or Sanfilippo disease [3]. 
Disorders predominantly affecting white matter (leukoencephalopathies) manifest with 
mainly motor features, e.g. progressive spastic paraparesis, and other extra-pyramidal signs 
[13]. 
 
In addition to the neurodegeneration seen in known IMDs, there is a large cohort of children 
with neurodegeneration and neurodevelopmental regression in whom a diagnosis of 
neurometabolic disease is suspected but no formal diagnosis reached despite extensive 
investigation. The recently reported British Paediatric Surveillance Unit (BPSU) Progressive 
Intellectual and Neurological Deterioration (PIND) of Childhood Study was established to 
gather epidemiological data on variant Creutzfeldt-Jakob Disease (vCJD), but concurrently 
studied all children with progressive deteriorating developmental and neurological function 
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based on the BPSU monthly surveillance card system [14]. This study identified 1558 
children who fulfilled the criteria for progressive intellectual and neurological deterioration; 6 
had vCJD, 293 are still being analysed, 1114 had a diagnosis other than vCJD, and 145 
remained undiagnosed despite full investigation. Of the 1114 with a formal diagnosis, the 
commonest disease groups were the leukoencephalopathies, neuronal ceroid lipofuscinoses, 
mitochondrial diseases, mucopolysaccharidoses and peroxisomal disorders. The undiagnosed 
cohort represented just fewer than 10% of reported cases in this study. However, the 
percentage of children with global developmental delay or neurological regression in whom 
no formal diagnosis is reached may be much higher than this figure suggests [1, 15]. 
 
Thus involvement of the central nervous system is a feature of many known IMDs, resulting 
in debilitating neurological impairment [3, 5, 16]. Reaching a conclusive diagnosis in many 
children with a suspected neurometabolic disorder presents an ongoing clinical challenge. In 
many IMDs the pathogenesis of the neurological insult is poorly understood, even when the 
fundamental biochemical enzymatic defect has been well characterised. Treatment strategies 
for many IMDs are successful at controlling the metabolic derangement, for example dietary 
control and supplementation in phenylketonuria (PKU), and yet even in PKU subtle 
neurologic dysfunction is common [17]. In other disorders current treatment strategies do not 
prevent or reverse central nervous system damage, for example enzyme replacement therapy 
in Hunter Syndrome has limited effect on the central nervous system as it does not 
significantly penetrate the blood-brain barrier [18]. For many disorders such as the 
mitochondrial cytopathies or leukodystrophies such as Alexander Disease there are no 
effective treatments. In propionic acidaemia best current practice does not prevent acute 
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metabolic crises and the associated neurological insult; the propensity for basal ganglia 
infarction in this and associated disorders is incompletely explained [10, 19]. 
 
There are, therefore, a number of current clinical challenges for which novel research is 
required. These include improving diagnostic methods for clinical investigation of the 
undiagnosed neurometabolic disorder cohorts, improving the understanding of the 
pathogenesis and pathophysiology of neurodegeneration in known IMDs, and identifying 
disease biomarkers that are required in evaluating the effect of novel therapies [20].  
 
Clearly given the diversity of IMDs, and the different metabolic pathways that each affects, 
such research needs to be specific for each group of disorders. That said, the complex 
interaction of metabolic pathways means that many disorders have overlapping features, both 
clinically and biochemically, and insights gained in one disorder may provide valuable insight 
in to other disorders. Furthermore, insights derived from the study of patients with rare IMDs 
can aid understanding of the normal role and function of specific metabolic pathways that 
may have implications in common diseases affecting the wider population. 
 
1.3. Approaches to investigating human brain pathology 
Biochemical analysis of body fluids, enzyme assays and genetic analyses provide the 
cornerstones of diagnosis and disease monitoring of the IMDs. Routine clinical biochemical 
analyses measure a wide variety of intermediary metabolites, including amino and organic 
acids, small molecule carbohydrates and lipids. However, alterations in blood or urinary 
metabolites may not reflect tissue-level metabolism in the brain and provide only indirect and 
remote information about CNS pathophysiology. 
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1.3.1. Cerebrospinal fluid analysis 
Cerebrospinal fluid (CSF) surrounds the brain and spinal cord, providing mechanical 
suspension for the central nervous system. CSF is synthesised and secreted by the choroid 
plexus, prior to circulation and subsequent absorption by the arachnoid granulations. In 
addition to its mechanical function, “CSF also has a function in circulating nutrients and 
chemicals filtered from the blood along with waste management by removing organic acids 
either by active transport or bulk flow from the extracellular fluid in the brain to the 
subarachnoid compartment, and ultimately into the venous blood stream and the lymphatic 
system” [21]. Analysis of CSF can therefore provide specific insights into pathologic 
mechanisms affecting brain function, for example quantification of CSF metabolites has a 
particular role in the evaluation of disorders of monoamine neurotransmitters [22] and in 
pyridoxal phosphate metabolism [23]. Profiling of the full range of metabolites found within 
CSF (metabolomics) has been proposed as a means of disease diagnosis and monitoring, 
either with targeted metabolite evaluation or global profiling of the entire “metabolome” [21]. 
 
1.3.2. Brain micro-dialysis 
The metabolite profile of CSF is, however, only an indirect reflection of brain tissue 
metabolites, being an excretory/ secretory product of the choroid plexus. Direct measurement 
of brain tissue metabolites is possible using microdialysis techniques, a method employed in 
clinical practice in neurointensive care, for example in the management of traumatic brain 
injury or acute stroke, and may provide insight into disease mechanisms [24-26]. Similar 
techniques are employed in experimental animal model work [27]. Due to the invasive nature 
of the procedure, however, it is only tenable in human patients in the context of disease 
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requiring intensive care support with invasive intracerebral monitoring, and is not widely used 
in UK paediatric intensive care practice (B Scholefield, personal communication). 
 
1.3.3. Direct brain tissue analysis 
Brain biopsy is a routine part of clinical evaluation of brain tumours, and indeed could also 
have an important role to play in the diagnosis of neurodegenerative disease, having a 
diagnostic yield of 48.5% in one series [26]. Material obtained at biopsy can be subjected to 
numerous analyses, primarily histological, but also including the evaluation of tissue 
metabolite profiles [28, 29]. Similarly in experimental animal models, brain tissue metabolite 
profiles are of significant value in investigating disease processes [30]. In the United 
Kingdom, however, brain biopsy is not a common investigation in the evaluation of paediatric 
neurodegenerative disease, due to the associated potential risk of morbidity and mortality. 
Post mortem pathological examination can yield useful information about disease processes, 
but the rate of consent for such examinations is very low, and the rapid post mortem changes 
in tissue metabolites need careful interpretation.  
 
1.3.4. Neuroimaging 
Since the discovery of the nuclear magnetic resonance phenomenon and the development of 
magnetic resonance imaging by Lauterbur, Damadian and Mansfield [31-33], magnetic 
resonance imaging (MRI) of the CNS in vivo has revolutionised the investigation of 
neurologic disorders. MRI plays a key role in the evaluation of neurologic disease, giving 
exquisitely detailed images of brain structures by a safe, non-invasive technique. MRI-based 
diagnostics are now fundamental in many areas of medicine, not least neuro-oncology and 
neurodegenerative diseases [33, 34]. These methods are invaluable in the diagnostic process 
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and in monitoring disease progression, and yet they are limited to detecting potentially late 
and irreversible brain damage. Thus MRI-visible abnormalities may reflect relatively late, 
often irreversible, structural CNS damage.  
 
1.3.5. Functional Imaging Techniques 
Functional imaging techniques go beyond the macroscopic appearance to probe tissue 
metabolism, blood supply, and micro-architecture [34, 35]. Magnetic resonance based 
functional imaging techniques include magnetic resonance spectroscopy (MRS), diffusion 
weighted and diffusion tensor imaging (DWI, DTI). MRS provides data on a range of tissue 
metabolites, while DWI/DTI detects alterations in water diffusivity magnitude and 
directionality giving insight in to alterations in tissue micro-architecture not detectable with 
conventional MRI.  
 
These techniques have the potential to augment current clinical and research approaches to 
IMD-related neurodegeneration, and their use has been reported in a number of IMDs. The 
ability to profile in vivo brain tissue metabolites using MRS is particularly attractive in the 
study of the IMDs, where abnormalities and alterations at the metabolite level are present. 
 
MRS and DWI/DTI can be readily obtained using standard clinical magnetic resonance (MR) 
scanner hardware. Standard MR scanner software includes the facility for these modalities. 
They do not require administration of additional contrast agents, and as with all MR-based 
modalities do not expose the subject to ionising radiation. It is therefore feasible to 
incorporate these modalities of investigation in to routine clinical investigations, the only 
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requirement being the additional scan time to complete the studies (approximately 15 minutes 
for MRS). 
 
1.4. Aims and objectives 
The long-term clinical aim of this work is to contribute to improved clinical outcome for 
children affected by neurodegeneration in the context of inherited metabolic disorders. 
 
1.4.1. Aims 
The aims of the project were to employ multimodal magnetic resonance imaging, particularly 
in vivo magnetic resonance spectroscopy-based brain metabolite profiling, in order to:  
(a) Identify potential novel biomarkers of disease with utility in disease diagnosis and in 
monitoring of disease progression and response to therapy, and  
(b) Improve the understanding of the pathogenesis of neurological damage in specific 
inherited metabolic disorders. 
1.4.2. Objectives 
The objectives of the project designed to achieve these aims were: 
(a) To establish methods for analysing in vivo MR spectroscopy data for neurometabolic 
patients and evaluate the reliability of data acquired in a standard clinical paediatric setting. 
(b) To investigate regional and age-dependent variation in standard brain metabolite profiles, 
and to establish normal baseline brain metabolite profile datasets to provide utilisable 
background comparator data for subsequent analysis of specific disease cohorts and individual 
cases. 
(c) To investigate the occurrence of non-standard brain metabolites that may have specific 
diagnostic value. 
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(d) To combine information from in vivo MR spectroscopy with other MR imaging modalities 
including conventional anatomical imaging and diffusion-based imaging, and with clinical 
parameters including biochemical and neurocognitive data. 
(e) To apply the methodologies developed to the investigation of specific disease cohorts.  
 
Chapter Two of the thesis provides an introduction to the theory and implementation of 
magnetic resonance spectroscopy including a discussion of the metabolites detected in brain 
using this method. The thesis then presents methods and data relating to each of the objectives 
outlined above. Chapter Three gives details of the general methods developed and Chapter 
Four describes the evaluation of the data quality, and addresses the development of standard 
baseline brain metabolite profiles. Chapter Five presents data on the identification of non-
standard brain metabolites.  
 
Chapters Six to Eight give examples of how the methodologies have been applied to the study 
of cohorts of children with three specific IMDs: firstly (Chapter Six) a disorder of complex 
molecule metabolism (mucopolysaccharidosis type II, Hunter Syndrome) where boys affected 
have an aggressive neurodegenerative disease for which the evaluation of novel therapies 
requires the identification of novel disease biomarkers; secondly (Chapter Seven) a disorder 
of  amino acid catabolism (propionic acidaemia) where patients have a high rate of strokes 
affecting the basal ganglia; and thirdly (Chapter Eight) a disorder of the urea cycle 
(argininosuccinic aciduria) which has unique neurological manifestations.   
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Chapter Two 
 
2. An Introduction to Magnetic Resonance Spectroscopy 
 
Magnetic resonance imaging and spectroscopy are based on the nuclear magnetic resonance 
phenomenon. This section provides a brief introduction to nuclear magnetic resonance theory, 
and how it is applied to achieve in vivo MR imaging and detection of metabolites by 
spectroscopy. 
2.1. Overview of the Nuclear Magnetic Resonance Phenomenon 
The MR-based functional imaging modalities are all based upon the phenomenon of nuclear 
magnetic resonance (NMR), discovered in the 1940s, whereby certain nuclei when placed in a 
strong magnetic field resonate at radio-frequencies that are characteristic for that nucleus (the 
Larmor frequency) [36]. The Larmor frequency depends on the strength of the external 
magnetic field and an intrinsic property of the nucleus, the gyromagnetic ratio. The decay rate 
of the signal detected from a sample depends on the relaxation time constants T1 and T2. 
 
Conventional MR imaging is concerned with detection of this signal predominantly from 
hydrogen nuclei in water molecules (which constitutes some 70% of body weight) with 
imaging contrast being detected by localised variation in the tissue relaxation time constants. 
The use of additional magnetic field gradients is required to allow spatial localisation of the 
signal detected, i.e. in order to obtain spatial information required for reconstruction of 
images across two (or three) dimensions. These additional magnetic field gradients alter the 
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Larmor frequency of water molecules depending on their spatial position in the field thereby 
allowing spatial encoding. 
 
Magnetic resonance spectroscopy is based on the dispersion of chemical shifts. The local 
chemical environment of a proton will alter the magnetic field that the nucleus experiences. 
This leads to a small change in the Larmor frequency for that nucleus, thus the signals from 
protons in different molecules (and hence different local chemical environments) can be 
differentiated, allowing detection of different metabolites. Different metabolites appear as 
distinct metabolite peaks on the MR spectrum that is generated. The chemical shift is reported 
in units of parts per million (ppm), and for a typical in vivo proton spectrum ranges from 0.5 
ppm to 9.0 ppm. Water itself resonates at around 4.65ppm. The downfield region (5 to 
9.0ppm) includes peaks from aromatic compounds such as phenylalanine, but is not usually 
included in the standard output from a clinical MRS study as the signal in this region is much 
weaker compared to the up-field region. 
 
2.2. Nuclear magnetic resonance theory 
Protons possess fundamental properties including electric charge (e=1.6x10-19C), mass 
(mp=1.67x10-27kg) and spin (I= ½). A spinning electric charge generates a magnetic field, 
thus protons possess a magnetic moment. The behaviour of protons placed in a strong external 
magnetic field (B0) can be described by both classical or quantum mechanics.  
 
The classical description states that when placed in a strong magnetic field, protons tend to 
align with the magnetic field. However, the interaction of the magnetic moment of the proton 
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with the external field causes the proton to precess (circular rotary motion) around the 
magnetic field (figure 2.1) [37]. 
 
Figure 2.1: Precession of a proton placed in a strong magnetic field. θ is the angle between 
the spinning magnetic moment (μ) and the external magnetic field (B0). 
  
The speed of rotation (precession) is given by the Larmor equation 
 
Equation (1)    υ0=γB0/2π 
 
where υ0 is the Larmor frequency (Hz), γ is the gyromagnetic ratio of the nucleus (2.675x108 
rad s-1T-1 for proton), and B0 is the external magnetic field strength. The magnetic energy (E) 
associated with a magnetic moment rotating in the external magnetic field is  
 
Equation (2)   E=-μB0cosθ 
 
where θ is the angle between the spinning magnetic moment μ and the external magnetic 
field, giving minimum energy when the magnetic moment is parallel with B0 (since θ =0o, and 
cos 0o = 1) and maximum when the magnetic moment is lying antiparallel with B0 (since θ 
=180o, and cos 180o = -1) [36]. 
 
θ μ
B0
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The quantum model dictates that protons are able to occupy one of two quantum states. In the 
absence of an external magnetic field these states have equal energy. In an external magnetic 
field one state is a lower energy state than the other (the lower energy state corresponding to 
the proton aligned parallel with the magnetic field, and the higher energy state corresponding 
to the proton aligned antiparallel to the magnetic field), the energy gap proportional to the 
magnetic field strength B0. Provision of a quantum of energy in the form of a photon that 
equals the energy gap ΔE to a proton in the lower energy state will promote it to the higher 
energy state: 
 
Equation (3)   ΔE=h υ0 
  = hγB0/2π 
 
where h is Planck’s constant. Note that in both the classical and quantum descriptions the 
Larmor frequency υ0 is proportional to the gyromagnetic ratio and the strength of the external 
field.  
 
If radiofrequency (RF) energy of the correct frequency is applied to the system, protons can 
move from the lower energy state to the higher energy state. This frequency is the Larmor 
frequency as given by both the classical and quantum mechanical models. 
 
A sample, be it a test tube of serum or in vivo brain, contains many more than one proton. The 
net (macroscopic) magnetisation is the “resultant of the sum over all the individual magnetic 
moments” [36] in a sample. Using the classical description, and assuming that all the spins lie 
at the same point in space, the distribution of the many spins can be depicted by adjoining two 
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cones with the upper cone representing the protons lying in the lower energy (α) parallel state 
and the lower cone representing protons lying in the higher energy (β) antiparallel state, all 
precessing (rotating) around the external magnetic field B0 (figure 2.2). 
 
Figure 2.2: Protons lying in external magnetic field B0. (α – lower energy parallel state, β – 
higher energy antiparallel state). 
 
The net magnetisation is the net effect of all the magnetic moments and is represented by a 
single vector Μ. Consider first the component of Μ in the horizontal x-y plane at equilibrium 
(Μxy): the individual magnetic moments are randomly distributed around the cones, and thus 
the horizontal components cancel out and at equilibrium there is no horizontal component to 
Μ. The net magnetisation is therefore proportional to the difference between the number of 
spins in the low energy state (upper cone) and the high energy state (lower cone). This 
population ratio is given by the Boltzmann distribution: 
 
Equation (4)   (nβ - nα)/( nβ + nα) =  tanh (ħB0/2kT) 
 
where nα is the number of protons in the low energy state, nβ is the number of protons in the 
high energy state, ħ is the reduced Planck constant,  is the gyromagnetic ratio,  B0 the applied 
magnetic field, k is the Boltzmann constant (1.38x10-23JK-1), and T is the absolute 
x 
y 
z 
B0 
α 
β 
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temperature. For B0=1 T and at room temperature (T=300K), the population ratio between the 
two states is equivalent to a few parts per million.  Although only a small difference, this 
equilibrium magnetisation Μ0 is detected by the NMR experiment. 
 
However, to detect Μ0 it must be rotated onto the transverse x-y plane, which is achieved by 
using a second magnetic field (B1 field) applied to the sample perpendicular to the main B0 
external field. This is accomplished using a radiofrequency pulse at the resonance frequency 
of the proton. This results firstly in an equal distribution of spins in the α and β states by 
providing quanta of energy that promote protons from the low energy α  state to the higher 
energy β state  and secondly phase coherence of the spins, i.e. all the spins are at the same 
“position” on the cone (i.e. they precess in phase), with the net effect that the net 
magnetisation then lies in the transverse plane, with Μ0 precessing around the z-axis (figure 
2.3) [36]. 
 
Figure 2.3: Net magnetisation M0 at equilibrium (left) and after application of perpendicular 
B1 field (right). 
 
After the B1 pulse is switched off the net magnetisation will precess (rotate) in the transverse 
plane generating an oscillating signal in the receiver coil. However the excited protons will 
gradually return to their equilibrium state and as they do so the emitted radiofrequency signal 
B0 
α
β
B0 
α
β
Μ0 
Μ0 
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decays. This is detected as the “free induction decay” or FID, and is the basis of the signal 
detected by the NMR experiment and consequently by MRS and MR imaging.   
 
Fourier Transform of the FID converts the signal from the time domain to the frequency 
domain, i.e. from a plot of signal intensity against time to a plot of signal intensity against 
frequency, resulting in a peak for each resonance frequency of nuclei in the sample (figure 
2.4).  
 
Time domain free induction decay 
(x-axis: time (s)) 
FT 
Frequency domain spectrum 
(x-axis: chemical shift (ppm)) 
 
Figure 2.4: Plots of time domain free induction decay (left) and frequency domain spectrum 
(right) after Fourier Transform (FT) 
 
The return to the equilibrium (Μ0) state following perturbation by the B1 radiofrequency pulse 
is described by the relaxation constants T1 and T2. T1 (longitudinal or spin-lattice) relaxation 
is caused by loss of energy from proton spins to the “lattice” or bulk structure of the sample, 
and depends on both B0 and the properties of the tissue. T2 (transverse or spin-spin) relaxation 
is caused by interactions between adjacent spins, resulting in loss of phase coherence of spins. 
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Equation (5)   Μ z= Μ 0[1-exp(-t/T1)]  
Equation (6)   Μ xy = Μ 0 exp (-t/T2) 
where Μ z is the component of the net vector Μ on the z-axis and Μ xy the component of the 
net vector Μ on the x-y plane. It can be seen from equations (5) and (6) that Μ xy decays 
exponentially with time while Μ z increases back to Μ 0 (figure 2.5). 
 
   
Figure 2.5: Plots of Mxy and Mz components of net magnetisation against time showing 
exponential decay and increase. 
 
T2 is constant with varying B0 and is characteristic of the sample. Differences in relaxation 
constants between different tissues and between normal and diseased tissues generate the 
image contrast seen in MRI.  
 
2.3. Magnetic resonance spectroscopy 
2.3.1. Chemical Shift Phenomenon 
Thus far the description has considered only a standard proton experiencing a uniform 
external magnetic field B0. Hence MR imaging relies on the signal from protons in water 
molecules. However, protons in different chemical (molecular) environments will experience 
a slightly different applied magnetic field, since the surrounding electron cloud of its chemical 
environment will generate a small local magnetic field that will either augment or subtract 
M0
Mz
t 
Mxy
t
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from the main B0 field. Protons in different molecules will therefore experience different local 
field alterations: 
 
Equation (7)   Blocal=B0(1-σ)  
 
where σ is the shielding effect of local electrons. From the Larmor equation (1) (υ0=γB0/2π), 
varying the actual magnetic field experienced by the proton will alter the Larmor frequency υ0 
of that proton, altering the signal detected by the NMR experiment.  This is known as the 
chemical shift effect, and is the basis for NMR spectroscopy [37]. The FID will contain 
information about the different proton resonances within the sample, and Fourier Transform 
of the FID will generate a spectrum of signal intensity against frequency. Peaks at different 
frequencies correspond to protons in different chemical environments, i.e. different 
molecules. 
 
The chemical shift is reported in parts per million, where   
 
Equation (8)   υact = (1.0 + δ x 10-6)/ υ0 
  and thus   
Equation (9)   δ = [(υact/ υ0)-1] x 106] 
 
where υact is the actual Larmor frequency of the proton in its unique chemical environment, 
and δ is the chemical shift. 
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By convention spectra are plotted with the chemical shift (x) axis inverted, so that a typical 
brain MRS spectrum has 4ppm on the left running to 0ppm on the right. Different chemicals 
will therefore produce peaks at characteristic positions on the spectrum allowing their 
identification, while the amplitude of the signal relates to the relative concentration of the 
metabolite. 
2.3.2.  J-coupling 
While chemical shift describes the effect of chemical bonds (electron clouds) on the local 
magnetic field experienced by a nucleus, J-coupling describes the effect of other close nuclei 
(i.e. 3 or less bonds away) on the experienced magnetic field [37]. Consider one proton Ha: 
another nearby proton nucleus Hb may be aligned in either the α or β state, and will 
consequently either augment or subtract from the magnetic field experienced by the Ha. As 
approximately 50% of the nuclei will be in each of the two states, the resonant frequency of 
Ha will be split in to two (nearby) peaks, separated by the coupling constant J (in Hz). This 
phenomenon is seen in in vivo brain MRS where lactate is seen as a “doublet” at around 
1.3ppm[38]. 
 
In molecules where there is more than one near proton the resultant splitting patterns are more 
complicated as there are increasing possible combinations of parallel/anti parallel alignment 
of the spins, with the number of peaks and intensity ratios given by Pascal’s triangle (figure 
2.6).  
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singlet 1 no neighbours  
doublet 1   1 one neighbour  
triplet 1   2   1 two neighbours  
quartet 1   3   3   1 three neighbours  
quintet 1   4   6   4   1 four neighbours  
Figure 2.6: J-coupling: effect of increasing numbers of near protons. (Adapted from figure 
1.5, [37]) 
 
2.4. In vivo spectroscopy considerations 
The same NMR phenomenon provides the basis for both in vitro NMR and in vivo MRS. In 
vivo MRS however has additional requirements and challenges, notably the need to select 
signal from a volume of interest only (and not for example the whole brain), the need to 
suppress the overwhelming signal from water that is the main constituent of most tissues, and 
to optimise detection of the relatively low concentration metabolite signal  
2.4.1. Volume selection 
There are a number of techniques available for volume selection, including Point Resolved 
Spectroscopy (PRESS) [39], Stimulated Echo Acquisition Mode (STEAM) [40] and Image 
Selected In Vivo Spectroscopy (ISIS) [41]. PRESS is the technique in clinical use at the 
Birmingham Children’s Hospital and will be briefly described.  
 
In order to detect signal from a volume of interest, pulse sequences are used in conjunction 
with magnetic field gradients to selectively excite only protons within the volume of interest. 
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Thus when the signal is obtained it will originate only from molecules within the volume of 
interest.  
 
Application of a linear magnetic gradient will alter the Larmor frequencies of protons relative 
to their position along x (figure 2.7). Application of a pulse with a narrow range of υ0 
frequencies will therefore only excite protons in the spatial position corresponding to the 
frequencies of the RF pulse.  Application of slice selection gradients in each plane x, y, and z 
will generate a signal only from the cuboid volume of interest (i.e. the intersection of 3 
excited “slabs”). 
 
 
 
Figure 2.7: Simplified PRESS pulse sequence. Three slice-selective gradients applied during 
sequence on each axis Gx-z. Initial 90o soft pulse places Μ0 onto transverse plane. The two 
180o pulses refocus the spins, the first generating a spin-echo at 2t1. The second 180o pulse 
refocuses to generate a second spin-echo at 2t2. The two 180o pulses also aid in the slice-
selection. Two pairs of crusher gradients (shaded) in orthogonal directions around 180o pulses 
assist selection of coherences. The final signal is detected at a time 2(t1+t2) (the echo time, 
TE). (Adapted from figure 6.13, [36].) 
 
 
Variation of the echo time (TE) generates different spectra, due to the differing relaxation 
constants of each metabolite. A greater number of metabolites are seen at short echo time (e.g. 
30ms), whereas at longer echo time (e.g. 135ms) certain metabolites, notably lipids and 
t1 t1 t2 t2 RF 
Gx
Gy
Gz
90o 180o 180o 
TE 
x
Gradient  
Gx=dB0/dx 
RF frequencies 
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Selected 
slice 
υ0 
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macromolecules, are no longer seen in the spectrum, as the signal from these metabolites has 
already diminished to zero during the echo time, due to short relaxation time constants.  
 
2.4.2. Water suppression 
Since metabolites of interest in brain are usually present in millimolar concentration, and 
water is around 50-100M, methods to suppress the water signal are required. Methods such as 
the Chemical Shift Selective (CHESS) pulse sequence selectively excite water molecules by 
use of a narrow band radiofrequency pulse, and then apply a “spoiler” gradient to dephase the 
excited spins. This water suppression is required both to aid the identification of very small 
metabolite peaks adjacent to the very much larger water peak, and also to enable optimal 
detection of these peaks by avoiding swamping of the analogue to digital converter by the 
very large water signal. 
 
Due to the relative insensitivity of the NMR experiment, further exacerbated by in vivo low 
concentrations of metabolites of interest compared to the concentration of water, the signal to 
noise ratio (SNR) is low for MRS compared to MRI. Subsequently to improve the SNR 
multiple repeated acquisitions are required and summed together, thereby allowing peak 
signal to summate while random baseline noise will cancel out. Typically for in vivo 
acquisition 128 repetitions are acquired for each voxel of interest. 
 
2.5. Spectral post-processing and metabolite quantification 
The FID acquired by the clinical MR scanner can be displayed as a basic spectrum after 
Fourier Transform, a functionality available on clinical MR systems. This unprocessed 
spectrum is useful for immediate clinical review by the radiologist. Some systems also 
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provide a basic metabolite identification and fitting algorithm, such as that on the Siemens 
system (figure 2.8). 
 
For detailed analysis, metabolite fitting and quantification, however, further offline processing 
is undertaken. This section gives a generic overview of the techniques involved in post-
processing, and introduces the standard software used in the current study. 
 
 
 
 
Figure 2.8: Example MR scanner unprocessed spectrum output. (A) Output from Siemens 
system including 3-plane images for voxel localisation. (B) Output from GE system. 
 
2.5.1. Post-processing 
The quality and appearance of the spectrum from the measured signal can be enhanced by a 
variety of post-processing techniques that aim to overcome some of the specific problems inherent 
in in vivo spectroscopy. While these techniques can improve the accuracy of metabolite 
quantification there is a risk of altering the FID parameters such that the accuracy is in fact 
decreased [42].  
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The post-processing steps described here are carried out automatically by many processing 
software programmes, including LCModelTM which is the software used here. However an 
understanding of these steps is required in the appraisal of spectral quality and of factors that may 
impinge on the reliability of metabolite quantification. 
 
2.5.1.1. Eddy current correction 
Eddy currents are currents induced within the MR scanner system components by the numerous 
rapidly switching magnetic field gradients applied during signal acquisition. Since a flowing 
electric current generates a magnetic field, eddy currents generate additional varying magnetic 
fields within the system. These result in time-dependent phase shifts within the FID and 
subsequent lineshape distortions in the post-Fourier transform spectrum, which restrict the 
accuracy of metabolite quantification.  
  
Eddy current correction (ECC) techniques overcome this by use of a reference FID acquired 
without water suppression. When the water signal is not suppressed, and assuming that the 
reference frequency Ω is set to the water frequency, the FID acquired will not have any 
components caused by the chemical shift of water since it is on resonance and the signal from the 
much lower concentration metabolites is negligible. Any phase evolution seen in this water 
unsuppressed FID/spectrum will therefore be due to the presence of eddy currents. This phase 
evolution data can then be used to correct the water suppressed (metabolite) FID. This makes the 
assumption that the two FIDs are acquired from exactly the same location, and with no change in 
the acquisition parameters except that water suppression is switched off, and only a single 
acquisition repetition is required for the water unsuppressed FID. It has also been noted for many 
newer MR scanners that have active gradient shielding that eddy current distortions are a less 
frequent problem [42]. 
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2.5.1.2. Zero filling 
The signal detected by the receiver coil is sampled at a finite number of time points by an 
analogue-digital converter. If the time interval is too great between sampled points the 
definition of peaks in the spectrum may be inadequate resulting in inaccurate metabolite 
fitting. Zero filling can improve the digital resolution of a spectrum by appending zeros to the 
end of the FID in the time domain and thereby allowing interpolation of the spectral signal. 
This can improve the digital resolution of the spectrum, allowing more accurate signal 
analysis as well as better visual presentation [42].  
 
2.5.1.3.Phase Correction 
The lineshapes of metabolite peaks in the spectrum may be distorted due to phase changes, 
including first order changes arising from the time delay in FID acquisition. To overcome this 
a phase correction must be applied, either manually or automatically, by observing the effect 
of altering the phase factor  to restore the peak to an absorptive shape [42]. The phase factor 
is made up of two components, the zero order phase 0 which is independent of the frequency 
and the first order phase 1 which varies with frequency, and phase correction techniques 
have to account for both of these with zero and first order corrections.  
 
2.5.1.4.Baseline correction 
It is commonly observed that the peaks in a spectrum do not arise from a zero intensity 
baseline. A baseline that deviates significantly from a zero intensity flat line can arise due to 
the presence of signal from macromolecules and lipids with short T2* values, and also due to 
hardware factors. (T2* refers to decay of transverse magnetisation due to spin-spin 
interactions and inhomogeneities in the magnetic field). Baseline correction concerns the 
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removal of this baseline. The inclusion of macromolecular and lipid signal parameters in 
metabolite fitting models significantly improves the modelling of the baseline [42].   
 
2.5.2. Spectral fitting algorithms 
Having acquired the FID using optimal parameters and then applied specific post-processing 
techniques, the next stage in analysis is to identify and quantify the metabolite signals present 
within the spectrum. While manual identification of peaks is possible by consideration of 
peak chemical shifts and evident J-couplings, the spectrum acquired from a typical in vivo 
MRS study is complicated by the presence of multiple overlapping resonances and so 
automated methods of metabolite identification are required. 
 
The approach used here is an example of fitting a linear combination of metabolite spectra, 
whereby a model is derived composed of a linear combination of the different individual 
metabolite spectra that together make up the complex total measured spectrum. The library of 
expected metabolite resonance profiles is referred to as the “basis set”. Linear combination 
modelling algorithms then derive the best fit to the actual spectrum by altering the amplitudes, 
frequencies, phases and linewidths of the basis set [36].  
 
The software programme employed in the current work is LCModelTM, which has been 
widely employed in many research settings [43, 44]. The programme automates the post-
processing steps discussed above including lineshape, eddy current correction and baseline 
functions, and zero and first-order phase corrections. It employs a constrained least squares 
analysis method to provide the best fit from a basis set containing seventeen metabolite and 
nine macromolecular and lipid spectra. The basis set spectra are adjusted to take account of 
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additional line spectral broadening and chemical shift referencing errors. The inclusion of the 
macromolecular and lipid components allows effective derivation of the baseline function.  
 
        
Chemical shift (ppm) 
 
Figure 2.9: Example of linear combination metabolite fitting demonstrating contribution of 
different individual metabolite spectra to overall fitted combination. Blue line: sum of all 
metabolites (fitted linear combination). Other lines: individual spectra from different 
metabolite that sum together to create the fitted combination. (Not all metabolites shown for 
clarity). 
 
 
2.5.3. Metabolite quantification 
The concentration of each metabolite present in a spectrum is proportional to the peak 
integral, i.e. the area under the peaks that constitute the individual metabolite spectrum. 
Relative metabolite concentrations can be established by comparing the area under peaks 
from different metabolites. It is, however, possible to derive an absolute quantification of the 
metabolite concentration by normalization to the area of the water peak from the non-water 
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suppression FID. Thus the acquisition of an additional spectrum without water suppression 
while keeping all other parameters constant is used to provide a standard reference for 
calculating metabolite concentrations as well as for eddy current corrections [45]. 
 
This method requires an assumption as to the brain water concentration. The default water 
concentration used by LCModel is 35880mM, based on data from Ernst et al [46]. Variation 
in the water content of different brain tissues would need to be considered to enable direct 
comparison of metabolite concentrations between regions, and furthermore variation in water 
concentration in different pathological states could invalidate the assumptions made. 
 
LCModel generates two outputs, one with and one without the application of eddy current 
correction steps. In addition to values for the estimated metabolite concentration it also 
generates estimates of the standard deviation of each concentration, expressed in percent of 
the estimated concentration (the Cramér-Rao lower bounds). 
 
2.6. Scanner hardware elements 
A full discussion of the hardware and component design of MR systems is beyond the scope 
of this thesis, but a brief description of the hardware components of MR system is required 
particularly to inform analysis of inter-scanner data variability [47]. A typical MR scanning 
system has several key components: Firstly, a constant magnetic field is generated by a 
superconducting magnet (the B0 field). This strong field (typically 1.5 – 3 Tesla) provides the 
constant magnetic field lying parallel to the bore of the magnet, required to initially align 
proton magnetic spins. Secondly, gradient coils are required to generate magnetic field 
gradients required for the localisation of MR signal, and also the generation of diffusion 
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weighting. Three sets of coils are required, one for each orthogonal axis. Thirdly, 
radiofrequency transmit and receiver coils are required to generate excitatory radiofrequency 
pulses and to detect the NMR signal. A body coil is built in to the scanner “doughnut”, though 
body-part specific coils may be used such as a head-coil which fit around the anatomical 
structure of interest and increase signal to noise ratio. Some such coils are “arrays”, i.e. have 
multiple coil elements. Fourthly a computer control system is required to operate the scanner, 
and finally the entire system must be enclosed within a Faraday cage to isolate the MR 
scanner from external RF interference. 
 
Figure 2.10: Photograph of 3T Magnetic Resonance scanning system (Philips), 3T Magnetic 
Resonance Suite, Birmingham Children’s Hospital. 
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2.7.  An Introduction to the Metabolites Detected by In Vivo proton MR 
Spectroscopy of Brain 
The purpose of this section is to provide an introduction to the main metabolites that may be 
detected in the brain using in vivo proton MR spectroscopy. For each metabolite, salient 
spectroscopic features are mentioned, and the clinical relevance of the metabolite is described. 
Selected metabolic pathways to which the metabolite contributes are also described, since 
perturbations in metabolite concentrations detected will have implications for these pathways.   
 
A typical brain MR spectrum (figure 2.11) contains several major prominent metabolite 
peaks. In general the limit of detection of metabolites by in vivo MRS is around 0.5-1mM. 
Table 2.1 provides specific chemical shift parameters and approximate normal brain 
concentrations for each metabolite. 
 
Figure 2.11: Example of in vivo brain MR spectrum with major metabolite peaks identified. 
(Ins, myo-inositol; Cho, choline; Cr, creatine; Gln, glutamine; Glu, glutamate; NAA, N-
acetylaspartate; Lac, lactate; Lip, lipid; MM, macromolecule.  
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Metabolite 
(abbreviation) 
Molecular 
groups 
Chemical 
shift (ppm) 
Multiplicity Human brain  
mmol/L 
N-acetylaspartate 
(NAA) 
Acetyl 2CH3 
Aspartate 2CH 
3CH2 
 
NH 
2.008 
4.382 
2.673 
2.486 
7.820 
s 
m 
dd 
dd 
d 
7.5 
N-acetylaspartyl 
glutamate 
(NAAG) 
Acetyl 2CH3 
Aspartate 2CH 
3CH2 
 
Glutamate 2CH 
3CH2 
 
4CH2 
2.042 
4.607 
2.721 
2.519 
4.128 
1.881 
2.049 
2.190 
2.180 
s 
dd 
dd 
dd 
dd 
m 
m 
m 
m 
0.5 
Creatine (Cr) CH3 
CH2 
NH 
3.027 
3.913 
6.650 
s 
s 
s 
4.5 
Glycerophosphoc
holine (GPC) 
Glycerol 1CH2 
 
2CH 
3CH2 
 
Choline (CH3)3 
7CH2 
8CH2 
3.605 
3.672 
3.903 
3.871 
3.946 
3.212 
4.312 
3.659 
dd 
dd 
m 
m 
m 
s 
m 
m 
0.5 
Phospho(ryl)choli
ne (PCh) 
(CH3)3 
1CH2 
2CH2 
3.209 
4.282 
3.643 
s 
m 
m 
0.2 
Phosphocreatine 
(PCr) 
CH3 
2CH2 
NH 
NH 
3.029 
3.930 
6.58 
7.30 
s 
s 
s 
s 
3.0 
Myo-inositol 
(Ins) 
1CH 
2CH 
3CH 
4CH 
5CH 
6CH 
3.522 
4.054 
3.522 
3.614 
3.269 
3.614 
dd 
dd 
dd 
dd 
dd 
dd 
4.0 
 
Table 2.1: (See also next page) Chemical shifts and peak multiplicity of metabolites 
detectable with MR spectroscopy in human brain. (Data from [36]. s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet; dd, double doublet). 
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Metabolite 
(abbreviation) 
Molecular 
groups 
Chemical 
shift (ppm) 
Multiplicity Human brain  
mmol/L 
Scyllo-inositol 
(Scy) 
1-6CH 3.340 s 0.2 
Glutamine 
(Gln) 
2CH 
3CH2 
 
4CH2 
3.757 
2.135 
2.115 
2.434 
2.456 
dd 
m 
 
m 
3.0 
Glutamate 
(Glu) 
2CH 
3CH2 
 
4CH2 
3.746 
2.042 
2.120 
2.336 
2.352 
dd 
m 
 
m 
6.0 
Lactate (Lac) 2CH 
3CH3 
4.097 
1.313 
q 
d 
0.2 
Alanine (Ala) 2CH 
3CH3 
3.775 
1.467 
q 
d 
0.1 
Aspartate (Asp) 2CH 
3CH2 
 
3.891 
2.801 
2.653 
dd 
dd 
dd 
1.0 
-aminobutryic 
acid (GABA) 
2CH2 
3CH2 
4CH2 
2.283 
1.889 
3.012 
t 
m 
d 
1.0 
Taurine (Tau) 1CH2 
2CH2 
3.420 
3.246 
dd 
dd 
2.0 
 
Table 2.1: (See also previous page) Chemical shifts and peak multiplicity of metabolites 
detectable with MR spectroscopy in human brain. (Data from [36]. s, singlet; d, doublet; t, 
triplet; q, quartet; m, multiplet; dd, double doublet). 
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2.7.1. N-acetylaspartate (NAA) 
The largest peak in a typical brain MR spectrum at 2.01ppm is assigned to N-acetylaspartate 
(NAA), particularly the methyl group of its acetyl moiety. Subsidiary peaks are seen at 
2.49ppm, 2.67ppm and 4.38ppm originating from protons in the CH2 and CH groups.  
 
NAA is found in very high (~10mM) concentrations in the brain [48]. NAA is mainly though 
not exclusively located in neuronal cells, axons and dendrites [49], and has been widely used 
in MRS studies as a marker of neuronal density and viability. However more recent data 
suggest that NAA is also found in other non-neuronal cell types within the central nervous 
system, notably within oligodendrocytes [49, 50].  
 
NAA is synthesised within neurons from L-aspartate by the L-aspartate N-acetyltransferase 
(EC 2.3.1.17, see figure 2.12) [51]. This enzyme is active in both the mitochondrial matrix 
and within the cytosol, potentially within the endoplasmic reticulum [52]. NAA is transported 
by transaxonal transfer to oligodendrocytes, where it is catabolised by aspartoacylase (ASPA, 
EC 3.1.5.15) releasing acetate and L-aspartate. The acetate groups are subsequently utilised in 
the synthesis of fatty acids and myelin lipids [52], while the L-aspartate enters the Krebs 
cycle. Thus NAA has a vital role in myelination of the developing brain. 
 
Two IMDs shed light on the function and biochemistry of NAA, Canavan disease and aralar 
deficiency. Canavan disease (OMIM #271900) is a progressive leucodystrophy due to 
deficiency of ASPA, the enzyme which catabolises NAA within oligodendrocytes. Patients 
have significantly elevated concentrations of brain NAA detectable by MRS, and impaired 
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ability to properly myelinate the CNS [53]. Whether NAA also has a direct toxic effect is a 
moot point [52]. 
 
The mitochondrial malate-aspartate shuttle transports malate, glutamate, aspartate and α-
ketoglutarate across the mitochondrial outer membrane [54]. One of the transporters involved 
is the aspartate-glutamate carrier isoform 1 (aralar, AGC1, encoded by SLC25A12), which is 
the only isoform expressed in the CNS and solely in neurons [54]. In a knockout animal 
model and human patients with AGC1 deficiency there is widespread lack of CNS 
myelination, and very low NAA concentrations detected by MRS, indicating that AGC1 plays 
an important role in providing aspartate for NAA synthesis [54], also supporting the cytosolic 
localisation of NAA synthesis. 
 
In addition to the important role in providing acetate groups for myelin synthesis, NAA is also 
the immediate precursor for N-acetyl aspartyl glutamate (NAAG, see below). NAA may also 
act as an organic osmolyte, and potentially facilitates some aspects of glutamate derived 
mitochondrial energy production [52].  
 
Alterations in NAA, as detected by MRS, have been reported in a wide range of disorders 
including ischaemic stroke, epilepsy, and Alzheimer’s disease, and monitoring serial variation 
in NAA suggested as a means to monitor disease progression [52]. Decreased NAA is also 
seen in a wide range of metabolic brain disorders, and while therefore not disease-specific, is 
a means to monitor the effect a given disease has on brain neurochemistry [55]. NAA also 
varies significantly between brain regions and with developmental stage, in particular relating 
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to the degree of myelination [56], factors which must be taken into account when studying the 
impact of disease states. 
 
 
Figure 2.12: Neuronal/oligodendrocytic interactions in the metabolic pathways of N-
acetylaspartate. ASPA: aspartoacylase; ANAT, aspartate N-acetyltransferase; AGC1, 
aspartate-glutamate carrier isoform 1; NAA, N-acetylaspartate. (Adapted from [54]). 
 
2.7.2. N-acetyl aspartyl glutamate (NAAG) 
N-acetyl aspartyl glutamate (NAAG) contributes to the peak seen in vivo at 2.01ppm from 
NAA, as its largest resonance is at 2.04ppm. NAAG is reported to be a neuronal glutamate 
storage pool [56], and may represent up to 20% of the total NAA signal. Differentiation 
between NAA and NAAG at 1.5 T is not robust, and therefore is usually reported as a value 
for the total NAA + NAAG (tNAA) as an indicator of the total peak concentration.  
 
NAAG is the most abundant brain neuropeptide [57], synthesised by an incompletely 
characterised NAAG synthase [58] by the ATP-dependent condensation of glutamate and 
NAA, primarily within neurons. NAAG is catabolised by various peptidases including 
glutamate carboxypeptidase II (EC 3.4.17.21), a membrane-bound enzyme found in neurons 
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and glial cells [59]. NAAG is an active agonist at various receptors including the 
metabotropic glutamate receptor 3, and is a partial antagonist of the N-methyl D-aspartic acid 
(NMDA) receptor [59]. It is purported to have a role in neuron to astrocyte signalling [60].  
 
Elevated levels of NAAG have been reported in a number of hypomyelinating disorders, 
including in the CSF of children with Pelizaeus-Merzbacher like-diseases [60, 61] and free 
sialic acid storage diseases who also had hypomyelination [59]. Corresponding elevations in 
the total NAA+NAAG peak has been reported using in vivo MRS in these conditions [62]. 
 
2.7.3. Creatine and Phosphocreatine  
Creatine (Cr) and phosphocreatine (PCr) have resonances at 3.01ppm and 3.9ppm and are not 
distinguishable at low field strengths in vivo, and are reported as total Creatine + 
phosphocreatine. (In this thesis, Cr represents the total creatine + phosphocreatine 
concentration). 
 
The creatine-phosphocreatine-creatine kinase system (figure 2.13) plays a central role in 
maintaining adequate ATP supplies for the high-energy demands of the active brain, 
particularly in facilitating the transport of high energy compounds from the site of production 
within the mitochondria to the sites of consumption such as at the synapse [63, 64], thereby 
providing “temporal and spatial energy buffering” [65]. Mitochondrial creatine kinase 
(mtCK) phosphorylates creatine to phosphocreatine; phosphocreatine thus formed is 
transported to sites of energy consumption, where cytosolic creatine kinases are coupled to, or 
associated with, glycolysis, ATP-dependent or ATP-gated processes, ion pumps and other 
energy consuming processes [65].  
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Figure 2.13: The creatine/phosphocreatine/creatine kinase system: high energy phosphate 
shuttling. mtCK, mitochondrial creatine kinase; CKa, cytosolic creatine kinase associated 
with ATPase. (Adapted from [65]). 
 
The crucial role of the creatine system in the CNS is highlighted by another group of IMDs, 
the creatine deficiency syndromes, which again provide “human knockout models” that have 
helped in the understanding of the physiological roles of the system. These include disorders 
of creatine synthesis due to deficiencies of the synthetic enzymes L-arginine:glycine 
amidinotransferase (AGAT; EC 2.1.4.1; OMIM #602360) or guanidinoacetate 
methyltransferase  (GAMT; EC 2.1.1.2; OMIM #601240), and disorders of creatine transport 
due to deficiency of the creatine transporter SLC6A8 (X-linked; OMIM #300036). Patients 
have a near-total lack of brain creatine detected by MRS, and have severe developmental 
delay and usually severe epilepsy [65, 66]. The disorders of synthesis are at least partially 
treatable by oral creatine supplements, whereas the phenotype of the transporter defect is not 
ameliorated by oral supplementation as the CNS is unable to import creatine [64]. 
 
Studied by in vivo MRS, the highest concentrations of Cr are reported in cerebellum, basal 
ganglia and thalamus, with lower levels in white matter [67], and developmental changes are 
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limited to the first year of life. Since concentrations were considered to not vary significantly 
between individuals or with pathology, Cr has been used widely as a denominator for 
comparing other metabolite ratios. This assumption, however, may not be valid, as Cr may 
alter in pathology as illustrated by the creatine deficiency syndromes, and elevated Cr has 
been reported in certain white matter disorders (leukodystrophies) and Sjogren-Larsson 
syndrome (OMIM #270200) [55]. 
 
2.7.4. Choline containing compounds 
The prominent peak at 3.2ppm is assigned to the methyl group of glycerophosphocholine 
(GPC) and phospho(ryl)choline (PCh); free choline contributes only a small amount to this 
resonance and is individually below the limit of detection by MRS [36]. The sum of these 
signals is reported as the total choline (tCho) concentration.  
 
These compounds are found in the phospholipid metabolic pathways and variation in the tCho 
signal is reported as a marker of membrane function. The phospholipids are the major 
constituents of the cellular bilayer membrane, in particular phosphatidylcholine and 
phosphatidylethanolamine; phosphocholine is required for the synthesis of 
phosphatidylcholine and is also generated by its degradation [68]. Choline-phospholipid 
metabolism requires numerous synthetic enzymes as well as active choline transporters 
(figure 2.14). Choline is also required in the synthesis of the neurotransmitter acetylcholine, 
and as a source of methyl groups that feed in to the synthesis of  S-adenosylmethionine, which 
is an important methyl group donor in various transmethylation reactions [69]. 
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Thus increased tCho is reported to reflect membrane disruption or cellular proliferation with 
alterations seen in various white matter disorders [13] and demyelinating disorders [70]. 
Alterations in GPC and PCh are important markers in malignant cells, and have been widely 
investigated in this context both in vivo and in vitro [68]. 
 
 
Figure 2.14: Outline metabolic pathways in choline phospholipid metabolism. Metabolites: 
Cho, choline; PCh, phosphocholine; CDP-Cho, cytidine diphosphate choline; PtdCho, 
phosphatidylcholine; GPC, glycerophosphocholine. Enzymes: CHK, choline kinase; CCT, 
cholinecytidyltransferase; CHPT1, diacylglycerol cholinephosphotransferase 1; PLA2, 
phospholipase A2; PLA1, phospholipase A1; PC-PLD, phosphatidylcholine-specific 
phospholipase D; PC-PLC, phosphatidylcholine-specific phospholipase C; GPC-PDE, 
glycerophosphocholine phosphodiesterase.(Adapted from [68]). 
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2.7.5. Myo-Inositol (Ins) and scyllo-inositol (Scy) 
The peak present in the typical brain MR spectrum at around 3.55ppm is assigned to myo-
inositol [36]. Myo-inositol is the predominant isoform of the 6-carbon sugar inositol 
(hexahydroxy-cyclohexane), present at particularly high concentrations within the brain [71].  
 
Myo-inositol is a precursor for the phosphoinositides important in second messenger signal 
transduction systems. The ubiquitous phosphoinositide second messenger system operates via 
the conversion by phospholipase C of phosphatidylinositol 4,5-bisphophate to inositol 
trisphosphate (IP3) and 1,2-diacylglycerol (DAG), both of which then initiate numerous 
intracellular cascades [72]. 
 
Myo-inositol also has an important role in osmoregulation within the central nervous system 
[71]. Osmoregulatory homeostatic mechanisms are required to maintain neuronal cell volume; 
while acute alterations in tonicity are counteracted by the rapid transport of electrolytes 
including sodium and potassium, chronic alterations are balanced by the shift of “organic 
osmolytes”, principally myo-inositol [71]. The osmoregulatory role of myo-inositol is 
facilitated by the presence within the CNS of specific transporters including sodium-myo-
inositol and hydrogen-myo-inositol transporters [73]. The expression of these is altered by 
osmotic stress, such that expression is increased by hyperosmolar conditions. Conversely in 
the context of hypotonic stress, myo-inositol efflux from the cell is mediated via a voltage-
sensitive organic osmolyte anion channel [71]. Astrocytes in particular have a central role in 
CNS osmoregulation, actively altering in volume to maintain and control extracellular fluid 
osmolarity [74]. 
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Within the MRS literature, myo-inositol is reported to be a “glial marker” as it is 
predominantly located in glial cells, although as with NAA this is not exclusive, being found 
in a range of other neuronal cell types [36]. Thus in diseases with prominent glial expansion 
such as gliosis or tumours of glial origin, the myo-inositol signal is increased [75, 76]. 
Elevated myo-inositol has been investigated as an early marker of Alzheimer’s disease [77].  
 
The physiological role of the isoform scyllo-inositol is not well described and unlike myo-
inositol may not be incorporated into inositol-lipids [78].  Elevated scyllo-inositol has been 
reported in mitochondrial disease, brain tumours and in Alzheimer’s disease [77], and scyllo-
inositol is a potential therapy in Alzheimer’s disease [78]. As scyllo-inositol has molecular 
symmetry, its protons give rise to an NMR signal at the single resonance of 3.34ppm and thus 
appears as a singlet peak visible separate from the complex myo-inositol signal [36]. 
 
2.7.6. Glutamine and Glutamate (Gln+Glu) 
Although the resonances of glutamine (Gln) and glutamate (Glu) overlap significantly in in 
vivo spectra acquired at 1.5 T (table 2.1) there is evidence that they can be distinguished (see 
Chapter 7). The two amino acids are closely linked in several metabolic pathways, and within 
brain a glutamine-glutamate cycle operates between neurons and glial cells (figure 2.15). 
Glutamate is synthesised from glutamine within neurons by glutaminase (EC 3.1.5.2), or from 
α-ketoglutarate by glutamate dehydrogenase (EC 1.4.1.2). Glutamate is the major excitatory 
neurotransmitter acting on several fast and metabotropic glutamate receptors [79]. It is 
released into the synaptic cleft from the pre-synaptic bouton, and subsequently initiates post-
synaptic signalling cascades via specific glutamate receptors. Glutamate is cleared from the 
synapse by rapid uptake into astrocytes which surround the synapse, maintaining the low 
 46
glutamate concentration within the synapse required for efficient synaptic signalling. This 
uptake is mediated by a specific Na+-glutamate transporter, resulting in an elevated astrocytic 
intracellular Na+ concentration which activates astrocytic Na+/K+ ATPase resulting in 
stimulation of glycolysis and hence glucose consumption [80]. 
 
Glutamate within astrocytes is converted to glutamine by incorporation of NH4+ by ATP-
dependent glutamine synthetase (EC 6.3.1.2). This enzyme is found only in astrocytes. The 
glutamine is then released by astrocytes and transported to neurons, where it can be converted 
again to glutamate, constituting the “glutamine-glutamate cycle”.  
 
Some of the glutamate taken up into astrocytes is converted to α-ketoglutarate by 
transamination of oxaloacetate or pyruvate with the formation of aspartate or alanine 
respectively, or via nicotinamide adenine dinucleotide (NAD)-requiring oxidative 
deamination by glutamate dehydrogenase, with the release of ammonium.  The α-
ketoglutarate is transported to the neuron, where it can re-enter the Krebs cycle, and is also 
consumed to generate glutamate. Since α-ketoglutarate is therefore consumed, proximal Krebs 
cycle metabolites must be replenished; this is achieved in part by pyruvate carboxylase (EC 
6.4.1.1) which generates oxaloacetate from pyruvate. Pyruvate carboxylase is predominantly 
found in astrocytes, indicating the important energy metabolism role played by these glial 
cells [74]. 
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Figure 2.15: Glutamate-glutamine cycle and anaplerotic supply of neuron by astrocytes. Lac, 
lactate; Pyr, pyruvate; AcCoA, acetyl Coenzyme A; α-KG, α-ketoglutarate; OxA, 
oxaloacetate; NH4+, ammonium; Ala, alanine; asp, aspartate; GDH, glutamate dehydrogenase; 
GS, glutamine synthase; Krebs, Krebs cycle. (Adapted from [74] and [80].) 
 
 
2.7.7. Lactate (Lac) 
Due to the J-coupling effect lactate appears as a doublet at around 1.31ppm. Acquired at 1.5 T 
with short echo time (30-35ms) the doublet is upright, but at longer echo times (135-144ms) 
the doublet is inverted. This is a useful phenomenon facilitating the detection of lactate and 
differentiation from lipid and macromolecular signals that resonate in the same region.  
 
The brain has high energy requirements, responsible for some 25% of glucose and 20% of 
oxygen total body utilisation [80]. Glucose is the predominant brain energy substrate, and is 
also required for biosynthesis of glycolipids, glycoproteins and the major neurotransmitters 
glutamate, GABA and acetylcholine. The high energy requirement of the brain is due to the 
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propagating action potentials, for the action of ionic pumps notably the Na+/K+ ATPase, as 
well as for biosynthetic pathways and axonal transport [80].  
 
Plasma glucose is transported across the blood brain barrier by specific transporters, 
predominantly GLUT1 (SLC2A1). Inherited deficiency of this transporter results in 
significant neuroglycopaenia and low CSF glucose concentrations manifest with 
microcephaly, infantile seizures and developmental delay [81]. GLUT1 is predominantly 
expressed by astrocytes, the foot-processes of which surround brain capillaries and form the 
blood brain barrier. Glucose is transported into neurons by the GLUT3 (SLC2A3) [82], found 
in both axons and dendrites. Thus astrocytes have an important role in regulating the entry of 
glucose in to the brain. 
 
Furthermore, the supply of energy (glucose) is coupled to the local activity of the brain, such 
that activated regions receive increased blood flow and glucose uptake. The glial cells, 
notably astrocytes, play a key role in regulating this coupling, and the astrocytes are also 
crucial in supplying neuronal energy substrates [80]. Glucose is metabolised by glycolysis in 
astrocytes with the generation of lactate; lactate is then transported to neurons where it is 
converted to pyruvate and can enter oxidative phosphorylation with the generation of ATP. 
 
Thus glycolysis is the principal pathway of glucose metabolism; the end product is the 
synthesis of pyruvate [83]. During glycolysis ATP is generated. In aerobic conditions and in 
the presence of functional mitochondrial systems, pyruvate is further oxidised and ATP 
generated via the Krebs cycle and mitochondrial electron transport chain. However in 
anaerobic situations, or in the absence of mitochondria (such as in erythrocytes), oxidative 
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phosphorylation does not occur, and there is a shift towards the conversion of pyruvate to 
lactate by lactate dehydrogenase (EC 1.1.1.27). Thus elevated lactate concentrations are 
detectable in brain tissue both in hypoxic/ischaemic conditions [84] and in some 
mitochondrial cytopathies [38, 85]. Indeed there is evidence that a transient rise in tissue 
lactate is a normal physiological event, for example following the activation of the visual 
cortex [86]. 
 
2.7.8. Other metabolites 
A number of other small molecular metabolites may also be detected, including alanine (Ala), 
aspartate (Asp), gamma-amino butyric acid (GABA), glucose, taurine (Tau), and 
guanidinoacetate (Gua). Many of these metabolites are usually at or below the limit of 
detection by MRS, and this together with the complexity of their resonance peaks means that 
advanced techniques are required to achieve robust identification and quantification. Such 
spectral editing techniques have been applied to several metabolites including GABA [87].  
 
Some of these metabolites may be robustly quantified when present in elevated concentrations 
since their NMR resonances do not significantly overlap other metabolites, such as taurine 
which is detectable in young infants, or alanine in some cases with lactic acidosis. 
 
2.7.9. Macromolecules (MM) and lipids (Lip) 
A substantial proportion of the signal detected by in vivo MRS is derived from 
“macromolecular resonances”. The macromolecular signal originates from proteins and amino 
acids and result in broad resonances. These have short T2 relaxation constants and so are not 
seen at longer echo time acquisitions [37, 88]. 
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Contributions from CH3 and CH2 groups of NMR-visible lipids are also detected, with 
characteristic peaks at 1.3ppm and 0.9ppm [89, 90], which have significant changes in various 
brain pathologies including brain tumours [76].  
 
2.7.10. Developmental & Age Variation in Metabolites 
It is expected that brain metabolites will vary according to brain development and maturation. 
This is reflected in the age-related variation in the MRS detectable brain metabolites. This 
must be taken in to consideration when evaluating MRS alterations seen in pathology, and 
also generates the requirement for age-specific control groups for different metabolites.  
 
Pouwels et al reported metabolite data from MRS studies in 97 children [67]. The most 
significant period of variation is in the first year of life, with in particular a rapid rise in tNAA 
seen in the first 6 months of life in most brain regions. In white and gray matter, taurine levels 
were highest in infancy and then fell, suggesting a specific role in brain development. Within 
white matter and basal ganglia glutamate and glutamine decreased with age, while Cr and 
myo-inositol levels were generally stable (figure 2.16).  
 
This data also highlights the regional variation in metabolite concentrations, notably the 
higher tNAA in gray matter regions (both parietal and deep basal ganglia), where Cr, 
glutamine and glutamate were also higher than in parietal white matter.  
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Figure 2.16: Regional and age variation in brain metabolites determined by MR 
spectroscopy. (A) basal ganglia, (B) parietal white matter, (C) parietal gray matter.(Data from 
[67]). 
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2.8. The Use of Magnetic Resonance Spectroscopy in Inherited Metabolic Disorders 
MRS has the potential to be a powerful tool in both clinical and research applications in 
particular with regard to the inherited metabolic diseases [55, 56, 91, 92]. Alterations in MRS-
visible brain metabolites reflect both non-specific alterations in cellular function or integrity 
that could be the common end point of several disease processes, and specific alterations in 
metabolic pathways that may have direct relevance to inherited disorders of these pathways. 
However, for most IMDs only case reports or small case series utilising MRS have been 
reported. 
 
2.8.1. Specific Disease Biomarkers  
MRS may provide a specific diagnosis when there is a qualitative alteration in the major 
metabolite peaks detected, either the absence of an expected peak, or the presence of an 
unusual peak representing a metabolite not normally seen in brain at levels detectable by 
MRS. Table 2.2 gives examples of IMDs that have specific qualitative brain metabolite 
alterations detectable using MRS. 
 
Absence of the expected creatine peak is the preferred method for diagnosing the creatine 
deficiency syndromes and MRS is also of value in monitoring the response to treatment with 
supplementary creatine [93]. 
 
Sjogren-Larsson syndrome (OMIM #270200) [94-97] may be detected by the presence of a 
characteristic lipid peak at 1.3ppm, while adenylosuccinate lyase deficiency (OMIM 
#103050) may be detected by the observation of a peak at 8.28ppm corresponding to 
succinyladenosine [98]. It should be noted that standard MRS software typically analyses the 
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region between 0.5 to 4.0ppm only, and does not analyse downfield of the water peak. In 
theory this is a region that could yield further important diagnostic information.  
 
MRS has been extensively used as a tool in evaluating potential mitochondrial disease, and 
the presence of detectable levels of lactate used as a marker of possible mitochondrial 
dysfunction [38, 99] although the sensitivity and specificity of lactate detection may not be 
high. As noted previously, Canavan disease has a characteristic MRS finding of very high 
levels of NAA  caused by deficiency of the enzyme aspartoacylase [53].  
 
2.8.2. Non-disease specific metabolite alterations  
As already noted in most IMDs disease-specific metabolite alterations detectable by MRS do 
not appear. The limitations to the sensitivity of the technique in detecting low concentration 
metabolites means that a metabolite must reach significant concentration levels in brain tissue 
before it could be detected. In many disease states alterations in the standard metabolites 
detected give a secondary reflection of the brain tissue pathological processes such as 
demyelination, neuronal loss or ischaemia, and therefore the pattern of alterations may still 
provide useful information as to the nature of the brain pathology and in known diseases may 
be a means to monitoring disease progression. MRS has been incorporated in to a few 
disease/therapy monitoring trials involving IMD, usually monitoring brain NAA levels [100]. 
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Metabolic Disease/ Enzyme deficiency OMIM # Metabolite Ref 
Ribose-5-phosphate isomerase deficiency 608611 Arabinitol/ 
ribitol 
[101, 
102] 
Mitochondrial Complex II deficiency (succinate 
dehydrogenase deficiency) 
 
252011 Succinic acid [101]
HMG Co-enzyme A lyase deficiency 
 
246450 Uncertain [103]
Phenylketonuria (phenylalanine hydroxylase 
deficiency) 
 
261600 Phenylalanine [104]
Canavan (aspartoacylase deficiency) 
 
271900 High NAA [53] 
Aralar deficiency (AGC1) 
 
612949 Absent NAA [54] 
Creatine deficiency (GAMT deficiency) 601240 Absent Cr 
High GAA 
[93] 
Creatine deficiency (AGAT or SLC6A8 deficiency) 602360 
300036 
Absent Cr 
Maple syrup urine disease (branch chain ketoacid 
dehydrogenase deficiency) 
248600 Branch chain 
amino acids 
 
[105]
Sjogren-Larsson (Fatty aldehyde dehydrogenase 
deficiency) 
270200 Fatty alcohol [94, 
96] 
Succinic semialdehyde dehydrogenase deficiency 
 
271980 GABA [106]
3-methylglutaconic aciduria type I 
 
250950 3-hydroxyiso-
valeric acid 
[107]
Adenylosuccinate lyase (ADSL) deficiency 
 
103050 Succinyl-
adenosine 
[98] 
Non ketotic hyperglycinaemia (glycine cleavage 
system defect) 
 
605899 Glycine [101]
Pyruvate dehydrogenase deficiency 
 
312170 Lac & alanine [55] 
Galactosaemia 230400 Elevated 
galactitol 
[55] 
 
Table 2.2: Disease-specific biomarkers of inherited metabolic disorders identified using in 
vivo brain MR spectroscopy 
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An extensive review of the case series and reports of MRS derived brain metabolite patterns 
in numerous IMD is available [55]. This review highlights some of the challenges in applying 
the MRS technique to the study of rare diseases. As well as the paucity of individual patients 
with a given disease, the case reports of neuroimaging and MRS have often sampled only one 
time point in the disease process. This coupled with the normal age-dependent alterations in 
brain metabolite profiles means that often “we are tracking moving targets” [55]. When 
numbers being studied are small, the impact of non-biological causes of data variability 
becomes more important, such as the discrepancies between different data acquisition 
protocols and post-processing techniques.  
 
This thesis demonstrates that it is possible to overcome some of these obstacles, with the use 
of standard acquisition and processing protocols, the combination of data from multiple 
scanner systems, and with the use of large comparator datasets, and that progress towards 
“tracking the moving targets” has been made. 
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Chapter Three 
 
3. General Methods 
 
3.1. Research Ethical Approval 
Magnetic resonance spectroscopy was established initially at Birmingham Children’s Hospital 
(BCH) in the context of diagnosis and evaluation of paediatric brain tumours. Approval for 
this study included extension to facilitate the acquisition of MRS data on children with other 
neurological disorders. ("A comparison of magnetic resonance spectroscopy and tumour 
genetics in childhood brain tumours." Dr A Peet, Dr R Grundy. Reference: LREC 5512M[B].) 
 
Subsequently further Research Ethics Committee approval for continuation and extension of 
the project was obtained. (“Multimodal investigation of childhood metabolic 
neurodegenerative disease”. REC Reference: 09/H1206/112, Birmingham, East, North and 
Solihull Research Ethics Committee, National Research Ethics Service). This includes 
provision for the acquisition of in vivo functional imaging data (including MRS and DTI) 
from patients with metabolic and neurological disorders, and also from patients undergoing 
imaging for other indications as a putative control cohort. The approval also includes 
obtaining body fluid samples for in vitro analysis. MRS and diffusion studies are also 
undertaken in some children under clinical indications (including investigation of possible 
mitochondrial disorder or possible creatine deficiency). Consent for access to medical records 
in these cases was also sought prior to accessing this information. 
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3.2. In vivo Magnetic resonance spectroscopy methods 
3.2.1. Standard in vivo MRS Acquisition 
A standard protocol for MRS acquisitions from non-oncological cases has been employed in 
this study (table 3.1). Single voxel spectroscopy was performed concurrently with MRI scans 
by clinical radiographers. Research-based MRS acquisitions were performed after other 
clinically indicated imaging sequences were completed. General anaesthesia or oral sedative 
drugs were used to facilitate MRI/MRS as indicated according to the Birmingham Children’s 
Hospital policies. 
 
MR scanner field strength 1.5 Tesla 
MR scanners Siemens Avanto 
Siemens Symphony Magnetom NUM4 
GE Signa Excite & HDx 
Voxel dimensions 2x2x2cm (8cm3) 
Voxel positions Left basal ganglia 
Right parietal white matter 
Volume selection method Point RESolved Spectroscopy (PRESS) 
sequence 
Water suppression Chemical Shift Selective (CHESS) 
Echo time (TE) 30ms & 135ms 
Repetition time 1500ms 
Number of repetitions 128 
Table 3.1: Standard MRS acquisition parameters employed in the present study. 
 
A water unsuppressed FID was also obtained from each voxel to enable subsequent eddy 
current corrections and metabolite concentration quantification by scaling to the water peak. 
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3.2.2. Voxel positioning 
Voxels were placed in two standard positions, one sited within the left basal ganglia and the 
second in right parieto-occipital white matter. Standard positioning of the voxels in these 
areas was selected as these regions are frequently involved in neurometabolic disease. A 
standard position with well defined landmarks also facilitated the independent acquisition of 
data by radiographers without need to consult clinicians on the selection of position. Use of a 
standard voxel position across all cases and controls allowed direct comparison between cases 
without need to consider the effects of differing anatomical positions. The standard voxel 
positioning protocol did mean, however, that in some cases the MRS was acquired from 
normal appearing brain regions rather than over other abnormal regions.  
 
Voxels were manually positioned on the MR scanner control station by reference to the 
standard three-plane anatomical (T1 and T2) image sequences. A composite 3 plane image 
view (Siemens) or screen capture images and spectrum protocol tagging (GE) were stored to 
allow subsequent re-examination and verification of the voxel localisation. 
 
3.2.3. Spectral Processing 
Raw data from the MR scanner were transferred for subsequent offline post-processing. The 
FID raw data was automatically processed using LCModelTM software as described above. 
LCModelTM automates the post-processing steps discussed above including lineshape and 
baseline corrections, and zero and first-order phase corrections. It employs a constrained least 
squares analysis method to provide the best fit from a basis set containing seventeen 
metabolite and nine macromolecular and lipid spectra. LCModel generated two outputs, one 
with and one without the application of an eddy current correction. Metabolite quantification 
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was achieved by normalization to the water reference peak area, with an assumption made 
that the water concentration is constant (35880mM).  
 
The outputs generated by LCModel include a portable document file (pdf) with images of the 
original data spectrum, fitted spectrum, unfitted residual and the baseline applied (figure 3.1) 
together with listings of the metabolite concentrations derived and the Cramér-Rao lower 
bounds. The file also documents the linewidth of the spectrum expressed as the full width at 
half maximum (FWHM) and the signal to noise ratio. A separate text file also contains the 
metabolite concentrations, Cramér-Rao lower bounds as well as coordinate points for the 
original data spectrum, fitted spectrum, baseline function and the constitutive component 
spectra for each metabolite fitted. 
 
 
Figure 3.1: Example LCModel spectrum output. Original data spectrum line (black), 
LCModel fitted line (red), fitted baseline (arrow), and residual (i.e. difference between 
original data spectrum and LCModel fitted line, dotted arrow). 
 
baseline 
residual 
LCModel fit line 
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3.3. Data Quality Assessment 
 
Figure 3.2: Quality assessment evaluation flowchart for MRS studies 
 
Each individual MRS acquisition was quality assessed as outlined in figure 3.2 by inspection 
of the LCModelTM spectral output (pdf file). The quality assessment process was adapted 
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from the procedure applied at Birmingham Children’s Hospital in the assessment of spectra 
acquired from brain tumours. The quality assessment process initially ensured correct patient 
demographics, and then assessed the voxel position by examination of the three-plane images 
of the voxel position. This evaluates the contents of the voxel as well positioning factors that 
could adversely affect the signal detected. As two standard locations were acquired, proximity 
to scalp and bone was not expected to be a significant issue unlike for brain tumours when the 
location was determined by the location of the tumour. Having evaluated voxel position, 
several parameters were evaluated including visual inspection of the baseline, water 
suppression, phasing, lipid contamination, eddy current and other artefacts. LCModel output 
includes two objective measures of quality, namely the FWHM which reflects adequacy of 
shimming, and is an estimate of the linewidth of the in vivo spectrum, and the signal to noise 
ratio (SNR). For brain tumour spectra, an SNR >5 is considered adequate, for metabolic cases 
a higher SNR is required because of the need to observe more subtle alterations in lower 
concentration metabolites.  
 
3.4. Metabolite and Spectral Data Processing 
Metabolite concentrations for defined groups of patients were exported from the LCModelTM 
text file to a standard spreadsheet package (Excel, Microsoft) using a specifically developed 
software programme script (developed in Matlab 7.1, The Mathworks Inc. by JED, N.Davies 
and E.Orphanidou). Metabolite concentrations from GE spectroscopy studies were adjusted 
by a specific factor derived from the analysis of the inter-compatibility of data from the 
different scanner systems used (see Chapter 4). The programme also extracted the coordinate 
points for the original data spectrum, fitted spectrum, and baseline function. The spectral 
output from LCModel binned each spectrum from the Siemens scanner in to 496 data points, 
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whereas GE spectra were binned in to 399. An interpolation technique was applied to the 
spectral coordinate points to convert the GE spectra to 496 points to allow direct comparison 
of GE and Siemens spectra. 
 
Mean spectra for specified cohorts were then generated by combination of each fitted 
spectrum after subtraction of the specific baseline function from each individual spectrum, 
and the mean and standard deviation of the spectra derived for each point. GE spectra were 
further adjusted by a specific calculated factor (see Chapter 4).  
 
3.5. Statistical Methods 
Statistical analysis was performed using SPSS Statistics 17.0 (SPSS Inc.). Concentrations of 
metabolites were compared between cohorts by use of either Student’s t-test or the non-
parametric Mann-Whitney U-test. Test of significance of trends between multiple groups was 
performed using analysis of variance (ANOVA).  
 
Principal component analysis (PCA) performed using SPSS Statistics was employed to reduce 
dimensions in complex datasets with large numbers of variables (such as plasma quantitative 
amino acid profiles). PCA was also implemented in the analysis of body fluid metabolite 
profiles as described below. 
 
3.6. Clinical Information 
Relevant clinical information pertaining to study subjects was obtained from the medical 
records and from clinical databases held at the Birmingham Children’s Hospital. Data 
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included past medical history, qualitative radiological reports of previous and current MRI 
studies, and biochemical assays.   
 
Biochemical results from clinical investigations were extracted from the medical records or 
from the clinical pathology results reporting system and tabulated in a standard spreadsheet 
(Excel, Microsoft). This included in particular quantitative assays of plasma amino acids 
determined using a standard method (cation exchange chromatography and photometric 
detection following derivatization with ninhydrin) in a single NHS service laboratory. Normal 
quoted control ranges were also obtained for all biochemical parameters extracted. 
 
3.7. In vitro NMR Spectroscopy 
One dimensional proton NMR spectroscopy of metabolite test solutions and a number of body 
fluid samples (urine and cerebrospinal fluid) from the patients was undertaken at the Henry 
Wellcome Building for NMR Spectroscopy, University of Birmingham. 
 
3.7.1. Sample Preparation 
3.7.1.1.Metabolite Test Solutions 
Test solutions of (a) 20mM succinic acid plus 20mM creatine and (b) 50mM glycerol plus 
20mM creatine (all reagents Sigma-Aldrich Ltd, Dorset, UK) were made. 100μL/L 
gadolinium contrast agent (dimeglumine gadopentetate, ‘Magnevist’, Bayer, Berkshire UK) 
was added to shorten the T1 component.  
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The pH of the solution was measured using a standard calibrated pH electrode (Mettler 
Toledo). The pH of 800μL aliquots of the succinate-creatine test solution was adjusted by 
addition of NaOH (1M) to give a series of pH values (pH 4 to 11).  
To 560μL of the test solution were added 40μL of deuterium oxide (D2O) to provide a lock 
signal, and 5μL of 50mM 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP) to 
provide a chemical shift reference (0ppm).  
3.7.1.2.Body fluid samples 
Random collection midstream samples of urine were collected into sterile universal 
containers. Cerebrospinal fluid samples were collected into sterile universal containers at the 
time of clinical indicated lumbar puncture by sterile technique. All samples were transferred 
immediately to the clinical biochemistry laboratory and then aliquoted and frozen at minus 
80oC prior to transfer for analysis. Samples were defrosted to room temperature immediately 
prior to analysis.  
3.7.1.2.1. Urine samples 
A standard phosphate buffer solution (pH 7.4) was made (1.44g Na2HPO4, 0.26g NaH2PO4 
added to 10mL D2O made up to total volume of 50ml with sterile distilled water), after the 
method described by Beckonert et al [108] to provide stabilisation of the urinary pH.  
 
 To 400μL of urine was added 200μL of phosphate buffer solution and 5μL of 50mM TSP. 
The pH of the sample was documented. 
 
3.7.1.2.2. CSF Samples 
To 400μL of CSF was added 200μL of D2O and 5μL of 50mM TSP. The pH of the sample 
was documented. 
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3.7.2. NMR Spectroscopy Acquisition 
Samples were transferred to Wilmad 7” length, 5mm diameter glass NMR tubes (Sigma 
Aldrich Ltd) for NMR experiments. NMR spectroscopy experiments were performed on a 
vertical bore Bruker Avance 500MHz spectrometer fitted with an HCN cryoprobe, using 
Topspin software. A standard pulse-acquire sequence with water presaturation was used with 
an acquisition of 16K complex points with bandwidth of 7200Hz. 
 
The sample tube was loaded into the spectrometer and the sample temperature set to 298K. 
Iterative tuning and matching was performed on the proton nucleus channel. The sample was 
automatically locked to the deuterium signal and lock gain adjusted. Optimal shimming was 
achieved by initial loading of a standard shim set followed by use of an automatic shimming 
algorithm and also further manual shimming if required. The 90o pulse was automatically 
calibrated and receiver gain automatically set. An initial brief acquisition with n=4 scans was 
performed and if satisfactory a full acquisition with n=32, 128 or 256 scans performed. FID 
data files and associated acquisition parameter files were transferred to a separate work station 
for subsequent analysis. 
 
3.7.3. Metabolite identification and fitting 
The one dimensional proton spectra were processed and viewed using Chenomx NMR Suite 
(v7.1, Chenomx Inc. 2011). The FID was imported into the Chenomx Processor module. 
Chemical shift was automatically calibrated to the TSP peak and the documented pH of the 
sample entered. Automatic zero filling, 0.5Hz line broadening, phase correction and baseline 
corrections were applied. The processed spectrum was exported to the Chenomx Profiler 
module. 
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This enabled visual inspection of the spectrum and identification of metabolite peaks seen. 
Metabolite fitting was performed by automated fitting of the standard Chenomx metabolite 
library (302 compounds) and the metabolite fits subsequently inspected. Alternatively 
targeted fitting of expected metabolites was performed. 
 
Metabolite peaks not accounted for by expected/ standard metabolite spectra were putatively 
identified by reference to, and comparison with, chemical shift parameters and experimental 
spectra from the Human Metabolome Database (HMDB, www.hmdb.ca, [109]).  
 
3.7.4. Principal component analysis 
To examine differences in body fluid spectral profiles between different cohorts of patients 
and controls an unsupervised principal component analysis (PCA) was employed. This 
obviated the requirement for specific metabolite identification prior to analysis, but enabled 
key differences in metabolite profiles to be identified. The identity of metabolites contributing 
to the differentiation of groups could then be established from the PCA loadings plots. 
 
FID files from the Bruker spectrometer were imported into the 1D NMR visualisation and 
processing application Dangerplotpy (http://www.pipegrep.co.uk/dangerplotpy/, M.Wilson). 
Spectra were manually phase corrected and chemical shift referenced to the TSP peak at 
0ppm. Processed spectra were saved and grouped into relevant cohorts. 
 
A software script (M.Wilson) executed in R (v2.13.0, The R Foundation for Statistical 
Computing) was used to further process the cohorted spectra. This applies automatic water 
filtering, line-broadening and baseline correction to each spectrum. Chemical shift regions 
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were selected to include as appropriate 0.4-4.5ppm plus/minus 6-10ppm with removal of the 
water peak region. The signal was normalised to the total integral of peaks and spectral 
binning applied. 
 
The script then executed a principal component analysis on the processed spectra generating 
principal component scores plot and loadings plots for first and second principal components. 
Loadings plots could then be visually examined to identify spectral regions and specific 
metabolite peaks that distinguished clusters of cases seen on the scores plot. 
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Chapter Four 
 
4. Preparatory Technical Development. 
 
4.1. Patient Cohort Investigated with MRS 
350 MRS studies with good quality data were available from 307 children who had studies 
performed for non-oncological indications at Birmingham Children’s Hospital. 58% of 
children were male. The distribution of age at time of the MRS investigation (figure 4.1) 
showed a positive skew indicating that the majority of MRS are undertaken in younger 
children but with a smaller number having the study throughout later childhood up to mid-
teenage years. The mean age at time of MRS study was 4.6 years, median 3.3years, range 0.0-
17.4 years. 
 
A wide range of diseases was represented by the cases acquired (figure 4.2). A specific 
diagnosis of an IMD was known in 104 (34%); 28 (9%) had a known specific non-IMD 
diagnosis; 175 (57%) did not have a known diagnosis at time of the MRS. Specific diseases 
identified with substantial cohorts of MRS data available included organic acidaemias 
(propionic acidaemia, methylmalonic aciduria, glutaric aciduria), urea cycle disorders, 
mucopolysaccharidoses and the mitochondrial disorders. 
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Figure 4.1: Histogram of age at time of MRS examination (6 month bins). 
 
        
Figure 4.2: Bar chart of numbers of children with specific known diagnoses in whom MRS 
was performed. 
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4.2. Data Quality Assessment 
It was important to establish that metabolite data generated were reliable. Several components 
of data fidelity were assessed, including (a) case-by-case spectral quality control analysis, (b) 
post-processing technique analysis and (c) inter-scanner data compatibility (i.e. could data 
from two different MRI systems be combined and directly compared). 
 
4.2.1. Spectral quality assessment analysis 
To evaluate the ability of the research protocol to generate a high rate of good quality MRS 
data, a detailed quality assessment was undertaken. 204 studies from the Siemens scanner and 
52 studies from the GE scanner were evaluated according to the quality assessment protocol 
(figure 3.2). 
 
4.2.1.1.Siemens quality assessment analysis 
Data from 204 separate studies completed on Siemens scanner were analysed.  370 voxel 
acquisitions (echo time 30ms) were analysed. Both the non-eddy current and eddy current 
corrected data sets were analysed.  
 
Of the 370 voxel acquisitions assessed, only 18 (4.9%) failed quality assessment analysis of 
both non-eddy current corrected and eddy-current corrected data sets (table 4.1). Of these 
cases, 10 were due to missing data, two due to inadequate signal to noise ratio, and four due to 
problems with phasing, baseline or water suppression. Two failed because of inappropriate 
voxel localisation (one in cerebrospinal fluid (CSF) completely, one unclear from stored 
images if in cerebellum). In a further 19 acquisitions there was some concern over voxel 
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location, mainly encroachment onto ventricle and therefore CSF contamination of voxel; 
these cases were not excluded at this stage.  
 
4.2.1.2.GE quality assessment analysis 
Data from 52 cases acquired using the GE scanner were analysed. Of these, 8 were excluded 
because of an incorrect echo time parameter (TE 35ms) or missing data. Of the 44 
acquisitions assessed 93.2% had useable data; in all cases that passed the quality assessment 
analysis the eddy-current corrected data was useable, and it was also observed that in many 
cases the quality of the spectrum produced was substantially higher in eddy-current corrected 
data (for example see figure 4.3) even though an eddy current correction should not 
significantly alter the SNR per se.  
 
Thus overall good quality spectral data was obtained in 93-95% of cases. 
 
 
Siemens Scanner System n = 
370 
Reasons 
Both ECC and non-ECC 271  
Non-ECC only 74  
ECC only 7 phasing/ baseline/ water suppression (5), SNR (1), other (1) 
Neither 18 Voxel location (2). No data (6), SNR (2), phasing/ baseline/ water 
suppression (4), no water unsuppressed file (4) 
 
GE Scanner System n = 
44 
Reasons 
Both ECC and non-ECC 36  
Non-ECC only 0  
ECC only 5 SNR and water suppression (1), SNR (4) 
Neither 3 SNR (3) and baseline/ water suppression (3) 
 
Table 4.1: Results of quality assessment analysis of MRS studies  
on Siemens and GE scanner systems 
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Figure 4.3: Example of LCModel spectrum output from GE system scanner showing 
improved SNR with eddy current correction. (A) Non-eddy current corrected, (B) Eddy 
current corrected. In (A) and (B) upper panel is the fitting residual, lower panel original data 
spectrum line (black), and LCModel fitted line (red). 
 
4.2.2. Post-processing technique analysis 
As described above, post-processing of raw spectroscopy data was performed using 
LCModelTM software [44]. The software processes the raw data using two methods, with and 
without eddy current correction, generating two output files. As demonstrated above, for an 
individual study one or other of these outputs may not pass the quality control filter, and so it 
was necessary to evaluate whether the two methods were inter-changeable, producing directly 
comparable metabolite values. To make this evaluation, data from cases where both the eddy-
current corrected (ECC) and non-eddy current corrected (non-ECC) outputs met the quality 
assessment criteria were selected, and a paired-sample analysis applied to compare 
concentration estimates of the major metabolites detected, namely total creatine, myo-inositol, 
total choline, total N-acetylaspartate and glutamine+glutamate.  At this stage consideration of 
anatomical position of voxels was not included in the analysis. 
 
A B 
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4.2.2.1.Siemens data 
299 studies acquired using the Siemens system were analysed (figures 4.4 and 4.5). For most 
of the major metabolites with the exception of choline and glutamine+glutamate there was 
only a small (although consistently statistically significant) difference in metabolite values as 
evaluated by paired sample t-test. There was no difference detected in choline concentrations. 
The ECC method gave a higher estimate of glutamine+glutamate.  
 
The quality assessment process had highlighted that in many cases the application of the ECC 
method by LCModel generated artefacts such that the data did not meet the quality 
assessment criteria, whereas the corresponding non-ECC method data did meet the quality 
assessment criteria. It was therefore decided that Siemens data should be solely processed 
using the non-ECC method, except in the few cases where the non-ECC method data did not 
meet the quality assessment criteria but the ECC method did (circa 1.9%).  
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Figure 4.4: Bar chart of mean brain metabolite concentrations determined for Siemens MRS 
data with and without eddy current correction. (n=299 studies. Paired sample t-test, * p<0.05, 
† p<0.01. Error bars indicated standard deviation). 
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Figure 4.5: Plot of mean spectra for Siemens in vivo MRS data from brain of n=299 studies 
processed with and without eddy current correction.   
 
 
4.2.2.2.GE Data 
118 studies acquired using the GE system were analysed (figures 4.6 and 4.7). In this case, the 
ECC method generated significantly (p<0.001 by paired sample t-test) higher metabolite 
concentrations for all of the major metabolites.  
 
These data indicate that metabolite concentration values derived from the GE scanner using 
ECC and non-ECC processing methods were not directly comparable. Since the quality 
assessment process found that for the GE scanner in the majority of cases the ECC data met 
the quality assessment criteria, it was decided that data from the GE scanner should be 
processed by the ECC method. 
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Figure 4.6: Bar chart of mean brain metabolite concentrations determined for GE MRS data 
with and without eddy current correction. (n=118 studies. Paired sample t-test, * p<0.05, † 
p<0.01. Error bars indicated standard deviation). 
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Figure 4.7: Plot of mean spectra for GE in vivo MRS data from brain of n=118 studies 
processed with and without eddy current correction.   
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4.2.3. Inter-scanner data compatibility 
The potential contribution of different scanner systems to “instrumental variation” in the 
metabolite data was assessed. 
 
4.2.3.1.Initial inter-scanner analysis 
Comparison of the mean spectra generated above was undertaken (figure 4.8). By visual 
inspection, data generated by the non-ECC method from the GE system corresponded with 
the non-ECC method data from the Siemens system, whereas the GE ECC data gave 
significantly higher spectral peaks. This was confirmed by comparison of the mean metabolite 
concentrations for each group (figure 4.9): the absolute difference in metabolite concentration 
was smaller between GE non-ECC and SM non-ECC than between GE ECC and SM non-
ECC data, although differences remained statistically different.  
 
As a first approximation, data from studies on the GE scanner could be processed using the 
ECC method, and then scaled to approximate to the values obtained using the non-ECC 
method which is comparable to the data obtained using the Siemens system. A scaling factor 
applied to the major metabolites was derived from the average ratio of ECC:non-ECC values 
from the dataset (ratio applied to ECC data, ~0.65). 
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Figure 4.8: Overlay plots of mean in vivo brain MR spectra for Siemens (n=299) non-eddy 
current corrected, and GE (n=118) eddy current corrected and non-eddy current corrected 
datasets. 
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Figure 4.9: Bar chart of mean brain metabolite concentrations for Siemens non-eddy current 
corrected, and GE eddy current corrected and non-eddy current corrected datasets. 
Independent sample t-test, † p<0.01. Error bars indicated standard deviation). 
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4.2.3.2.Detailed inter-scanner analysis 
A further detailed analysis of inter-scanner compatability was then undertaken, this time 
taking account of the different anatomical regions being analysed.  
4.2.3.2.1. Basal ganglia 
215 basal ganglia voxel acquistions from the Siemens scanner were compared with 104 basal 
ganglia voxel acquistions from the GE system, combining both those with and without MRI 
abnormalities. In line with the previous analysis, all data from the GE system were processed 
using the ECC method. The metabolite concentrations were compared by independent sample 
t-test (figure 4.10). As seen in the prior analysis, all major metabolite values were 
significantly different, with all except lactate significantly higher for GE system with the ECC 
method. The lactate was significantly lower (p<0.05) for the GE system ECC method than 
Siemens system data, but there was a correspondingly significantly higher concentration of 
macromolecules/lipids at 1.3ppm in the GE data suggesting that the signal at ~1.3ppm was 
being assigned more to macromolecule/lipids than lactate. Glutamine was higher for GE data 
but not significantly different from Siemens data. 
 
A plot of mean metabolite value for Siemens and GE systems was generated (figure 4.11). A 
linear regression line fitted to the data points demonstrated a very strong linear correlation (R2 
= 0.989); the regression coefficient derived from the linear regression fit of 1.26 could be 
applied to the metabolite data from GE scanner (ECC method) to approximate to the Siemens 
scanner data set. 
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4.2.3.2.2. White matter: 
The analysis was repeated for data from the white matter voxel. Thus 183 white matter voxel 
acquistions from the Siemens scanner were compared with 92 white matter voxel acquistions 
from the GE system, combining both those with and without MRI abnormalities. Again all 
data from the GE system were processed using the ECC method. The metabolite 
concentrations were compared by independent sample t-test (figure 4.10). Again, all major 
metabolite concentrations were signicantly higher from GE system. Glutamine and taurine 
concentrations were higher in GE dataset but not significantly different from Siemens data.  
 
A plot of mean metabolite value for Siemens and GE systems was generated (figure 4.11). 
Here the linear regression line fitted to the data points again demonstrated a strong linear 
correlation (R2 = 0.987); the regression coefficient derived from the linear regression fit of 
1.25 could be applied to the metabolite data from GE scanner (ECC method) to approximate 
to the Siemens scanner data set. 
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Figure 4.10: Bar charts of ratio mean metabolite concentration in (top) basal ganglia and 
(bottom) white matter for Siemens (normalised to 1) and GE systems. Independent sample t-
test, * p<0.05, † p<0.01. 
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Figure 4.11: Plot of mean metabolite concentration in (top) basal ganglia and (bottom) white 
matter from two scanner systems and linear regression analysis. Each point represents a 
different metabolite. Error bars: horizontal (Siemens) and vertical (GE) standard deviation of 
metabolite concentrations. Dotted line: linear regression line. 
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Figure 4.12: Bar chart of GE:Siemens ratio for mean metabolite concentration comparing 
basal ganglia and white matter. 
 
 
4.2.4. Discussion – quality assessment 
The variability in metabolite data obtained by MRS is generated from several sources. The 
“biological variation” in metabolite data is that which is of interest in answering clinical 
research questions, i.e. alterations in metabolite concentrations due to pathological or 
physiological reasons. However, variability may also be generated by “instrumental variation” 
and “acquisition variation”. Minimising acquisition variation requires a set standard pulse 
sequence for acquisiton, such that all acquistion parameters remain the same between cases. 
Furthermore, voxel positioning should be standard and relies on radiographer input. This 
factor can be further explored by post hoc analysis using recorded voxel localisation images.  
 
Instrumental variation arises when different hardware systems are used to obtain data, which 
may have different configurations and designs that result in systematic differences in data. 
The analysis above demonstrates that data from the two scanner systems pertaining to the 
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current work are systematically different. It should be noted that the data presented are not a 
direct comparison of the two scanners, as the datasets being compared are from different 
cohorts of children. That said, the cohorts being compared are large, with no overt systematic 
differences in age, gender or disease characteristics, and so should provide a representative 
spread of data. 
 
A number of factors may contribute to this instrumental variation. Firstly, the two systems 
have differing water suppression modules, with the GE system considered to have a more 
“aggressive” water suppresion system that may affect the integrity of metabolites signals in 
proximity to the water peak (i.e. close to 4.0ppm). Secondly, the radiofrequency coils have 
different technical specifications, in particular the GE system RF coil is composed of an array 
of coils, each of which receives and collects an individual FID, whereas the Siemens systems 
operate in an effective single channel (CP) mode. Thus the post-processing software (e.g. 
LCModelTM) has to handle the  combination of this data, and there may be limitations in how 
that is performed regarding differences in phasing between coil elements.  
 
Further variability may be introduced by post-processing methodologies. In particular, this 
analysis has demonstrated the systematic differences in data generated by use of ECC and 
non-ECC methods. It is important, therefore, that a single methodology is applied as far as 
possible to eliminate this systematic source of data variability. The analysis above dictates 
that for data from Siemens scanner, the non-ECC method is used, and the ECC method for 
data from the GE scanner. Importantly it has been observed that for newer generation MR 
systems eddy currents may not represent a significant issue, and this is observed for the 
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Siemens data here where the systematic application of a post-processing eddy current 
correction did not improve data quality [42]. 
 
Methods have been proposed to enable comparison of data acquired from different scanner 
systems. These are based upon the concept of using known conversion factors to translate data 
from the GE system to be comparable to Siemens system data. The first approach made the 
assumption that GE non-ECC data was comparable to Siemens non-ECC data, and applied a 
conversion factor to GE ECC data (where this needed to be used if the non-ECC data was not 
available) to convert it to the GE non-ECC data ranges. Later analysis found that this method 
provided only an approximation. The second approach entailed systematic usage of GE ECC 
data, and applied a conversion method to this data to translate it to be comparable to the 
Siemens non-ECC data using a static ratio applied to all metabolite data acquired from the GE 
system.  
 
While it would be ideal to use one scanner system for all data acquisition, different clinical 
settings have differing scanner systems, and even within one institution more than one 
scanner system may be present. Thus for single centre studies, and more so for multi-centre 
studies, data from differing systems is likely to be encountered. Given the importance of 
multi-centre studies, particularly for rare diseases such as those under consideration in the 
present work, approaches to combining data from different systems must be considered, 
although the potential problems from acquisition and instrumental variation in the data must 
be accounted for before biological conclusions drawn from the data. To this end, 
“reproducibility studies” are required to evaluate the ability to generate combinable data from 
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different studies. This could include the use of static test objects (phantoms) loaded with 
known concentrations of metabolites, as well as by scanning volunteers on multiple scanners. 
 
4.3. Metabolite concentration age variation analysis 
Previous studies have established that MRS-detectable brain metabolites vary with age (see 
Chapter 2, [67]). To assess the variation in metabolites within the current cohort, metabolite 
data from studies that had passed quality assessment were analysed. To remove potential 
confounding from inter-scanner variability, only data acquired using the Siemens system were 
included here. This analysis included 215 voxel acquisitions from basal ganglia and 183 from 
white matter. All studies were included irrespective of diagnosis or MR imaging features. 
Studies were analysed first in age cohorts (0-3m, 3m-1y, 1-2y, 2-5y, 5-10y, >10y; table 4.2 
and figure 4.13) with differences between age cohorts evaluated by one-way analysis of 
variance (ANOVA). Data were then evaluated with age as a continuous variable (figure 4.14), 
with correlation between age and metabolite concentration evaluated by calculation of the 
Pearson correlation coefficient. Mean spectra for each age cohort were generated for basal 
ganglia and white matter (figure 4.15). As previously reported, the most significant alterations 
in metabolites occurred during the first year of life, particularly the first 6 months. 
 
4.3.1. Total N-acetylaspartate + N-acetylaspartylglutamate  
The concentration of tNAA increased with age in both basal ganglia and white matter, as 
determined both by ANOVA analysis of age cohorts and by correlation analysis (Pearson 
coefficient 0.34 and 0.62 for basal ganglia and white matter respectively, indicating moderate 
to high correlation). Previous studies have demonstrated a similar finding [67]. The biggest 
increase was seen during the first year of life but the trend continued throughout childhood. 
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4.3.2. Creatine 
Creatine did not alter significantly with age in the basal ganglia, although there did appear to 
be a trend towards increasing with age, but creatine did increase with age in white matter 
(r=0.30, p<0.01). As with tNAA, the largest increase was seen in the first 6 months of life. 
Pouwels et al reported a similar finding in basal ganglia, but found a trend towards falling 
creatine concentration with age in white matter, albeit based on a smaller cohort of children 
[67]. 
4.3.3. Choline compounds 
Total choline was seen to decrease with age in both white matter and basal ganglia, though 
once again the biggest changes were demonstrated in the first year of life, consistent with 
previous studies [67].  
4.3.4. Inositol (Ins) 
Myo-inositol showed a weak correlation with age, with decreasing concentration with age in 
basal ganglia (r=-0.18). This trend was again similar to that previously reported. 
4.3.5. Glutamate & Glutamine  
Analysis of the composite result for glutamate+glutamine demonstrated no significant change 
in concentration with time, although inspection of the cohort trends suggests an increase in 
both white matter and basal ganglia in the first year of life. Evaluating the separate 
concentrations of glutamate and glutamine found that glutamate increased with age in both 
basal ganglia and white matter (r=0.20 and 0.23 respectively), while glutamine decreased with 
age in white matter but did not alter significantly with age in basal ganglia (r=-0.19 and -0.07 
respectively). Pouwels et al found that glutamate decreased with age in both white matter and 
basal ganglia in contradiction to the current data, but they found that glutamine showed a 
strong trend to decrease with increasing age in white matter consistent with the data presented 
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here [67]. They also demonstrated a strong trend to decreasing total glutamine+glutamate 
with age in both regions. 
4.3.6. Taurine 
As has been reported previously, taurine concentrations fell with increasing age in both brain 
regions analysed. It is thought that taurine may have specific functions in early neuronal 
development since it is detected at much higher concentrations in the neonatal period [67]. 
4.3.7. Lactate 
No specific trend was seen in lactate concentration (figure 4.14) as it is not normally detected. 
It was evident that most of the cases with high lactate levels were in the youngest patients, 
reflecting the occurrence of both aggressive early onset mitochondrial disease and also the 
propensity of this age group to suffer hypoxic ischaemic insults, both of which cause elevated 
brain lactate. The age cohort mean spectra (figure 4.15) have wide standard deviations around 
the lactate peak indicating the occurrence of cases with significantly increased levels on a 
background of most cases having no detectable lactate. 
4.3.7.1.Lactate in mitochondrial disorders 
 
A specific comment on the detection of lactate in mitochondrial disease is warranted, since 
the detection of elevated brain lactate by MRS is reported to be suggestive of mitochondrial 
disease, caused by the shift from oxidative phosphorylation to glycolysis [110-112]. The 
mitochondrial diseases are a group of disorders caused by inherited abnormalities of the 
electron transport chain [12, 113]. However, the sensitivity of lactate may not be high [114], 
and its detection can vary during the course of the disease process and across anatomic 
regions within the brain [115-117]. 
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15 MRS studies were available from patients with mitochondrial disorders confirmed on the 
basis of electron transport chain complex activity assay or genetic abnormality, all of whom 
had evidence of cerebral involvement evidenced by either neurologic symptoms or MR 
imaging abnormalities. A cut-off of 0.6mM lactate was used since this was the concentration 
above which the Cramér-Rao lower bounds were less than 30%. Using this definition, 
elevated brain lactate was detected in 4/15 patients in basal ganglia and 6/15 in white matter, 
corresponding to a test sensitivity of only 27-30% for the identification of mitochondrial 
disease, confirming previous reports of the limited sensitivity of MRS-detected brain lactate 
as a stand-alone test [114]. (See Appendix D for preliminary results evaluating the use of a 
multivariate statistical analysis approach to improving the diagnostic power of MRS in this 
context). 
 
Mean metabolite concentration (mM (standard deviation)) 
Basal ganglia  
 n Cr Ins tNAA Gln+Glu tCho Tau 
0-3m 20 3.90 (0.89) 3.54 (0.92) 2.93 (0.90) 5.39 (2.12) 1.32 (0.31) 1.33 (0.54) 
3m-1y 37 4.14 (1.02) 2.77 (1.33) 3.87 (1.31) 5.97 (1.95) 1.20 (0.32) 0.91 (0.59) 
1y-2y 19 4.50 (0.80) 2.70 (0.82) 4.41 (1.09) 6.31 (1.51) 1.19 (0.19) 0.85 (0.41) 
2y-5y 62 4.51 (0.85) 2.63 (0.62) 4.79 (0.94) 6.28 (1.62) 1.10 (0.22) 0.75 (0.47) 
5y-10y 44 4.36 (0.83) 2.61 (0.71) 4.75 (1.07) 6.53 (1.68) 1.08 (0.24) 0.41 (0.42) 
>10y 33 4.27 (0.73) 2.48 (0.64) 4.96 (0.83) 6.32 (1.47) 0.94 (0.16) 0.15 (0.29) 
ANOVA 
p-value  0.07 0.00 0.00 0.22 0.00 0.00 
        
White matter  
 n Cr Ins tNAA Gln+Glu tCho Tau 
0-3m 17 2.16 (0.83) 3.67 (1.36) 1.97 (1.22) 4.06 (1.98) 1.00 (0.40) 1.14 (0.75) 
3m-1y 26 3.09 (0.56) 3.19 (0.93) 3.52 (0.90) 5.06 (1.51) 1.15 (0.20) 1.04 (0.51) 
1y-2y 14 2.99 (0.78) 2.70 (1.23) 4.02 (0.76) 5.11 (1.96) 1.11 (0.37) 0.62 (0.35) 
2y-5y 56 3.16 (0.38) 2.74 (0.50 4.57 (0.63) 5.08 (1.50) 1.06 (0.21) 0.42 (0.31) 
5y-10y 37 3.11 (0.54) 2.69 (0.65) 4.64 (0.87) 4.89 (1.37) 1.08 (0.21) 0.22 (0.24) 
>10y 33 3.36 (0.49) 2.99 (0.86) 5.52 (0.85) 4.92 (1.44) 0.98 (0.12) 0.10 (0.21) 
ANOVA p-
value  0.00 0.00 0.00 0.29 0.09 0.00 
Table 4.2: Variation in mean MRS derived metabolite concentrations across different age 
cohorts. 
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Figure 4.13: Line chart showing age variation in mean metabolite concentrations in basal 
ganglia (upper panel) and white matter (lower panel). (Here Glx represents Gln+Glu) 
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Figure 4.14: (see also next page) Scatter plots of concentration against age for each 
metabolite determined in basal ganglia (, n=215) and white matter (, n=183).  
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Pearson coefficient for correlation between age and metabolite concentration 
 
 Cr Ins tNAA Gln+Glu Gln Glu tCho Tau 
Basal ganglia 0.05 -0.18† 0.34† 0.09 -0.07 0.20† -0.36† -0.57† 
White matter 0.30† -0.07 0.62† 0.02 -0.19† 0.23† -0.16* -0.56† 
       
 
Figure 4.14: (see also previous page) Scatter plots of concentration against age for each 
metabolite in basal ganglia (, n=215) and white matter (, n=183). Correlation coefficients 
for age and metabolite concentration, *, p<0.05; †, p<0.01. 
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Figure 4.15: Mean spectra from white matter voxel for each age cohort. n=183. Shaded area 
indicates standard deviation. 
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Figure 4.16: Mean spectra from basal ganglia voxel for each age cohort. n=215. Shaded area 
indicates standard deviation. 
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4.4. Metabolite statistical distributions 
The typical distribution of concentrations was examined by generation of histograms for each 
metabolite and the skewness statistic calculated (SPSS v 17). The basal ganglia age variation 
dataset (n=215) was used for this analysis. It can be seen that the major metabolites detected 
by in vivo brain MRS approximate to a normal distribution, with skewness values within 1.5 
for Ins, Cr, Gln+Glu, tNAA, tCho, Gua, and Tau. The lower concentration metabolites tended 
to have substantial positive skews (e.g. lactate). The parametric statistical analyses applied in 
this thesis (including Student’s t-test) assume normality of variables. The skewness values for 
the major metabolites here suggest that these tests can be validly applied to those metabolite 
variables. 
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Figure 4.17: (See also next page) Histograms of metabolite concentration distribution in 
n=215 acquisitions from basal ganglia. Number in parentheses indicates skewness statistic. 
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Figure 4.17: (see also previous page). Histograms of metabolite concentration distribution in 
n=215 acquisitions from basal ganglia. Number in parentheses indicates skewness statistic. 
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4.5. Comparator cohort generation 
Analysis of MRS data from a single case or group of cases from a disease cohort of interest 
requires a normal control group to provide information about normal metabolite 
concentrations. Ideally this should be matched to the age profile of the cohort of interest, 
given the variability of metabolite concentrations with age. An initial comparator cohort was 
established using children over 6 months of age, as there is significantly less alteration in 
metabolite concentrations after this initial developmental period. 
4.5.1. Cohort identification 
In the absence of MRS data from a large cohort of “normal” children, interim alternative 
comparator cohorts were required. Indeed there is some merit in establishing normative data 
for the type of child that might be undergoing investigation by MRS, namely children with 
neurodegenerative or developmental delay-related symptoms. In order to establish a pseudo-
normal control group, a sub-cohort of children was identified with normal neuroimaging, as 
established by assessment by consultant paediatric radiologist. All MRS studies included had 
passed the quality assessment analysis. Cases from children under 6 months of age were 
excluded at this stage, as the predominant age variation in metabolite concentrations was 
found in the group less than 6 months of age. 
 
63 studies from basal ganglia in children aged over 6 months and 53 from white matter were 
identified. Metabolite and spectral data were extracted and mean (standard deviation) spectra 
and mean (standard deviation) metabolite values established (figures 4.18 and 4.19, table 4.3). 
To evaluate the effect of selecting cases with normal MR imaging features, comparison was 
made with mixed cohorts of children (over 6 months) with abnormal MR imaging (basal 
ganglia n=82, white matter n=68).   
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Figure 4.18: Basal ganglia data. (A) Bar chart showing mean metabolite concentrations (error 
bars – standard deviation) for normal and abnormal MRI cohorts. Between group unpaired t-
test: * p<0.05, † p<0.01. (B) Mean spectra for normal and abnormal MRI cohorts. (C) Mean 
spectra (shaded area - standard deviation) of normal MRI cohort. (D) Mean spectrum (shaded 
area - standard deviation) of abnormal MRI cohort. 
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Figure 4.19: White matter data. (A) Bar chart showing mean metabolite concentrations (error 
bars – standard deviation) for normal and abnormal MRI cohorts (see text). Between group 
unpaired t-test: * p<0.05, † p<0.01. (B) Mean spectra for normal and abnormal MRI cohorts. 
(C) Mean spectra (shaded area - standard deviation) of normal MRI cohort. (D) Mean 
spectrum (shaded area - standard deviation) of abnormal MRI cohort. 
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Figure 4.20: Comparison of normal MRI cohort spectra for white matter and basal ganglia.  
(A) Bar chart showing mean metabolite concentrations (error bars – standard deviation) for 
white matter and basal ganglia. Between group unpaired t-test: * p<0.05, † p<0.01. (B) Mean 
spectra for white matter and basal ganglia  
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Basal ganglia White matter Normal MRI 
basal ganglia v 
white matter 
 
Normal 
MRI 
Abnormal 
MRI 
t-test 
p-val 
Normal 
MRI 
Abnormal 
MRI 
t-test 
p-val 
t-test 
p-val 
n 63 82  53 68   
Age (y) 5.73 (4.69) 5.15 (3.58) ns 6.23 (4.73) 5.76 (3.93) ns  
tNAA 5.21 (0.51) 4.48 (0.95) <0.001 5.11 (0.73) 4.29 (0.93) <0.001 ns 
Cr 4.55 (0.59) 4.35 (0.77) ns 3.18 (0.47) 3.08 (0.54) ns <0.001 
tCho 1.11 (0.18) 1.10 (0.23) ns 1.08 (0.15) 1.05 (0.27) ns ns 
Ins 2.49 (0.43) 2.68 (0.76) ns 2.57 (0.39) 2.83 (0.84) <0.05 ns 
Gln+Glu 6.43 (1.39) 6.47 (1.82) ns 4.84 (1.18) 4.84 (1.82) ns <0.001 
Gln 1.98 (0.79) 2.31 (1.34) ns 1.32 (0.62) 1.64 (1.26) ns <0.001 
Glu 4.45 (0.78) 4.17 (1.03) ns 3.51 (0.78) 3.20 (0.96) ns <0.001 
Lac 0.11 (0.20) 0.74 (2.10) <0.05 0.21 (0.28) 0.79 (2.45) ns <0.05 
Scyllo 0.07 (0.08) 0.07 (0.07) ns 0.09 (0.06) 0.08 (0.06) ns ns 
Tau 0.63 (0.49) 0.61 (0.52) ns 0.32 (0.37) 0.35 (0.33) ns <0.001 
Gua 1.01 (0.32) 1.05 (0.36) ns 0.75 (0.21) 0.76 (0.22) ns <0.001 
MMLIP1.4 4.27 (1.63) 5.19 (4.07) ns 4.88 (2.18) 5.80 (3.85) ns ns 
MMLIP0.9 4.12 (0.95) 4.27 (1.38) ns 3.73 (0.66) 3.75 (1.39) ns <0.05 
MMLIP2.0 8.20 (1.30) 8.11 (2.02) ns 7.65 (1.52) 7.12 (2.06) ns <0.05 
Table 4.3: Mean metabolite values for basal ganglia and white matter in cohorts with normal 
and abnormal MR imaging. Difference between cohorts evaluated by Student’s t-test. 
 
4.5.2. Comparison of normal MRI and abnormal MRI cohort 
Visual inspection of mean spectra (figures 4.18 and 4.19) revealed a lower NAA peak and 
elevated lactate in the abnormal MRI group for both basal ganglia and white matter. 
Comparison of the mean metabolite concentrations demonstrated significantly (p<0.05) lower 
tNAA and elevated lactate in basal ganglia of children with abnormal MR imaging. In white 
matter the tNAA was also significantly lower in the abnormal MRI group, and inositol was 
significantly elevated in the abnormal MRI group. There were no other statistically significant 
differences. Choline was consistent in all cohorts, and there were no significant differences in 
the lipid/macromolecular peaks in the normal and abnormal cohorts.  
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4.5.3. Comparison between anatomical regions 
The two groups used to generate the normal MRI comparator groups for basal ganglia and 
white matter did not differ significantly in age. Significant differences in several metabolites 
were evident by visual inspection of the mean spectra (figure 4.20) and by formal analysis of 
the LCModel derived metabolite concentrations (table 4.3). Thus in basal ganglia there was 
higher creatine, taurine and guanidinoacetate. Glutamate+glutamine, glutamine and glutamate 
were also higher in basal ganglia. There were no significant differences in tNAA, choline or 
inositol between the two regions. 
 
These regional differences correspond to previous studies that demonstrated significantly 
higher creatine, glutamine+glutamate and taurine in basal ganglia, and similar tNAA, choline 
and inositol levels in the two regions [67]. 
 
4.6. Discussion 
 
The metabolite variations across anatomical regions seen in the current dataset are similar to 
those previously described, and the typical “normal” metabolite profiles generated are similar 
to other published normal control cohorts [67, 118]. However, the absolute concentrations for 
each metabolite were different to these other published normal cohorts, likely due to 
differences in MR scanners, acquisition parameters and post-processing techniques. This 
underlines the need for such factors to be accounted for when comparing data from multiple 
sources, and also in the future design of multicentre studies. 
 
The standard deviation in the data on the spectra is relatively small, suggesting good 
reproducibility in the data collected across a large number of cases. Although the data for the 
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comparator cohorts is not from a strictly normal population since the majority of children had 
an MRI performed because of neurologic or developmental signs or symptoms, the selection 
of data from children with normal MRI features does provide a workable comparator cohort 
which has parameters consistent with those published elsewhere. Indeed, a similar approach 
to generating control datasets has been employed in other studies [118]. 
 
It should also be noted that although differences between the normal and abnormal MRI 
groups were seen, that many of the differences were relatively subtle and significantly less 
prominent that the alterations in the metabolite profile seen in MRS profiles from brain 
tumours and other lesions [76]. This emphasises the importance of using large cohorts of 
children and repeated sampling to validate observations of metabolite alterations, as well as 
the importance of removing as far as possible non-biological sources of variability within the 
data generated. 
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Chapter Five 
 
5. The identification of non-standard brain metabolite 
peaks 
 
The appearance in an MR spectrum of a metabolite peak not expected in normal brain can 
suggest specific metabolic disorders, as discussed in Chapter 2. Tools that estimate metabolite 
profiles by fitting a linear combination of known metabolite spectra rely on a priori 
assumptions of the metabolites that will be present in the spectrum, and thus unexpected 
metabolites will result in either distortion of the fitting of standard metabolites, or leave a 
large residual between the fitted and original data spectra [45]. LCModel has a standard 
metabolite basis set with 17 expected metabolites [44]. 
 
The MRS dataset acquired in this study was evaluated for the presence of such unfitted 
metabolite peaks, with the objective of identifying potential specific disease biomarkers or 
metabolites that give specific information about alterations in brain metabolites in known 
diseases. 
 
 
5.1. Methods 
 
5.1.1. Case identification 
All MR spectra acquired were visually reviewed for the appearance of obvious unfitted peaks 
or significant baseline distortions that may suggest erroneous fitting due to the presence of an 
unfitted metabolite.  
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All MR spectra were also screened by plotting the residual signal remaining by subtraction of 
the LCModel fitted spectrum from the original data spectrum. Spectra with large residuals 
were further evaluated to determine whether the residual was due to low signal to noise ratio, 
appearance of technical artefact, or potentially from the presence of an unfitted peak. 
 
5.1.2. Metabolite identification 
Spectra that had potential unfitted peaks were further evaluated. Standard libraries were 
screened on the basis of the chemical shift of the unfitted peak, and sample experimental or 
predicted spectra for potential candidate metabolites examined [109].  
 
In some cases, test solutions of candidate metabolites were prepared for one dimensional 
proton NMR spectroscopy using high field laboratory NMR spectrometers (see Chapter 3). 
MR spectra of the test solutions were also acquired using the clinical MR scanner to evaluate 
differences between the high field spectrometer and the clinical system. 
 
 
 
5.2. Results 
 
Potential unfitted metabolite peaks were identified in a small number (circa 2.3%) of children 
(table 5.1, figure 5.1). Several of the metabolites detected corresponded to the underlying 
metabolic defect in the child. Thus succinate was detected in a child subsequently found to 
have succinate dehydrogenase deficiency (see below); glycerol was detected in a child with 
glycerol kinase deficiency (see below); while glycine was detected in a child with non-ketotic 
hyperglycinaemia due to a novel AMT mutation and also in a neonate with an incompletely 
characterised fatty acid oxidation defect. Of these metabolites, the in vivo detection in brain of 
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glycerol has not been previously described. Elevated glycine may be a useful biomarker of 
malignancy in childhood brain tumours [45] and the identification in the IMD cohort 
benefitted from the availability of an extended LCModel basis set that included glycine 
parameters (see figure 5.1 E and F).  
 
In some cases peaks were identified that appeared to be not due to artefact or low signal to 
noise ratio, but no specific metabolite identity was able to be assigned. 
 
 
Peak 
Chemical 
shift (ppm) 
Metabolite 
Identity 
Seen at short 
echo time? 
Seen at 
long echo 
time? 
Metabolic Disease OMIM 
reference 
2.40 Succinate Y Y Succinate dehydrogenase 
deficiency (SDHB 
mutation) 
#252011 
*185470 
3.65 Glycerol Y N Glycerol kinase 
deficiency 
#307030 
3.55 Glycine N 
(Co-resonant 
with Inositol) 
Y Non-ketotic 
hyperglycinaemia (AMT 
mutation) 
#605899 
3.55 Glycine N 
(Co-resonant 
with Inositol) 
Y Uncharacterised fatty 
acid oxidation defect 
 
2.25 ?Acetone/ 
acetoacetate 
Y Y Pyruvate carboxylase 
deficiency 
#266150 
1.9 ?Acetate Y Y, 
inverted 
Methylmalonic aciduria, 
Down’s Syndrome 
#190685 
#251000 
1.1, 1.2 Unidentified Y Y, 
inverted 
Mitochondrial (DGUOK 
mutation) 
#251880 
Table 5.1: Non-standard brain metabolite peaks identified using MR spectroscopy. 
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Figure 5.1: MR spectra showing peaks not accounted for by LCModel fit. (A) and (B): Short 
echo time (TE 30ms) spectra from (A) Basal ganglia and (B) white matter in child with 
succinate dehydrogenase deficiency giving rise to peak at 2.4ppm in white matter but not in 
basal ganglia consistent with succinate accumulation. Also note low glutamine+glutamate in 
white matter (B). (C) and (D): Short echo time (TE 30ms) spectra from child with glycerol 
kinase deficiency and pyruvate dehydrogenase deficiency giving rise to peak at ~3.6ppm seen 
before (C) and after bilateral basal ganglia stroke (D) when high lactate signal was seen. (E) 
and (F): Long echo time (TE 135ms) spectra from child with clinical Leigh-like syndrome 
showing prominent peak at 3.55ppm leading to over-fitting of inositol (E) but improved 
fitting when glycine parameters added to LCModel basis set (F). (G) and (H): Short echo time 
(TE 30ms) from two neonates with high lactate levels, with peaks identified of uncertain 
significance and identity at ~1.2ppm. 
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5.2.1. Succinate 
 
5.2.1.1.Clinical Case Description 
A female child was born at term to consanguineous Asian parents. Growth and developmental 
milestones were normal until one year of age by which time she could cruise around furniture 
and was babbling. Subsequently over a six week period she lost the ability to walk, and 
became unsteady and had repeated falls. There was no associated head injury or febrile 
illness.   She became very hypotonic with poor head control and difficulty feeding. After the 
six week period of deterioration she made slow developmental progress, and by the age of 
four years she could stand briefly with support but was mainly wheelchair-bound. There were 
no further episodes of developmental regression, but by 6 years of age she remained 
wheelchair dependent, and had developed flexion contractures in arms and legs.  
 
5.2.1.2.MRI and MRS 
Magnetic resonance imaging acquired at the initial presentation and at four years of age 
(figure 5.2) revealed a leucodystrophy with extensive white matter signal changes in the deep 
cerebral white matter sparing U-fibres, with abnormalities also present in cerebellum and 
brainstem. MRS was acquired concurrently with the MRI scan at age 4 years (figure 5.2). The 
short echo time MR spectrum of the dystrophic white matter demonstrated the presence of a 
singlet peak at 2.4ppm, seen also at long echo time (not shown), not detected in the control 
group or in the normal appearing basal ganglia of the child. The MRS profile of the white 
matter also demonstrated significantly decreased glutamine and glutamate, relative 
preservation of N-acetylaspartate, and increased myo-inositol. The metabolite profile of the 
basal ganglia appeared normal with no succinate detected. 
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D 
 
E 
 
Figure 5.2: MR spectra and MR imaging from child with SDHB mutation. MR spectra (TE 
30ms) from patient (red line) and control groups (mean, gray line; standard deviation, shaded 
area), from (A) basal ganglia, (B) white matter and (C) succinate-creatine solution. Major 
metabolite peaks: N-acetylaspartate, NAA; glutamine+glutamate, Glx; creatine, Cre; choline 
compounds, Cho; myo-inositol, Ins; succinate, Succ. Chemical shift (x) axis: parts per 
million, ppm. (D) T2 weighted axial MR image at 1 year age demonstrating high signal 
intensity in white matter (arrow), sparing subcortical U-fibres (arrow head). Normal basal 
ganglia signal. (E) T2 weighted coronal MR image at age 4.5 years demonstrating persistent 
high signal intensity in white matter with cystic degeneration, sparing subcortical U-fibres 
(arrow), and abnormal high signal in corticospinal tracts in pons (arrow head) and upper 
cervical cord. 
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5.2.1.3.Metabolite Peak Identification 
By reference to a standard metabolite library the chemical shift of the observed peak was 
found to be consistent with that of succinate [109]. The molecular structure of succinate has 
four magnetically equivalent protons (figure 5.3) giving rise to a singlet resonance peak [36]. 
This was observed in the in vivo spectra at both short (TE 30ms) and long (TE 135ms) echo 
times. 
 
Figure 5.3: Structure of succinic acid 
 
One dimensional proton NMR spectra of a test solution of succinic acid and creatine at 
various pH values were acquired as described (Chapter 3). The singlet resonance peak of 
succinate was observed at 2.4ppm at physiologically relevant pH; at more acidic pH the 
resonance moved further downfield (figure 5.4).  
 
MR spectroscopy was also acquired from a 1L bottle of the test solution using the clinical MR 
scanner (pH 5.6). Identical parameters to that used for the in vivo MRS were used. Again, the 
singlet resonance peak of succinate was seen at 2.4ppm (figure 5.2C).  
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Figure 5.4: Plot of chemical shift of succinate and creatine peaks at varying pH, ascertained 
using 500MHz spectrometer.  
 
5.2.1.4.Further Metabolic Investigations 
An open rectus femoris muscle biopsy was obtained at 5 years of age (figure 5.5). This 
demonstrated decreased succinate dehydrogenase staining. Assay of mitochondrial respiratory 
chain complex activity demonstrated a marked decrease in Complex II (succinate 
dehydrogenase) activity (0.049 nmol DCPIP reduced /min (control mean 0.145). She has 
subsequently been found to have a novel homozygous mutation in SDHB (C.Alston and 
R.Taylor, Mitochondrial Research Group, Institute for Ageing and Health, Newcastle 
University, Newcastle upon Tyne, UK).  
5.2.1.5.Case Discussion 
The in vivo MRS demonstrated significant accumulation of succinate within abnormal brain 
regions, but not in a non-affected brain region. The identity of the succinate peak was 
suggested by its chemical shift consistent with published and experimental test solution data, 
and also consistent with the underlying enzyme defect subsequently demonstrated both 
 111
histochemically and by direct enzyme assay. The genetic basis for the disease was confirmed 
by identification of a novel homozygous SDHB mutation. 
  
The detection in vivo of elevated brain succinate has been reported in three children 
previously with confirmed SDH enzyme deficiency [119], although not in a child with a 
genetically confirmed diagnosis, and represents a specific biomarker of SDH/complex II 
deficiency. 
 
 
 
Figure 5.5: Skeletal muscle biopsy histology from child with SDHB mutation. (A) H&E 
stain: tightly packed uniformly sized muscle fibres. x40 magnification. (B) SDH stain: 
generalised decrease in staining. x40 magnification. (C) Oil Red O stain: very subtle increase 
in intrafibre lipid. x60 magnification. (D) COX stain: normal checkerboard pattern, no COX 
negative fibres x40 magnification (Images courtesy of Dr Marie-Anne Brundler). 
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5.2.2. Glycerol 
5.2.2.1.Case description 
A Caucasian male child was diagnosed with X-linked glycerol kinase deficiency (OMIM 
#307030) after the finding of pseudohypertriglyceridaemia during investigation following of 
an episode of hypoglycaemia. (The analytic method for quantification of blood triglycerides 
measures glycerol released by the action of lipase by a colorimetric method, thus 
hyperglycerolaemia gives a false high estimate of blood triglycerides). Blood glycerol was 
1910 μmol/l (normal 61-232 μmol/l), and urinary glycerol was elevated. Fibroblast C14 
glycerol incorporation studies demonstrated a marked deficiency. He was shown to be a 
hemizygote for the C256R gene mutation.  
 
Following the symptomatic presentation of Leigh encephalopathy in his sibling, both children 
were also diagnosed with pyruvate dehydrogenase deficiency due to a defect of the E3 subunit 
(chromosome 7q31-q32). 
5.2.2.2.MRI & MRS 
MR imaging at age 15 years demonstrated tiny foci of high T2 signal intensity in bilateral 
globus pallidi (figure 5.6). At 15 ½ years he suffered an extensive metabolic stroke following 
an influenza-like illness (figure 5.6) necessitating palliative care.  
 
MRS was acquired with both MRI studies from the basal ganglia, demonstrating the presence 
of an unfitted peak just downfield of the inositol peak (figure 5.1C and D) at circa 3.65ppm. 
There was also substantial elevation of lactate demonstrated in the second MRS study 
following the stroke. 
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Figure 5.6: T2-weighted images from child with glycerol kinase deficiency and pyruvate 
dehydrogenase deficiency. (A) Axial view at age 15 years. (B) Coronal and (C) axial views at 
age 15 ½ years following metabolic stroke. Note high T2 signal in bilateral basal ganglia  
 
5.2.2.3.Metabolite Peak Identification 
By reference to a standard metabolite library the chemical shift of the observed peak was 
found to be consistent with that of glycerol [109]. The molecular structure of glycerol has five 
spins from two equivalent methylene groups and a single CH proton (figure 5.7) giving rise to 
resonances centred at 3.55 and 3.65ppm [36].  
 
Figure 5.7: Structure of glycerol 
 
One dimensional proton NMR spectra of the glycerol-creatine test solution was acquired as 
described (Chapter 3). The multiplet resonances of glycerol were seen centred at 3.55 and 
3.65ppm (figure 5.8). MR spectroscopy was also acquired from a 1L bottle of the test solution 
using the clinical MR scanner. Identical parameters to that used for the in vivo MRS were 
used. The glycerol resonances were seen as a broad peak at around 3.6-3.62ppm (figure 5.9). 
CH2-OH 
 
CH-OH 
 
CH2-OH 
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As seen in figure 5.9, automated fitting software partially accounted for the glycerol peak by 
fitting inositol. 
 
Figure 5.8: Proton NMR spectrum of glycerol and creatine test solution acquired on 500MHz 
spectrometer. Spectral region 3.0-4.0ppm shown only. 
 
 
 
Figure 5.9: TARQUIN fitting of glycerol-creatine test solution spectroscopy acquired on 
1.5T clinical MR scanner. Creatine peaks seen at 3.0 and 3.9ppm; broad peak centred at 3.6-
3.62  from glycerol, partially fitted as inositol. 
 
5.2.2.4.Case Discussion 
 
Glycerol is not observed in MRS from normal brain, probably because it is embedded in 
membrane phospholipids and therefore has restricted rotational mobility, but has been 
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detected in post mortem brain homogenates [36]. The detection in vivo of elevated brain 
glycerol has not previously been reported. 
 
Glycerol kinase deficiency usually presents with hypoglycaemic episodes in childhood but 
may not present until adulthood [120]. Beyond secondary effects of hypoglycaemia it is not 
usually associated with brain pathology. The case described here is complicated by the 
presence of a second disease, pyruvate dehydrogenase deficiency, which often results in a 
Leigh-like syndrome as encountered in this patient. Thus the clinical relevance of the elevated 
brain glycerol demonstrated is uncertain, although it is possible that these two energy 
metabolism disorders may have had synergistic pathological effects. 
 
 
5.3. Discussion 
 
Unfitted metabolite peaks were identified in only a small number of cases in the current 
cohort (circa 2.3%). In several children, however, the metabolites detected related directly to 
the underlying metabolic disorder and contributed significantly to the diagnostic process. 
 
The putative identification of unfitted metabolite peaks described here relied on a 
combination of chemical shift libraries and evaluation of test solutions of potential 
metabolites using high field and clinical magnet spectroscopy. The certain identification of 
metabolite peaks may also be aided by analysis of body fluid samples from patients, as has 
been demonstrated for several disorders including adenylosuccinate lyase deficiency [98], 
while in brain tumour studies it has been possible to correlate in vivo spectroscopy with high 
resolution magic angle spinning spectroscopy of ex vivo tissue samples [29]. In the cases 
described here CSF samples were not available for NMR spectroscopy, although the children 
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with high glycine on brain MRS also had elevated CSF glycine on routine clinical testing. The 
putative assignment of metabolite identities described here is supported by the direct 
correlation to the underlying metabolic disorder. 
 
In clinical practice the identification of unexpected metabolites in MR spectra would rely 
initially on clinical radiologists recognising their presence, and thus dissemination of 
information about these rare but potentially clinically very useful findings will be important. 
For some of the metabolites discussed here, such as glycine, post-processing steps would 
likely be required to distinguish the presence of the metabolite from other metabolite peaks in 
close proximity. 
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Chapter Six 
 
6. Mucopolysaccharidosis Type II (Hunter Syndrome) 
 
In this chapter, the use of MR spectroscopy in monitoring disease progression in Hunter 
Syndrome is evaluated. The initial baseline MRS data presented in this chapter have been 
published in the Journal of Inherited Metabolic Disease 2010 (see Appendix B) [121]. 
 
6.1. Introduction to lysosomal storage disorders  
The lysosomal storage disorders (LSD) are caused by defects within the endosomal-lysosomal 
system, resulting in the abnormal accumulation of products that are normally degraded by the 
lysosomal system (figure 6.1). The endosomal-lysosomal system is responsible for the 
trafficking and recycling or degradation of internalised materials including endocytosed 
signalling molecules (e.g. hormones, neurotransmitters), phagocytosed bacteria or 
pinocytosed extracellular fluid. The lysosomes, which appear as “dense bodies” on electron 
microscopy, characteristically have a low acidic pH and contain enzymes that function 
optimally in an acidic environment [122]. Many LSD are caused by deficiency of the acidic 
enzymes, but defects at several other points with the endosomal-lysosomal system also result 
in LSD. This includes defects of protective or activator proteins within the lysosome; 
abnormalities of processing of lysosomal enzymes within the endoplasmic reticulum (e.g. 
multiple sulfatase deficiency, OMIM #272200); and failure of mannose-6-phosphate receptor 
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addition resulting in defective trafficking of correctly synthesised enzymes to the lysosome 
(e.g. I-cell disease, OMIM #252500) [123]. 
 
 
Figure 6.1: The endosomal – lysosomal system. (Early endosome, EE; recycling endosome, 
RE; late endosome, LE; lysosome, Ly; endoplasmic reticulum, ER; autophagic vesicle, AV; 
Adapted from [123]). 
 
6.2. Introduction to the Mucopolysaccharidoses 
The mucopolysaccharidoses (MPS) are a subset of the LSD characterised by the lysosomal 
accumulation of glycosaminoglycans (GAGs, also known as mucopolysaccharides), which are 
normal components of connective tissues and widely expressed in the CNS with a variety of 
functions [124]. Proposed diverse GAG functions in the CNS include roles in cell-cell 
interactions, axon growth and targeting, neurogenesis and dendrite maturation [124]. GAGs 
are polysaccharides formed of uronic acid and hexosamine residues that are degraded within 
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the lysosomal system, a process requiring a number of acid hydrolases including sulfatases, 
exoglycosidases, transferases and endoglycosidases [125]. The deficiency of these enzymes 
results in the specific MPS disorders [126]. The main classes of GAGs are the heparan, 
dermatan, chondroitin and keratan sulfates and hyaluronic acid, which accumulate depending 
on the specific enzyme defect in the different MPS disorders (table 6.1). 
 
The MPS are progressive multisystem disorders,  characterised by typical “coarse” facial 
appearances, skeletal dysplasia (dysostosis multiplex),  organomegaly, cardiorespiratory 
compromise and neurological deterioration in several of the disorders [126].  
 
Disease Name Deficient Enzyme Stored 
material 
Chromosome 
locus 
MPS I Hurler/Scheie Iduronidase DS, HS 4p16.3 
MPS II Hunter Iduronate-2-sulfatase DS, HS Xq27-28 
MPS III Sanfilippo 
 IIIA Heparan-N-sulfatase HS 17q25.3 
 IIIB N-acetyl-glucosaminidase HS 17q.21.1 
 IIIC Acetyl CoA glucosamine 
N-acetyl transferase 
HS ? 
 IIID N-acetyl-glucosamine-6-
sulfatase 
HS 12q14 
MPSIV Morquio 
 IVA N-Acetylglucosamine-6-
sulfatase 
KS 16q24 
 IVB β-Galactosidase KS 3p21-pter 
MPSVI Maroteaux-Lamy N-Acetylgalactosamine-
4-sulfatase 
DS  
MPSVII Sly β-Glucuronidase HS,DS  
MPS IX  Hyaluronidase HA  
 
Table 6.1: The mucopolysaccharidoses: enzyme defect, storage material and chromosome 
locus. Dermatan sulfate, DS; heparan sulfate, HS; keratan sulfate, KS; hyaluronic acid, HA. 
(Adapted from [126]). 
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6.3. Mucopolysaccharidosis type II (Hunter Syndrome) 
Mucopolysaccharidosis type II (MPS II; Hunter syndrome; OMIM #309900) is an X-linked 
MPS caused by deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S, EC 3.1.6.13) 
[127]. Iduronate-2-sulfatase is encoded by the IDS gene located at Xq27-28. MPS II is 
characterised by intra-lysosomal accumulation of dermatan and heparan sulfates in most 
organ systems, with expected mortality if untreated in the second decade of life [128]. MPS II 
has an estimated prevalence of around 1 in 150,000 live births, predominantly affecting males 
although female cases have been reported [129].  
 
The diagnosis of MPS II is based on the analysis of urinary GAGs, with confirmation by 
assay of I2S enzyme activity in leukocytes, fibroblasts or plasma (multiple sulfatase 
deficiency should be excluded). Molecular genetic studies may also be undertaken [129]. In 
excess of 300 different mutations in IDS have been reported [127], including gene single point 
mutations, whole/partial deletions and gene rearrangements. In the context of significant gene 
disruption resulting in complete absence of enzyme activity, the phenotype is usually severe, 
however there is significant phenotypic variation in the context of preserved enzyme activity 
[127].  
 
6.3.1. Central Nervous System Disease in MPS II 
Data from the Hunter Outcome Survey (HOS) suggest that cognitive involvement is 
indicative of more severe disease and a lower life expectancy [130]. This dichotomy between 
a “severe” and an “attenuated” phenotype was confirmed in a recent neurocognitive study of 
50 male patients [131]. Around 2/3 of patients manifest the severe phenotype [132]. Patients 
who are likely to progress to the severe phenotype usually present at an earlier age, and during 
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follow-up will develop progressive signs and symptoms of CNS involvement with 
progressive intellectual deterioration [133]. The measured enzyme activity level does not 
correspond to the clinical phenotype [129, 131], and other biomarkers including urinary GAG 
concentrations, and the heparin cofactor-II thrombin complex do not correspond well to 
disease severity [129]. It has been suggested that early clinical markers of CNS involvement 
can be identified that could potentially identify patients who could benefit from brain targeted 
therapies. These clinical markers included sleep disturbance, increased activity, behaviour 
difficulties, seizure-like activity, chewing behaviour, and failure to achieve  bowel and 
bladder training [134]. These clinical parameters are, however, non-specific and may not 
accurately predict the likely disease trajectory. Indeed, no well-validated severity scoring 
system has yet been produced [129] and remains an important research goal, particularly 
given the need to appraise the efficacy of novel brain-targeted therapies. 
 
Central neurological involvement manifests with behavioural problems (50%), seizure 
disorders (39%), sensorineural hearing loss (45%), and progressive cognitive decline (32%) 
[130]. The cellular pathogenesis of CNS involvement in MPS II and other MPS disorders is 
however not well elucidated. For the LSDs in general Walkley has proposed that defective 
function of the endosomal-lysosomal system results in  
 
“…a host of downstream or cascade events, which take time to accrue, [and] is the ultimate 
cause of cell and organ dysfunction. Importantly, this finding offers a glimmer of hope that if 
corrective measures could be taken to intervene early in the disease process, significant 
neurological dysfunction might be prevented.” [124] 
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This cascade of events may affect intrinsic cell function, and also affect cell-cell interactions. 
Potential mechanisms include loss of function of the parent molecule being degraded, 
depletion of a product of the degradative process used in downstream synthesis, secondary 
disruption of the normal function of the endosomal-lysosomal system and its roles in signal 
transduction, and direct toxicity of the sequestered material e.g. psychosine in Krabbe disease 
[124]. It has also been noted that the storage material is not restricted to the primary 
compound acted upon by the (defective) enzyme, but that secondary storage of other 
compounds may also occur. Thus in the MPS disorders there is evidence for the accumulation 
of GM2 and GM3 gangliosides and unesterified cholesterol [135] in addition to the primary 
GAG. These secondarily stored compounds may then result in cascades of events common to 
disorders accumulating those products. 
 
Neuropathological studies in MPS II have demonstrated brain atrophy, cortical neuronal and 
Purkinje cell dendritic swelling due to storage material, enlarged perivascular spaces and 
decreased white matter density without significant gliosis [136]. This study did not detect 
significant neuronal loss in the basal ganglia, thalami or other deep gray nuclei. 
 
6.3.2. Limitations of current disease modifying therapies in MPS II 
Enzyme replacement therapy (ERT) with recombinant iduronate-2-sulfatase is clinically 
available (idursulfase, Elaprase®; Shire Human Genetic Therapies, Inc., Cambridge, MA, 
USA) [128, 132, 137, 138]. This is administered by regular (weekly) intravenous infusions, 
and utilises the mannose-6-phosphate receptor system to target the enzyme to the lysosomal 
compartment (the principle of “cross-correction”).  A recent Cochrane Review concluded that 
evidence for the efficacy of the ERT was limited, restricted to improvements in “functional 
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capacity (distance walked in six minutes and forced vital capacity), liver and spleen volumes 
and urine glycosaminoglycan excretion in patients with mucopolysaccharidosis type II 
compared with placebo” [139]. The clinical relevance of these endpoint measurements has 
been questioned [140]. 
 
While ERT results in improvement to systemic features idursulfase does not cross the blood 
brain barrier and so is not anticipated to alter the CNS pathology, nor the cognitive or 
behavioural manifestations of the disease [129]. That said, ERT may provide benefit to 
patients with the severe phenotype by improving systemic manifestations [129, 132]. A recent 
small case series reported that MRI features may stabilise or improve in children receiving 
ERT in MPS I and II, however this study did not include control data [141]. 
  
The existence of insulatory layers around the CNS provides the effective isolation required for 
reliable neuronal electrochemical signalling. This isolation is achieved by the blood-brain 
barrier formed by capillary endothelial cells, the blood-cerebrospinal fluid barrier formed by 
the choroid plexus epithelia, and the avascular arachnoid epithelium beneath the dura mater 
that effectively encloses the CNS and so isolates the extracellular fluids of the CNS from the 
remainder of the body [142]. The function of this multi-component barrier is achieved by 
physical tight junctions, transport mechanisms and metabolic mechanisms [142]. 
Macromolecules including proteins can not cross the barrier, and indeed many serum proteins 
are deleterious if they enter the CNS. Furthermore mechanisms exist, including the presence 
in the CSF of protease inhibitors, to deal with “micro-leaks” of proteins in to the CNS [142]. 
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This poses a significant challenge for the delivery of large molecule therapies to the CNS in 
neurodegenerative diseases such as MPS II. Various brain-targeted approaches have been 
attempted in pre-clinical studies including the use of fusion proteins, encapsulation techniques 
(liposomal delivery), and nanoparticle systems that attempt to overcome the blood brain 
barrier by utilising its various transport mechanisms [143]. The direct application of large 
molecule therapies to the CNS has been attempted by intraventricular injection or via the 
intrathecal route. Intrathecal injection of radio-iodine labelled recombinant idursulfase to 
canine and nonhuman primates has been shown to result in widespread enzyme distribution 
throughout the CNS including specifically in the lysosomal compartment, and furthermore in 
a murine model of MPS II this technique resulted in a reduction in storage of 
glycosaminoglycans in the brain [143]. A phase I/II clinical trial is currently evaluating the 
safety of intrathecal idursulfase in human subjects (Shire Human Genetic Therapies, Inc., 
Cambridge, MA, USA; US National Institutes of Health clinical trials register 
(www.clinicaltrial.gov) reference NCT00920647). The primary endpoint of this trial is drug 
safety, but a number of CSF and other biofluid biomarkers are also being evaluated to assess 
the effect of the therapy. 
 
6.3.3. MR Imaging Features and Monitoring of MPS II 
Typical MR imaging findings in MPS II include progressive brain atrophy, white matter 
lesions which correlate to disease duration [144], dilated perivascular spaces (PVS), 
progressive ventriculomegaly and hydrocephalus. In a large cross-sectional and longitudinal 
study of 36 Italian MPS II patients (14 with the attenuated form and 22 the severe form) MRI 
findings that correlated with the severe phenotype included white matter abnormalities (97%), 
third ventricular dilatation (100%), and cranial hyperostosis (19%). White matter 
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abnormalities, cerebral atrophy, communicating hydrocephalus and spinal stenosis progressed 
over time, and the authors suggested that these may provide potential disease severity markers 
[145]. 
 
A study of 60 patients with MPS (types I, II, IVa and VI combined) analysed the correlation 
between disease duration and several quantitative MR parameters [144]. Only the normalised 
white matter lesion load was found to correlate, albeit weakly (r=0.28), with disease duration. 
In analysis of MPS II patients only (n=31), this correlation was somewhat stronger (r=0.44, 
p=0.02). In this study, no correlation between MRS derived metabolites and age or disease 
duration was identified. Furthermore, no correlation was found between urinary GAG 
concentrations or enzyme activity and the MR parameters. 
 
In a prospective study of 19 male patients with MPS II, patients were subjected to standard 
neurocognitive assessments as well as neuroimaging [146].  Patients were classified according 
to the presence or absence of cognitive impairment. MRI investigations were analysed for the 
presence of white matter lesions (mild or severe), brain atrophy (present or absent), and 
hydrocephalus (as adjudged by the semi-quantitative ratio of maximum occipital horn 
diameter/ biparietal diameter). Single voxel spectroscopy was also performed in gray matter 
and white matter. Of the 19 patients studied 12 had cognitive impairment. The authors found 
that white matter lesion severity was greater in the cognitively impaired group (p=0.04), and 
that hydrocephalus and brain atrophy were also more common in the cognitive impairment 
group. Children with cognitive impairment had a significantly (p<0.05) higher 
inositol/creatine ratio in both gray and white matter compared to those without cognitive 
impairment, although levels were similar to the control group. There was a non-significant 
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trend to lower NAA/Cr in the white matter of children with cognitive impairment. The authors 
proposed that the higher inositol levels may indicate astrogliosis, or be an indirect marker of 
GAG deposition. This study relied on MRS peak area estimation using in-built scanner 
hardware and used metabolite ratios and not absolute quantification. 
 
A previous study reported the use of MRS in 7 patients with MPS including 4 with MPS II. 
This demonstrated elevated Cho/Cr ratio in white matter lesions in MPS. Peaks in the 
spectrum to the left (downfield) of myo-inositol were assigned to “presumptive MPS”, i.e. 
GAG accumulation. However this assignment is not accurate as the peaks identified in the 
paper are properly assigned as the secondary peaks of creatine, glucose, glutamine and 
inositol [147].  
 
6.4. Aims and Objectives 
Robust and objective tools to monitor neurological involvement in MPS II would enable 
evaluation of the effects of ERT and of novel therapies on neurological progression. 
Furthermore such biomarkers could provide early indication of patients likely to develop CNS 
manifestations and who could benefit from such novel therapies. In addition to clinical and 
biochemical evaluation methods, objective magnetic resonance (MR) based techniques could 
make a valuable contribution [144]. As discussed above, MR based scoring systems have 
been produced to this end [145]. However, visible MRI features correspond to significant 
structural damage to the brain that may not be reversible, and may not possess the required 
sensitivity in assessing small effects/ benefits of therapy. Functional imaging modalities 
including MRS could provide additional information about brain disease processes that could 
be used in understanding the disease pathogenesis, and in identifying biomarkers of disease 
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that could be combined in the assessment of the efficacy of novel brain-targeted therapies. 
The few previous reported MRS studies in MPS II (and MPS generally) as discussed above 
had several methodological limitations that may restrict the sensitivity of the technique to 
detect subtle early features. 
 
We aimed therefore to evaluate the potential contribution of MR spectroscopy in describing 
the neuropathology in MPS II, and in providing means of monitoring disease progression 
alongside conventional MR imaging. 
 
 
6.5. A brief introduction to Morquio Syndrome (MPS IVa) 
Available MR imaging studies from a cohort of children with a different MPS disorder, MPS 
IVa (Morquio syndrome, OMIM #253000) were used as a comparison dataset for the 
quantitation of ventricular size (see methods below). MPS IVa is an autosomal recessive 
lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfatase 
(GALNS, EC 3.1.6.4; encoded by GALNS gene at 16q24.3). The classical phenotype includes 
skeletal dysplasia with short stature, dental abnormalities, impaired endurance and corneal 
clouding, with the high risk of cervical spine instability and respiratory failure as the main 
causes of death [148]. In contrast to other mucopolysaccharidoses the CNS has not previously 
been reported to be directly affected in MPS IVa and intelligence has been thought to be 
normal [149, 150], although a recent combined neurocognitive and neuroimaging study has 
provided some evidence that subtle neuroimaging and neurocognitive abnormalities may form 
part of the MPS IVa phenotype [151]. Any CNS abnormalities in MPS IVa are, however, 
subtle. Substantial numbers of serial MRI studies were available in this cohort, and thus this 
data was considered to be suitable to provide an initial comparison for the MPS II imaging 
data. 
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6.6. Methods 
6.6.1. Patients 
Patients were recruited from a single tertiary paediatric IMD unit. Clinical data were extracted 
from medical records including age at diagnosis, enzyme activity assay at baseline where 
available, and history of ERT treatment. 
 
Formal neurocognitive assessment was not universally available. Therefore the degree of 
cognitive impairment was determined by consensus opinion of senior medical and nursing 
professionals, and binary-classified depending on age-appropriate performance in standard 
areas of neurodevelopment (speech-language-hearing, social-emotional functioning, fine 
motor and vision, gross motor), into either no-slight or moderate-severe cognitive impairment. 
Consensus opinion was also gathered on the clinical progression of the disease in each patient. 
6.6.2. Neuroimaging analysis 
All available brain MRI studies were retrospectively reviewed, including review of the 
qualitative radiology report by the consultant paediatric radiologist. Two quantitative 
parameters were derived from the axial T2-weighted image sequences to assess firstly white 
matter abnormalities and secondly the degree of hydrocephalus. White matter abnormalities 
were scored according to the method of Manara et al [145] (figure 6.2) by a single operator 
(JED, not blinded to other data). Thus the supratentorial white matter involvement was scored 
as 0 (minimal/absent), 1 (mild), 2 (moderate) or 3 (severe).   
 
The degree of ventricular enlargement was quantified using the method of Vedolin et al by 
measurement of the occipital horn: biparietal diameter ratio (maximum distance between 
outer borders of occipital horns / maximum biparietal distance, i.e. B/A in figure 6.3). Evan’s 
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ratio (index) was also calculated, i.e. the maximum distance between outer borders of the 
frontal horns / maximum biparietal distance (C/A in figure 6.3) [152]. Comparison was made 
with Evan’s ratio and occipital horn ratio data derived from 40 MRI examinations carried out 
on 14 children with MPS IVa (Morquio syndrome). 
 
Figure 6.2 White matter abnormality scoring system for MPS II, from [145] assessed on T2 
weighted image at level of lateral ventricles. (A) minimal/absent (score 0); (B) mild (1); (C) 
moderate (2); (D) severe (3). 
 
 
Figure 6.3: Anatomic landmarks used to derive occipital and 
frontal horn: biparietal diameter ratios 
 
6.6.3. Magnetic resonance spectroscopy 
MRS studies were performed concurrently with clinically indicated MRI studies at 1.5Tesla 
facilitated by general anaesthesia as needed according to the standard protocol, with voxels in 
standard positions in the white matter and basal ganglia. Metabolite data from the initial MRS 
from each child were compared with metabolite data from the standard comparison cohort of 
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children with normal appearing MRI (white matter, n=53, median (range) age 4.7(0.5-16.7) 
years; basal ganglia n=63, 4.1(0.5-16.7) years) by inspection of mean spectra and independent 
sample t-test to compare mean metabolite concentration.  
 
Correlations between age, quantitative MR parameters and MRS metabolite values were 
assessed using Pearson correlation coefficient or between-group ANOVA, and the 
correlations also re-analysed for metabolite values corrected for the total metabolite 
concentration detected. For children with serial imaging and MRS data, trends in parameters 
were compared to the observed clinical course. 
 
 
6.7. Results 
6.7.1. Patient characteristics 
Thirty three neuroimaging studies were available from 10 boys with MPS II. Nineteen MRS 
studies were available from 8 of the boys. Clinical characteristics are summarised in table 6.2. 
The majority had some evidence of CNS involvement (severe phenotype), although the 
degree of impairment was variable. One of the boys had the attenuated form of MPS II. 
6.7.2. Conventional MRI Findings 
All boys had evidence of multiple enlarged perivascular spaces; the degree of other MR 
features including white matter abnormalities, ventricular enlargement/hydrocephalus and 
cerebral atrophy varied between patients and also over time. Examples of typical MRI 
features from three of the patients at three consecutive time points are shown in figure 6.4, 
illustrating the variable clinical course. 
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6.7.3. Quantitative MRI parameters 
6.7.3.1.Ventricular ratios 
Baseline comparison values for Evans ratio and the occipital horn ratio were established from 
the MPS IVa group, demonstrating no alteration with increasing age (figure 6.5). The Evans 
ratio and occipital horn ratios correlated well with each other (figure 6.6, r=0.91) although the 
occipital horn ratio appeared to give greater separation between MPS II and MPS IVa 
children (figure 6.7). Figure 6.7 presents the Evans ratio and occipital horn ratio for each MRI 
study plotted against age of patient at time of study. Serial data from individual patients are 
indicated by lines joining data points.  
 
Most of the MPS II boys have ratios above the range established by the MPS IVa cohort. One 
MPS II child (patient 7) with the attenuated form had normal ratio values that were stable 
over time. The rate of change of the ratio scores appears to correspond to the clinical course 
encountered by each child. Thus patients with more rapid clinical deterioration (e.g. patients 
1, 5) had correspondingly rapid rises in ventricular ratio scores; those with stable clinical 
disease (e.g. patients 2, 6) had more stable although still progressively increasing ventricular 
ratios.  
 
6.7.3.2.White matter abnormalities 
The alterations in the ventricular ratios were mirrored by the white matter abnormality score 
(figure 6.8). Increasing ventricular ratio corresponded significantly to increasing white matter 
abnormality score (ANOVA:  p<0.001). 
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      MRI Features 
Patient Age at 
diagnosis 
(m) 
 
Residual 
enzyme 
activity 
Age starting 
ERT 
(y-m) 
Age first 
MRS (y) 
Cognitive impairment 
WMA 
Score 
Cerebral 
atrophy 
Ventricular 
enlargement 
Perivascular 
spaces 
1 ~24 2.5% 12-0 12.5 Moderate-severe 1 → 2 +++ Ex-vacuo 
dilatation 
Multiple 
enlarged 
2 21 n/a 7-2 7.6 Moderate-severe 2 → 2 ++ Ex-vacuo 
dilatation 
Multiple 
enlarged 
3 48 0% 7-0 7.6 Moderate-severe 2 → 2 + Slight Multiple 
enlarged 
4 24 n/a 7-0 6.4 Moderate-severe 1 → 3 ++ Ex-vacuo 
dilatation 
Multiple 
enlarged 
5 12 n/a 3-10 4.0 Moderate-severe 1 → 3 + Slight-
moderate 
Multiple 
enlarged 
6 24 0% 2-2 2.1 Normal-slight 1 → 2 + Normal Multiple 
enlarged 
7 ~48 n/a 12-0 12.1 Normal-slight 0 → 0 - Normal Multiple 
enlarged 
8 35 n/a 4-0 - Moderate-severe 1  - Normal Multiple 
enlarged 
9 38 n/a 3-2 - Normal-slight 1 ++ Moderate Multiple 
enlarged 
10 42 n/a 3-6 8.6 Normal-slight 2 + Moderate Multiple 
enlarged 
 
Table 6.2: Summary of clinical characteristics of MPS II patients. ERT, enzyme replacement therapy; m, months; y, years; MRS, magnetic 
resonance spectroscopy; WMA, white matter abnormality score (see text for details; 1 → 2 indicates progression of score during study). 
 133
 
Figure 6.4: T2 weighted images of three MPS II patients. (Coronal (or sagittal if coronal not 
available) and axial slices). Top panel patient 2: moderate cerebral atrophy, ventricular 
enlargement and mild white matter abnormalities stable over sequential imaging. Middle 
panel patient 5: progressive ventricular dilatation and development of severe white matter 
abnormalities with less evidence of atrophy. Bottom panel patient 7: attenuated phenotype. 
No/absent white matter changes, no ventriculomegaly, no atrophy, and stable over time. 
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Figure 6.5: Evans ratio and occipital horn ratio plotted against age for the MPS IVa 
(Morquio) cohort 
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Figure 6.6: Correlation between frontal horn (Evans) ratio and occipital horn ratio across 
MPS II and MPS IVa patients. 
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Figure 6.7: Plots of Evans ratio (upper panel) and occipital horn ratio (lower panel) against 
age. + indicates data from MPS IVa (Morquio) comparison set. Lines connecting points 
indicate data from individual children obtained at sequential time points. (Patient 1- , 2-, 
3-, 4-, 5-, 6-, 8-, 9-, 10-, MPS IVa - +).  
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Figure 6.8: Boxplot of occipital horn ratio according to white matter abnormality score in 
MPS II cohort. (ANOVA p=0.000 between groups). 
 
 
6.7.4. MR Spectroscopy data 
Metabolite values from the initial MRS study for each child in the MPS II cohort were 
compared to the standard normal MRI comparator groups (figures 6.9 and 6.10 and table 6.3). 
In white matter MPS II patients had significantly decreased tNAA, creatine, 
glutamine+glutamate and choline and significantly elevated macromolecular/lipid signal at 
1.3ppm compared to the standard normal MRI comparator group. These metabolite changes 
were not seen in basal ganglia, where the only significant difference was in glutamine which 
was higher in the MPS II group although total glutamine+glutamate was not significantly 
elevated. 
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Chemical shift (ppm) 
 
Figure 6.9: Mean MR spectra for MPS II (red line) and comparator group (black line, shaded 
area indicates standard deviation) for white matter (left) and basal ganglia (right). 
 
 
 Basal ganglia 
  
White matter 
 MPS2 Comparator MPS2 Comparator 
n  8 63 8 53 
Median (range) age (yrs) 7.9 4.1 (0.5-16.7) 8.6 4.7 (0.5-16.7) 
Cr 4.22 (0.63)  4.55 (0.59) 2.47 (0.53) † 3.18 (0.47) 
Gln 3.01 (1.27)† 1.98 (0.79) 1.35 (0.60) 1.32 (0.62) 
Glu 4.56 (1.34) 4.45 (0.78) 2.26 (1.00) † 3.51 (0.78) 
Ins 2.77 (0.65) 2.49 (0.43) 2.77 (0.59) 2.57 (0.39) 
Lac 0.19 (0.49) 0.11 (0.20) 0.27 (0.33) 0.21 (0.28) 
Scyllo 0.14 (0.09)* 0.07 (0.08) 0.12 (0.05) 0.09 (0.06) 
Tau 0.32 (0.65) 0.63 (0.49) 0.21 (0.22) 0.32 (0.37) 
Gua 1.14 (0.20) 1.01 (0.32) 0.70 (0.21) 0.75 (0.21) 
tCho 1.01 (0.18) 1.11 (0.18) 0.81 (0.17) † 1.08 (0.15) 
tNAA 4.82 (0.87) 5.21 (0.51) 3.34 (1.24) † 5.11 (0.73) 
Gln+Glu 7.57 (2.55) 6.43 (1.39) 3.60 (1.32) † 4.84 (1.18) 
MMLip1.4 5.21 (2.31) 4.27 (1.63) 7.27 (2.35) † 4.88 (2.18) 
MMLipd0.9 3.80 (1.09) 4.12 (0.95) 3.64 (0.56) 3.73 (0.66) 
MMLip2.0 7.97 (2.53) 8.20 (1.30) 6.83 (1.40) 7.65 (1.52) 
 
Table 6.3: Mean MR spectroscopy derived brain metabolite values for MPS II and 
comparator cohorts for basal ganglia and white matter. Student’s t-test between MPS II and 
comparator cohorts, † p<0.01, * p<0.05. 
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Figure 6.10: Bar charts of mean metabolite concentrations for MPS II and comparator cohort 
from basal ganglia (upper panel) and white matter (lower panel). Student’s t-test between 
MPS II and comparator cohorts, † p<0.01, * p<0.05. 
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6.7.5. Correlation of MRS, age and quantitative MRI parameters 
Correlations between the MRS-determined metabolite concentrations, age and the quantitative 
MRI parameters were analysed (figures 6.11 and table 6.4). No significant correlation was 
found between white matter metabolites and age, whereas in basal ganglia there was a 
significant (p<0.01) negative correlation between creatine (r=-0.61), inositol (-0.67) and 
choline (-0.79) and age (table 6.4). 
 
All metabolites had a negative correlation with both of the ventricular ratio scores, reaching 
statistical significance for white matter creatine, tNAA and glutamine+glutamate and for basal 
ganglia tNAA and glutamine+glutamate. The strongest correlation was between white matter 
tNAA and occipital horn ratio (r=-0.79).   
 
 
The data above have shown that the white matter abnormality score correlated with the 
ventricular ratio. The white matter tNAA also varies significantly with the white matter 
abnormality score (ANOVA p=0.001; figure 6.13).  
 
All of the metabolites showed a trend to decrease with increasing ventricular index, with 
several reaching significance. To evaluate whether this simply reflected a loss of metabolites 
within the voxel due to generalised cell loss, individual metabolites were normalised to the 
total metabolite concentration detected and the correlation between the corrected metabolite 
values and the ventricular index re-appraised (figure 6.12, table 6.5). 
 
Corrected white matter tNAA and white matter glutamine+glutamate were significantly 
negatively correlated to ventricular index, while white matter inositol was significantly 
positively correlated to ventricular index. In basal ganglia only glutamine+glutamate showed 
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significant (negative) correlation with ventricular index. The negative correlation between 
white matter creatine and ventricular index and between basal ganglia tNAA was not seen in 
the analysis of the corrected metabolite data. 
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Figure 6.11: (see over for caption) 
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Figure 6.11: (See also previous page). Plots of correlation between metabolites (absolute 
value) and occipital horn ventricular ratio for white matter (WM) and basal ganglia (BG). 
 
 
 
 
 White matter    Basal ganglia    
 Cr Ins Cho tNAA Gln+Glu Cr Ins Cho tNAA Gln+Glu 
Age at MRI 
 
0.12 -0.19 0.23 0.22 0.20 -0.61† -0.67† -0.79† -0.31 0.05 
Evans Ratio 
 
-0.40 -0.11 -0.15 -0.56* -0.70† -0.48 -0.31 -0.25 -0.38 -0.60* 
Occipital 
horn Ratio 
-0.55* -0.16 -0.38 -0.79† -0.69† -0.48 -0.11 -0.24 -0.60* -0.56* 
 
Table 6.4: Pearson correlation coefficients for correlation between brain metabolites, age, 
Evans ratio and occipital horn ratio in MPS II cohort. Significance, † p<0.01, * p<0.05 
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Figure 6.12: (see over for caption) 
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Figure 6.12: (See also previous page) Plots of correlation between metabolites (corrected for 
total metabolite concentration) and occipital horn ventricular ratio for white matter (WM) and 
basal ganglia (BG). 
 
 
 White matter    Basal ganglia    
 Cr Ins Cho tNAA Gln+Glu Cr Ins Cho tNAA Gln+Glu 
Age at MRI 
 
-0.09 -0.36 0.11 0.10 0.09 -0.17 -0.45 -0.40 0.07 0.33 
Occipital 
horn ratio 
 
0.24 0.52* 0.39 -0.68† -0.72† 0.13 0.29 0.34 0.01 -0.57* 
 
Table 6.5: Pearson correlation coefficients for correlation between brain metabolites 
corrected for total metabolite concentration, age and occipital horn ratio in MPS II cohort. 
Significance, † p<0.01, * p<0.05 
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Figure 6.13:  Boxplot of tNAA concentrations in each white matter abnormality score 
(WMA) category in MPS II cohort. 
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6.7.6. Serial trends in imaging and MRS data 
Serial trends in metabolite concentrations were analysed across the cohort and on a case-by-
case basis. As shown above, several of the metabolites varied significantly with age in the 
basal ganglia. A strong correlation was found between white matter tNAA and occipital horn 
ratio, seen in both uncorrected data and data corrected for total metabolite concentration. 
White matter tNAA was also significantly different in the MPS II cohort from the normal 
MRI comparator group.  
 
On this basis, case-by-case trends in white matter tNAA were analysed (figure 6.14, which 
also shows the normal age variation in tNAA from the normal MRI comparison datasets). All 
MPS II cases apart from patient 7 (attenuated phenotype) had white matter tNAA levels that 
were below the range of normal values. The lowest tNAA levels corresponded to the most 
severely affected boys (e.g. case 1).  In all children where serial MRS data was available the 
tNAA fell with time, with progressive decreases seen in children with ongoing clinical 
deterioration (e.g. case 5).   
 
The trends seen in case-by-case analysis of tNAA corresponded to the trends in occipital horn 
ratio (figure 6.15), e.g. for case 5 the ventricular ratio increased as tNAA decreased in white 
matter; for case 2 the ventricular ratios remained relatively stable, although in this child there 
appeared to be a progressive fall in the tNAA in both white matter and basal ganglia 
suggesting ongoing disease progression. 
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Figure 6.14: Plot of white matter tNAA concentration against age for normal MRI 
comparator group (open circles) and MPS II patients with serial determinations (squares) and 
single time point only (diamonds) 
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Figure 6.15: Age related trends in occipital horn (filled squares) and Evans (filled triangles) 
ratios and white matter tNAA (open squares) and basal ganglia tNAA (open circles) for two 
MPS II patients with serial data. 
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6.8. Discussion 
Involvement of the CNS in MPS II is indicative of the “severe” phenotype; in the present 
study the majority of subjects had some degree of CNS disease evidenced by clinical 
characteristics and supported by MR imaging features. Only one of the boys studied (patient 
7) fell within the classical “attenuated” phenotype, with relatively normal neurology and 
cognitive function maintained to the middle of the second decade. That said, considerable 
variation in the degree of cognitive and neurological disease was evident in the cohort, 
supporting the concept of a disease continuum rather than two distinct phenotypic groupings 
often reported in the literature. 
 
All of the subjects studied were receiving ERT, and the MRS data presented (apart from one 
examination) were obtained in boys while on ERT. Some MR imaging data was available 
ante-dating the commencement of ERT. The clinical and imaging features described here are, 
therefore, a description of the amended natural history of the disease in the “ERT era” [128]. 
The fact that the same range and progression of imaging abnormalities are seen here as 
reported in the older (pre-ERT) literature supports the view that systemic ERT has little 
impact on CNS involvement in MPS II. Many of the subjects described here, however, did not 
start ERT until several years of life when ERT first became clinically available, and it can be 
argued that they may have already accrued several years of neuronal damage before the start 
of treatment. 
 
The MRI features seen in this cohort are consistent with previous descriptions of brain 
involvement in MPS II, in particular progressive ventricular enlargement/ hydrocephalus, 
brain atrophy, white matter abnormalities and enlarged perivascular spaces (PVS) [144-146]. 
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Enlarged PVS were seen in all children irrespective of neurocognitive status, as previously 
reported. The quantitative assessment of ventricular size and assessment of white matter 
abnormality scores found that these two features correlated with each other, suggesting that 
they are common features of the brain pathological insult rather than independent processes. 
Furthermore, progressive alterations in both measures of brain disease were seen in all 
children, with more rapid elevations in ventricular size corresponding to children with more 
aggressive clinical deterioration. This finding is in agreement with a previous study of MRI 
features in MPS II that found that white matter abnormalities, ventricular enlargement and 
spinal stenosis (not assessed in the current work) are potential disease severity markers [145]. 
It should be noted that the quantitative MR parameters assessed in this work were derived by 
a single observer (JED) not blinded to diagnosis, MRS data or clinical information; for future 
prospective analyses multiple observers blinded to clinical characteristics should undertake 
confirmation of these preliminary findings. 
 
  
Previous studies using semi-quantitative MRS have demonstrated an elevated inositol/creatine 
ratio and a non-statistically significant trend to decreased NAA/creatine ratio in cognitively 
impaired children with MPS II [144, 146]. The present data confirm and extend these MRS 
findings in the cohort of children with MPS II using a large comparator cohort with normal 
MR imaging. In general, metabolite alterations were more pronounced in the white matter 
than the basal ganglia.  
 
In this study tNAA was decreased in both white matter and to a lesser degree in basal ganglia, 
reflecting the predominantly white matter changes seen on MRI and neuropathological 
studies. However the decreased tNAA in basal ganglia implies that the deep gray matter 
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structures are not spared entirely, as reported in severely affected patients [153]. NAA 
originates in neuronal cells [50], and decreased concentrations have been correlated with 
disease progression and loss of neuronal viability in many lysosomal storage disorders [8, 9].  
The observation of higher tNAA in children with mild cognitive impairment compared to 
those with moderate-severe impairment, and the progressive alterations with time mirroring 
clinical progression suggest that tNAA may be a useful disease biomarker.  
 
Elevated inositol, a phosphoinositide precursor located in glial cells, may imply glial 
proliferation or gliosis. Inositol was higher (non-significant trend) in MPS II in white matter 
and basal ganglia compared to the normal MRI comparator group; the ratio of inositol to 
creatine was increased in both regions compared to the comparator group in line with the 
previous MRS studies reported. This underlines the problem of using creatine as a supposed 
static denominator, since it can be seen that creatine does in fact alter in pathological states. 
That said, the relative preservation or modest increase in inositol compared to loss of creatine 
and tNAA suggests that there may be a mild expansion of the glial compartment, in 
agreement with neuropathological reports in MPS that found minor gliosis [136]. Further 
evidence for this is given by the positive correlation between the total metabolite-corrected 
white matter inositol and ventricular index, suggesting that there is relatively more inositol 
present with increasing brain degeneration as documented by ventricular index. 
 
White matter also showed decreased levels of glutamine+glutamate, predominantly due to a 
decrease in glutamate, reflecting loss of active neuronal cells, while glutamine which is 
predominantly synthesised in glial cells was relatively spared (see Chapter 7 for discussion of 
validity of interpretation of glutamate and glutamine separately). Elevated lipids were 
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detected in white matter but not basal ganglia and this may reflect the neuropathological 
process in white matter. Increased lipids are seen in a range of brain pathologies including 
malignancies and acute inflammatory disorders and are associated with cell stress, apoptosis 
and necrosis [154]. 
 
In the analysis of the correlation between brain metabolites and the quantitative MRI 
parameters, all metabolites were seen to have a negative correlation with the ventricular 
index, reaching statistical significance for white matter tNAA, glutamine+glutamate and 
creatine, and for basal ganglia tNAA and glutamine+glutamate. This suggests that there may 
be general loss of metabolite signal due to either increased water (CSF) within the voxel or 
loss of tissue (cell number). Gross contamination of voxels with CSF was excluded by visual 
appraisal of voxel contents, but to assess whether the metabolite alterations seen were simply 
a reflection of tissue loss, such that there was less cell mass within the MRS voxel giving rise 
to the metabolite signal, metabolites were corrected using the total metabolite concentration as 
denominator.  
 
This revealed some interesting findings: corrected white matter tNAA and 
glutamine+glutamate again showed a significant negative correlation with ventricular index, 
and corrected white matter inositol was significantly positively correlated with ventricular 
index. These data suggest that as the brain disease worsens (evidenced by increasing 
ventricular index) there is progressive neuronal loss (decrease in tNAA and Gln+Glu) but 
relative increase in the glial compartment as evidenced by the rising inositol levels.  Within 
the basal ganglia, corrected tNAA did not correlate with the ventricular index (r=0.1) 
suggesting preservation of the basal ganglia neuronal cells. However, there was a negative 
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correlation between basal ganglia glutamine+glutamate and ventricular index, suggesting that 
these amino acids are depleted. 
 
The trends in metabolite alterations were detected on analysis of the total cohort. Analysis of 
the data on a per-case basis found that the changes in both the quantitative MRI parameters 
and also the white matter tNAA corresponded to the clinical course of the disease in each 
patient, such that the tNAA was higher and ventricular index lower with better neurocognitive 
status, and that rates of progressive changes corresponded to alterations in the clinical status. 
In the absence, however, of formal neurocognitive assessment it is difficult to convincingly 
demonstrate this link, and neurocognitive assessment should be a part of future prospective 
studies. 
6.9. Conclusions & Future Perspectives 
The MRS data presented here throws light on the neurochemical correlates of conventional 
imaging features, and seem to be consistent with current understanding of the disease 
neuropathology of MPS II. Furthermore, alterations in the neurochemical profile do 
correspond to the alterations in quantitative MR parameters, suggesting that a composite 
model combining multiple parameters from conventional and functional imaging could 
provide a means of monitoring disease progression, as has been proposed for another LSD, 
late infantile neuronal ceroid lipofuscinosis [100]. That said, incorporation of MRS data into a 
multi-parameter imaging scoring system must be shown to provide added benefit over and 
above the conventional imaging parameters. While both the conventional parameters and 
metabolite data seem to track the clinical progression well, loss of brain mass (i.e. 
ventriculomegaly) and the development of white matter abnormalities are relatively late steps 
in the pathological cascade. MRS has the potential to detect earlier alterations, prior to the 
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appearance of MRI-visible changes. As has been noted, the boys studied here already have 
established brain disease. In all cases with brain involvement, the tNAA was below the 
normal comparator range even in the earliest available MRS studies, at a time when the 
ventricular index scores were (near) normal, suggesting that neurochemical alterations may 
predate the neuroimaging alterations. It would be interesting to have further prospective 
multimodal imaging data acquired in boys from a young age without evidence of clinical CNS 
involvement to evaluate this hypothesis further.  
 
In addition to conventional MRI and MR spectroscopy, other functional modalities may also 
provide further information that could be incorporated in to a multi-parameter model, such as 
diffusion weighted or diffusion tensor imaging that give information about tissue 
microstructural alterations. These modalities warrant further investigation, particularly for 
their ability to detect early microstructural alterations prior to changes visible on conventional 
MRI. A direct method of non-invasive quantification of tissue GAG content would provide 
another means of monitoring disease progression. GAGs are not readily visible using the 
standard one dimensional proton MRS technique presented here, and a previous paper that 
reported GAG detection was methodologically flawed as discussed above [147]. Alternative 
imaging methods are available with the potential to measure GAGs, specifically the chemical 
exchange-dependent saturation transfer (CEST) method which is based on the transfer of spin 
saturations from protons to the bulk water pool [155], achieving significant enhancement of 
the signal detected. This method has been used to image tissue pH and liver glycogen [156], 
and a similar technique has been applied to brain experiments [157]. 
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Chapter Seven 
 
 
7. Propionic Acidaemia 
 
 
 
In this chapter data are presented illustrating the use of MR imaging and MR spectroscopy in 
the evaluation of the brain pathology of a specific disorder of branch chain amino acid 
metabolism, propionic acidaemia. In particular, the techniques are employed to investigate the 
pathogenesis and pathophysiology of strokes affecting children with this disorder. The MR 
spectroscopy data has been reported in Orphanet Journal of Rare Diseases  2011 and is the 
first report of the use of MRS in this disorder during acute metabolic decompensation (see 
Appendix B)[158]. 
 
7.1. Introduction to Propionic Acidaemia 
 
The organic acidaemias are disorders resulting from abnormalities within the branch chain 
amino acid (BCAA) catabolic pathways (figure 7.1) [159]. Propionic acidaemia (PA, OMIM 
#606054) is an autosomal recessive disorder resulting from deficiency of the biotin-dependent 
mitochondrial enzyme propionyl CoA carboxylase (PCC, EC 6.4.1.3) [160, 161].  
 
PCC is composed of six α and six β subunits; the α subunit is encoded by PCCA 
(chromosome 13q32) while the β subunit is encoded by PCCB (3q13.3-q22) [162]. Over 100 
mutations in PCCA and PCCB have been reported [162, 163]. PCCB mutations are more 
frequent, the commonest being c.1218_1231del14ins12 reported in 32% of alleles in a 
Caucasian population [161]. PCC normally converts propionyl-CoA to methylmalonyl-CoA, 
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which is subsequently metabolised to succinyl-CoA which enters the Krebs cycle (figures 7.1 
and 7.2) [164]. Propionyl-CoA is formed from the catabolism of the branch chain amino 
acids, cholesterol side chains and odd-chain length fatty acids and is also generated by 
gastrointestinal bacterial activity [165]. In the absence of functional PCC, propionyl-CoA is 
alternatively metabolised resulting in accumulation of propionate, 3-hydroxy-propionate, 2-
methylcitrate (from condensation with oxaloacetate) and propionylglycine. Common 
biochemical derangements in PA include ketoacidosis, hyperglycinaemia and 
hyperammonaemia [166]. 
 
 
Figure 7.1: Branch chain amino acid catabolic pathways. (Adapted from [167]). 
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The commonest and most severe form of PA presents in the neonatal period with acute 
metabolic acidosis, hyperammonaemia and progressive encephalopathy requiring urgent 
intensive medical support [164]. Newborn screening can identify PA by elevated 
propionylglycine, but in countries including the UK where this expanded screening panel is 
not employed patients still present clinically [168]. The ability of newborn screening to 
provide benefit in terms of reduced morbidity has however been questioned [169]. 
 
PA is associated with numerous multi-system complications in addition to the acute metabolic 
decompensation. Outside the CNS these include dilated cardiomyopathy, cardiac arrhythmias 
(including prolonged QT syndrome and sudden death), pancreatitis, and pancytopaenia in 
particular neutropaenia [161].  
 
The mainstays of treatment are: dietary protein restriction with attention to ensuring adequate 
nutrition is provided, sometimes necessitating nasogastric or gastrostomy feeding; carnitine 
supplementation; use of pro-motility agents and bactericidal therapy to reduce gastro-
intestinal bacterial load and consequent propionate production; and aggressive management of 
acute metabolic derangements and other associated pathologies including pancreatitis [170]. 
Some centres utilise alternative pathway drugs including sodium benzoate to minimise the 
consequences of hyperammonaemia although the evidence for their use is not strong [170]. 
Orthotopic liver transplantation may prevent neurocognitive decline but its role remains 
controversial [171, 172], and current consensus guidelines recommend it may be considered 
where individuals suffer recurrent episodes of hyperammonaemia or acidosis [170].   
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7.2. Neurologic involvement in propionic acidaemia 
The neurological manifestations of PA include both acute events (e.g. acute coma and 
metabolic stroke-like episodes) and chronic long-term complications. Despite optimal 
management, later neurologic sequelae are a major cause of morbidity, and include hypotonia, 
neurodevelopmental delay, seizure disorders and myoclonus, episodic acute encephalopathy, 
and movement disorders due to a propensity to basal ganglia infarction [10, 19] which can be 
responsive to L-DOPA therapy [173]. Additionally optic nerve atrophy, cerebral atrophy and 
extra-pyramidal syndromes have been reported [161]. Developmental delay and intellectual 
impairment are very common in PA, even where metabolic control is well maintained [174]. 
The degree of cognitive impairment is related to the age of disease onset, such that children 
with early-onset PA have lower IQ scores than those presenting with a presumably milder 
disease at an older age [175]. However, other neurological features including acute basal 
ganglia injury and movement disorders may affect children presenting with either early or late 
onset disease [175]. 
 
The natural history of neuroimaging features in PA has not been systematically studied. 
Common MRI features reported in small case series include generalised brain atrophy [176] 
and delayed myelination [19]. Cerebellar haemorrhage has been reported at presentation in 
neonates, but may be an incidental finding [19]. Imaging features corresponding to acute basal 
ganglia injuries include increased T2 signal and alterations in diffusion parameters, with later 
evidence of atrophy of these structures. A combined MRI and positron emission tomography 
(PET) study demonstrated progressive alterations in the basal ganglia: initial imaging and 
uptake were normal, but subsequent examinations found increased basal ganglia T2 signal and 
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increased 18fluro-2-deoxyglucose (18FDG) uptake [177]. At a later time point the basal ganglia 
were found to be atrophied with decreased 18FDG uptake implying a “burned out” end stage.  
 
The deep gray matter structures are vulnerable particularly during metabolic decompensation 
[175, 178, 179] but may also be affected during apparent metabolic stability [19]. Acute basal 
ganglia injury may be the initial presentation of late onset disease in previously asymptomatic 
children [10, 180, 181]. Acute changes in the basal ganglia can be seen at an earlier age, for 
example in a 6 month old child presenting with infantile spasms [182]. In this case, the child 
received vigabatrin therapy for the infantile spasms that the authors suggested protected the 
basal ganglia from irreversible excitotoxic damage. 
 
The basal ganglia are gray matter nuclei sited near the base of each cerebral hemisphere, 
comprised of the striatum (caudate, putamen and ventral striatum), globus pallidus, substantia 
nigra and subthalamic nucleus [183]. They facilitate action selection in the control of 
movement, and damage to the pathways results in movement disorders such as in Parkinson’s 
disease [184]. The striatum receives excitatory inputs from the cortex and thalamus; 
dopaminergic projections flow from the striatum to the globus pallidus and substantia nigra; 
finally outputs from the basal ganglia arising from the globus pallidus then connect to the 
thalamus and other nuclei resulting in the modulation of cortical movement signalling [184]. 
 
Post mortem neuropathological studies in children with PA have demonstrated a range of 
abnormalities. A 9 year old child was found to have acute haemorrhagic lesions in the basal 
ganglia with evidence of vascular proliferation and swollen endothelial cells suggestive of 
compromise of the blood brain barrier [185]. A 3 year old child was reported to have vascular 
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and parenchymal mineralisation and spongy change with foci of acute neuronal injury [185]. 
An infant who succumbed to severe disease in the first two weeks of age had spongiform 
changes in the white matter and basal ganglia [186]. Interesting findings were demonstrated in 
one child with neonatal onset disease who died of respiratory complications at 4 years of age 
[187]. The child was found to have a normal brainstem and cerebellum, but there was 
significant vacuolization in the frontal and occipital cortices, with prominent changes and loss 
of neurons in the hippocampus. The basal ganglia (caudate, putamen and globus pallidi) also 
showed vacuolization. 
 
7.3. Pathophysiological mechanisms of neurologic complications 
The pathophysiology of the neurological complications of PA is incompletely understood, 
with different mechanisms at work during acute metabolic decompensation and the chronic 
“insidious” phase [19]. In particular, it is not known why the basal ganglia appear to be so 
vulnerable to infarction in PA. During acute presentations systemic metabolic alterations may 
have deleterious effects on the CNS, including hypoglycaemia, keto-lactic acidosis and 
hyperammonaemia which may all cause neuronal injury. Cerebral oedema is common, 
resulting in hypoperfusion of the CNS and subsequent ischaemic/hypoxic insults.  
7.3.1. Hyperammonaemia 
High blood ammonia concentrations (hyperammonaemia) is an important contributor to 
neuropathological processes in PA [188]. Hyperammonaemia is known to be deleterious in 
urea cycle disorders and acute liver failure [189]. In these disorders several mechanisms are 
postulated to mediate the deleterious effects of ammonia, including: direct neurotoxicity; cell 
and brain oedema secondary to the conversion of ammonia to glutamine by astrocytes; 
glutamate mediated excitotoxicity; effects on vasculature (vasogenic oedema) and or altered 
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water and potassium homeostasis [189]. Similar mechanisms may play a role in PA. 
Hyperammonaemia in PA arises by different mechanisms, and may be secondary to inhibition 
of the urea cycle enzyme carbamoyl-phosphate synthase-1 due to decreased availability of its 
activator N-acetylglutamate, which is caused by competitive inhibition of N-acetylglutamate 
synthase by propionyl CoA [190]. In contrast to urea cycle disorders, hyperammonaemia in 
PA may be associated with low glutamine levels [188]. 
 
7.3.2. Toxic metabolite accumulation 
A number of metabolites accumulate in PA, which may have neurotoxic effects. For example, 
intra-striatal injection of propionate causes seizures in rats. These effects are ameliorated by 
the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist MK801 suggesting 
that the NMDA receptor may play an important role in the disease pathogenesis [191]. 
Propionate is metabolised oxidatively by glial cells but not neurons, suggesting that glia may 
be more vulnerable to toxicity in PA [192]. 
 
Glycine may have excitatory effects via the NMDA receptor, which may be important given 
the high glycine concentrations found in CSF and blood in PA [178].  Furthermore, locally 
synthesised dicarboxylic acids and tricarboxylic acids may be trapped within the central 
nervous system exacerbating their pathological effects [193].  
 
7.3.3. Compromised energy metabolism  
Several components of normal energy metabolism may be compromised in PA, which would 
have the greatest impact on tissues with the highest energy requirements such as the basal 
ganglia. Several key enzymes including the pyruvate dehydrogenase complex, complex III of 
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the electron transfer chain, and the α-ketoglutarate dehydrogenase complex are all inhibited 
by propionyl-CoA, and in vitro analysis of energy pathways in muscle biopsies of patients 
with PA supports the finding of compromised energy metabolism [194]. There is also 
evidence for a role of oxidative stress, thus for example ascorbic acid affords protection to 
rats injected with propionate [19]. 
 
7.3.4. Compromised Krebs Cycle Anaplerosis Theory  
Dysfunction of the Krebs cycle may also result from depletion of its intermediary metabolites 
due to compromised “anaplerosis”. Anaplerosis is “the re-filling of the catalytic intermediates 
of the [Krebs] cycle that carry acetyl-CoA as it is oxidized” [195]. Cataplerosis is the 
opposite balancing mechanism of removal of excess Krebs cycle intermediates. The Krebs 
cycle converts the carbon atoms of acetyl-CoA to carbon dioxide, with the production of 
reducing equivalents NADH and FADH2 (reduced flavin adenine dinucleotide) that then enter 
the electron transport chain resulting in ATP generation. The Krebs cycle finally regenerates 
the acetyl group acceptor oxaloacetate (figure 7.2) [196]. 
 
It has been estimated that 1-2% of the total pool of Krebs cycle intermediates is depleted via 
cataplerosis per minute [195]; this loss of metabolites must be corrected by anaplerotic 
mechanisms to ensure the cycle can continue to function. In addition to maintaining 
appropriate pools of the Krebs cycle intermediates, these pathways also play roles in 
gluconeogenesis from amino acids, lactate and pyruvate, the regulation of neurotransmitter 
synthesis in brain, and insulin secretion in pancreatic β-cells [195]. 
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There are several important anaplerotic reactions (figure 7.2), notably the supply of 
oxaloacetate from pyruvate by pyruvate carboxylase, the supply of α-ketoglutarate from 
glutamate and glutamine, and the supply of succinyl CoA via the metabolism by PCC of 
propionyl-CoA derived from intestinal propionate, odd chain fatty acids, propionylcarnitine 
and branch chain amino acids. This third anaplerotic route has been successfully manipulated 
in the treatment of pyruvate carboxylase deficiency by supply of the propionyl-CoA precursor 
triheptanoin [197]. 
 
Krebs cycle anaplerosis is compromised in PA for several reasons. Firstly, propionyl CoA 
cannot be metabolised and therefore the third anaplerotic supply route cannot function. 
Secondly, oxaloacetate is depleted by condensation with propionyl-CoA to form 
methylcitrate. Thirdly, propionate may also inhibit pyruvate conversion to oxaloacetate. There 
is evidence that there is subsequent citrate depletion, and the functional lack of α-
ketoglutarate shifts the equilibrium of reactions catalysed by glutamate dehydrogenase 
resulting in the production of ammonia and consumption of glutamate [188]. It is proposed 
that supply of anaplerotic substrates could improve Krebs cycle function in several conditions, 
and a clinical trial of dietary supplements in PA with glutamine or α-ketoglutarate is in 
progress (US National Institutes of Health clinical trials register (www.clinicaltrial.gov) 
reference NCT00645879).  
 
Extensive alterations in the plasma amino acid profile are detected in PA, many of which may 
be secondary to the depletion of α-ketoglutarate [166, 198]. Depleted amino acids include 
glutamine, histidine, threonine, the branch chain amino acids leucine, isoleucine and valine, 
phenylalanine and arginine. Concentrations of glycine, lysine, alanine and aspartate are 
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increased [198]. Hyperglycinaemia is caused by inhibition of the hepatic glycine cleavage 
system, although this is not the case within the brain [199]. Alanine is elevated secondary to 
lactic acidosis caused by propionyl CoA inhibition of pyruvate dehydrogenase.  
 
Amino acids within the CSF are also deranged, with particular elevations of alanine and 
glycine reported at times of metabolic decompensation [179]. Glutamine in CSF was elevated 
in the presence of low plasma glutamine and hyperammonaemia in an acutely ill neonate 
[200]; in a 10 year old child during an acute encephalopathic episode CSF glutamine was 
elevated and plasma glutamine decreased following hyperammonaemia. However other 
reports have demonstrated low/normal CSF glutamine in metabolic stability associated with 
normal ammonia concentrations [201]. 
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Figure 7.2: Anaplerosis of the Krebs cycle. Main points of anaplerosis indicated by (+). PC, 
pyruvate carboxylase; PDH, pyruvate dehydrogenase; GDH, glutamate dehydrogenase; SDH, 
succinate dehydrogenase. NADH, FADH2 (Adapted from [196]). 
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7.4. In vivo brain MRS in propionic acidaemia 
The many suggested pathogenic mechanisms discussed above could result in alterations in 
brain tissue metabolism which would be amenable to study using non-invasive MRS. Two 
previous small studies have been reported in the context of PA, all reporting findings in 
patients who were “well” i.e. metabolically stable at the time of MRS. 
 
Chemelli et al reported brain MRS data from four patients with PA using long echo time 
single voxel or chemical shift imaging with semi-quantitative peak area estimation [202]. Two 
children had mild brain atrophy, and these patients had decreased NAA/Cho ratio in 
periventricular white matter, while NAA/Cho was normal in the two children with normal 
MR imaging. None of the patients had basal ganglia abnormalities on MRI, and MRS did not 
sample the basal ganglia. All four children had elevated levels of lactate detected, not seen in 
control patients. This suggests that brain tissue metabolism may be compromised even when 
systemic metabolism is well controlled; organic acids within the CSF are known to be 
elevated even in stable patients [193, 203].  
 
Bergman et al investigated three children with PA and compared them to eight controls [201]. 
This study employed a single voxel short echo time acquisition technique (STEAM) at 1.5T, 
sampling over the basal ganglia and using peak area estimation to quantify NAA, choline and 
inositol, and glutamine+glutamate/creatine ratio. All patients had normal ammonia at the time 
of MRI, and all had mild ventricular enlargement. One of the three had T1 and T2 signal 
abnormalities in the caudate and putamen. In general, NAA and myo-inositol were decreased, 
and one child had elevated choline. The glutamine+glutamate/creatine ratio was elevated 
compared to controls. The authors suggest a mechanism whereby hyperammonaemia results 
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in elevated glutamine, with a secondary compensatory decrease in inositol to regulate osmotic 
pressures. However, since ammonia levels were normal alternative mechanisms may exist 
within the brain.  
 
7.5. Aims & Objectives 
This section of the current work aimed to explore the various pathogenesis hypotheses 
described above, specifically by analysis of the differential alterations in brain metabolite 
profiles seen during metabolic stability and during acute metabolic decompensation in PA 
patients. 
 
7.6. Methods 
7.6.1. Patients 
Patients were recruited from a single tertiary paediatric IMD unit. Clinical data were extracted 
from medical records including age at diagnosis, mode of presentation, therapeutic modalities 
and history of subsequent acute neurological events. Available blood quantitative amino acid 
and ammonia determinations were also collated from the medical record. MR imaging and 
MR spectroscopy were performed either electively or in the context of acute metabolic 
decompensation requiring intensive care support. 
7.6.2. Conventional MRI: qualitative and quantitative analysis 
All available brain MRI studies were retrospectively reviewed, including review of the 
qualitative radiology reports by the consultant paediatric radiologist with particular attention 
paid to appearances of the basal ganglia. 
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Signal abnormalities within the basal ganglia were further assessed by a semi-quantitative 
analysis of the T2 signal and apparent diffusion coefficient (ADC; see Appendix A for 
discussion of this DWI parameter). An axial slice at the level of the inferior border of the 
corpus callosum was identified and axial T2 weighted and axial ADC maps were co-
registered. Regions of interest (ROI) defining the head of caudate, putamen, globus pallidus 
and posterior-medial thalamus were manually delineated (single observer, JED) on T2 images 
and ADC maps and the average signal from each ROI recorded. The ratio of signal from each 
basal ganglion ROI to the signal from the medial thalamus was calculated to allow inter-scan 
comparison. Measurements were made using the clinical picture archiving and 
communication system (PACS, Agfa Impax 6.4.0.4841, Apache Software Foundation, Agfa 
Healthcare, Belgium) by a single observer (JED) (figure 7.3). Comparison of data from PA 
patients was made with data from 47 MRI studies from patients without PA who had normal 
MR imaging as adjudged from the qualitative radiologist report. 
 
 
 
Figure 7.3: Manual identification of basal ganglia structures in axial T2 weight image (left) at 
level of inferior border of corpus callosum (right). 
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7.6.3. MR Spectroscopy 
MRS studies were performed concurrently with clinically indicated MRI scans at 1.5 Tesla 
facilitated by general anaesthesia as needed. It was possible to acquire MRS for some patients 
during episodes of acute metabolic decompensation/ encephalopathy, when patients required 
intensive care support. Comparison was made with MRS metabolite data from the standard 
cohort of children with normal appearing MRI and similar age profile (white matter, n=53, 
median (range) age 4.7(0.5-16.7) years; basal ganglia n=63, 4.1(0.5-16.7) years). Comparison 
was also made between MRS data acquired in stable PA patients with data acquired from 
acutely unwell children to evaluate alterations in brain metabolite profile in these settings.  
7.6.4. Urine NMR Spectroscopy 
Mid stream random urine samples were collected from PA patients attending outpatient clinic. 
Samples were processed, stored and analysed as described in Chapter 3.  
 
7.7. Results 
7.7.1. Patient characteristics 
Nine children (two female) with propionic acidaemia were studied (median age at first MRS, 
36 months (range 4-190 months) (see table 7.1). All were diagnosed in the neonatal period, 
four requiring neonatal haemofiltration due to severe hyperammonaemia and metabolic 
acidosis. Two children had received elective orthotopic liver transplantation during early 
childhood. The remaining seven children all received regular oral carnitine and sodium 
benzoate, and three received sodium phenylbutyrate, in addition to dietary protein control 
under management of a specialist dietetic team.  
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Four children had one or more severe acute episodes with encephalopathy beyond the 
neonatal period requiring intensive care support (“severe acute episode” hereafter). During 
these episodes all children required ventilatory support and three required continuous veno-
venous haemofiltration (CVVH), and only one episode was associated with significant 
persistent hyperammonaemia. During these episodes three children received intravenous 
sodium benzoate and two received sodium phenylbutyrate, while two received N-
Carbamylglutamate to treat hyperammonaemia with good effect. 
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 Neonatal 
CVVH? 
Liver 
Transplant 
(age, years) 
Other 
diagnoses 
Age at MRI 
(years) 
Status at 
time of 
MRI 
Metabolic Drugs & 
Dietary Restrictions 
Acute 
encephalopathic 
episodes: 
complications 
 
MRI findings  
 
Maintenance 
 
Acute 
 
Basal ganglia 
 
Other features 
1 
 
Yes   1.3 Stable LC, SB, PR   Normal  
2 Yes  Hypo-
throidism 
1 Enceph. SP, SB, LC,  
T, M, PR 
SP, SB, 
NC 
Sepsis & hyper-
ammonaemia,  
Acutely swelling 
caudate, dentate  
 
1.2 Stable SB, LC, T, 
PR 
 
  Resolving 
swelling 
Delayed myelination, enlarged ventricles  
3 Enceph. SB, LC, T, 
PR 
 Cardiomyopathy, 
pneumonia 
 
Acute swelling 
caudate, putamen, 
dentate 
Delayed myelination, enlarged ventricles, hippocampal 
atrophy 
3 No  Epilepsy 6.2 Enceph. SB, LC, PR SB, LC  Atrophic, high 
T2. Haemorrhage 
Global loss of cerebral volume 
    9.5 Enceph. SB, LC, PR SB  
LC 
Rhabdomyolysis Cystic 
encephalomalacia
Enlarged ventricles / cerebral volume loss 
4 Yes  Hypo-
thyroidism 
1.2 Stable SB, SP, LC, 
PR 
  Normal Mild volume loss 
4 Stable SB, SP, LC, 
PR 
  Normal 
 
Mild volume loss, thin corpus callosum 
6 Enceph. 
 
SB, SP, LC, 
PR 
SP, SB, 
LC 
 
Pneumonia 
 
Acute swelling 
caudate + 
putamen 
Cerebral volume loss, small hippocampi 
5 Yes   0.6 Stable SB, LC, PR 
 
  Normal Mild ventricular dilation 
3.1 Stable    Normal Disturbed myelination 
6 No   3 Stable SB, SP, LC, 
PR 
  Normal 
 
Hippocampal sclerosis 
 
7 No Yes (1.3) 
 
 15 Stable Anti-
rejection 
  Normal  
8 No Yes (2.5) Myoclonic 
epilepsy 
6.5 Stable Anti-
rejection 
LC 
  Normal Mild ventricular enlargement 
    13 Stable Anti-
rejection 
LC 
  Normal Mild ventricular enlargement. Unilateral mesial temporal 
sclerosis 
9 No   0.3 Stable* LC, PR   Normal Normal 
    1.5 Enceph LC, PR NC (x2) Varicella  Acute high T2 
signal globus 
pallidi. 
Increased ventricular size & white matter T2. 
  *required ventilation for RSV bronchiolitis but not encephalopathic.  
Table 7.1: Summary of clinical characteristics of propionic acidaemia cohort and MR imaging findings. MRS, magnetic resonance 
spectroscopy; CVVH, Continuous veno-venous haemofiltration; LC, L-carnitine; SP, Sodium Phenylbutyrate; SB, Sodium Benzoate; M, 
metronidazole; T, thyroxine; NC, N-Carbamylglutamate; PR, dietary protein restriction; Enceph., denotes acute encephalopathic episode. 
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7.7.2. Magnetic Resonance Imaging 
The basal ganglia appeared qualitatively normal in all children (n=7) prior to any severe acute 
episode beyond the neonatal period (figure 7.4), and also the quantification of T2 and ADC 
signal in the basal ganglia was also normal in this group (figure 7.5). MRI scans obtained 
during severe acute episodes demonstrated abnormal signal in the basal ganglia variably 
including the caudate heads, putamen and globus pallidi and in some cases there was also 
evidence of acute changes in the dentate nuclei and cerebral cortex. Affected areas had 
elevated T2 signal, while alterations in the ADC demonstrated both increased and decreased 
values, reflecting the heterogeneity of the insult. One child demonstrated evidence of previous 
basal ganglia infarction relating to a previous acute encephalopathic episode, with cystic 
degeneration of caudate, putamen and globus pallidus.  
 
Interestingly the hippocampi appeared atrophic in seven cases; however, formal quantitative 
volumetric analysis of hippocampal structures was not possible as 3D volume series had not 
been routinely included in the MRI protocol. Cerebral volume loss was most marked in 
children with preceding severe acute episodes.  The two children who had liver 
transplantation had normal appearing basal ganglia, cortex and white matter on MRI 
undertaken more than 10 years post-transplant, with one showing probable temporal mesial 
sclerosis. 
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Figure 7.4: MR images of propionic acidaemia patients. Upper row: T2 weighted axial 
images. Lower row: ADC maps. (A) Patient 5 aged 3.1years. Normal basal ganglia. (B) 
Patient 9 with (left) normal basal ganglia aged 0.3months and (right) hyperintense T2 signal in 
globus pallidus with restricted diffusion on ADC map aged 1.5 years. (C) Patient 2 with (left) 
acutely swollen hyper intense basal ganglia with mixed pattern of restricted and increased 
diffusion on ADC map aged 1 year and (right) resolution of swelling and abnormal diffusion 
aged 1.2 years. (D) Patient 3 aged 9.5 years, hyperintense and atrophic basal ganglia (cystic 
encephalomalacia) with increased ADC. 
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Figure 7.5: Quantitative analysis of basal ganglia T2 and ADC signal in propionic acidaemia 
patients and normal MRI control group. Values plotted as ratio to signal from medial 
thalamus. 
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7.7.3. Magnetic Resonance Spectroscopy 
Six studies from four children were acquired during severe acute episodes requiring intensive 
care support. Seven studies from six children were acquired with elective outpatient MRI 
studies undertaken during metabolic stability and before any severe acute episode had 
occurred. Analysis of mean spectra (figure 7.7) and mean metabolite concentrations (figure 
7.6 and table 7.2) demonstrated metabolite alterations in basal ganglia and parieto-occipital 
white matter, in particular during severe acute episodes.  
 
MRS studies undertaken during metabolic stability before any severe acute episodes beyond 
the neonatal period demonstrated decreased Gln+Glu in basal ganglia compared to the normal 
MRI comparator group but a trend to increase in white matter. Glutamine alone was 
significantly decreased in basal ganglia during metabolic stability. Mean lactate was not 
elevated, although two cases had reliably detected lactate in basal ganglia.  There was no 
significant decrease in the total N-acetylaspartate and N-acetylaspartylglutamate (tNAA) in 
this group. 
 
MRS studies acquired during severe acute episodes demonstrated significantly decreased 
tNAA, Gln+Glu and creatine, and significantly elevated lactate, in the basal ganglia compared 
to both the normal MRI comparator group and to the metabolically stable propionic acidaemia 
cohort. In white matter lactate was significantly elevated but other metabolites were not 
significantly altered. (Data shown are for all severe acute episodes; analysis of first severe 
acute episode only demonstrated similar findings). There were no significant differences 
between groups in brain myo-inositol.   
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Separate analysis of brain metabolites from the two children post-liver transplant 
demonstrated normal basal ganglia tNAA and slightly decreased Gln+Glu. tNAA was 
elevated in white matter and total choline decreased.  
7.7.3.1.Detection of brain glycine and propionate precursors   
MR spectra acquired at long echo time (TE 135ms) were reviewed visually for the presence of 
the singlet peak of glycine at c. 3.54ppm. This peak co-resonates with myo-inositol, but at 
longer echo times the myo-inositol peaks have usually decayed due to the short T2 and so the 
glycine peak may be detected (see also Chapter 5). In two cases (during metabolic stability), 
possible small glycine peaks were identified, with putative glycine concentrations of c. 
0.7mmol/L. In the remainder, visible glycine peaks were not identified. The spectral region 
3.4-4.0 was noted to often have lower signal/noise ratio than up-field regions making the 
identification of small glycine peaks difficult. 
 
Spectra were also visually reviewed for the presence of other unfitted peaks that could 
represent propionic acid or associated propionate metabolites, but no such peaks were 
identified. 
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Basal ganglia metabolites (mM, mean (standard deviation)) 
  
 
Propionic Acidaemia 
Normal MRI 
comparator 
group 
Metabolic 
stability 
(7 studies from 6 
patients) 
Acute 
encephalopathy
(6 studies from 4 
patients)
Post-liver 
transplant 
(2 studies from 2 
patients)
 
 
(63 studies) 
 
Median age  
(years, (range)) 
 
3.1 (0.6-15.9) 
 
4.6 (1.0-9.4) 
 
14.4 (12.9-15.9) 
 
4.1 (0.5-16.7) 
N-Acetylaspartate 5.06 (0.49) 4.07 (0.35)†# 5.35 (0.28) 5.21 (0.51) 
Creatine 4.56 (0.43) 4.02 (0.25)† $ 4.42 (0.14) 4.55 (0.59) 
Glutamine 1.39 (0.39) * 0.99 (0.90)* 1.27 (0.25) 1.98 (0.79) 
Glutamate 4.34 (0.27)  3.37 (0.49)†# 4.30 (0.39) 4.45 (0.78) 
Glutamine+Glutamate 5.73 (0.57) * 4.36 (0.80)†# 5.57 (0.28) 6.43 (1.39) 
myo-Inositol 2.62 (0.26) 2.88 (0.71) 2.39 (0.0) 2.49 (0.43) 
Lactate 0.31 (0.34) 0.80 (0.53)† 0.00 (0.32) 0.11 (0.20) 
Choline 1.08 (0.18) 1.22 (0.21) 0.90 (0.63) 1.11 (0.18) 
 
White matter metabolites (mM, mean (standard deviation)) 
  
 
Propionic Acidaemia 
Normal MRI 
comparator 
group 
Metabolic 
stability 
(7 studies from 6 
patients) 
Acute 
encephalopathy
(5 studies from 4 
patients)
Post-liver 
transplant 
(2 studies from 2 
patients)
 
 
(53 studies) 
 
Median age  
(years, (range)) 
 
3.1 (0.3-15.9) 
 
6.13 (1.5 -9.4) 
 
14.4 (12.9-15.9) 
 
4.7 (0.5-16.7) 
N-Acetylaspartate 4.91 (0.90) 4.41 (0.58) * 6.11 (0.39) 5.11 (0.73) 
Creatine 3.48 (0.26) * 3.47 (0.28) 3.70 (0.00) 3.18 (0.47) 
Glutamine 1.76 (0.79) 1.30 (1.22) 1.62 (0.49) 1.32 (0.62) 
Glutamate 3.45 (0.78) 2.58 (0.70) †$ 4.27 (0.31) 3.51 (0.78) 
Glutamine+Glutamate 5.21 (0.73) 3.88 (1.72) 5.89 (0.80) 4.84 (1.18) 
myo-Inositol 2.76 (0.38) 2.86 (0.60) 2.79 (0.02) 2.57 (0.39) 
Lactate 0.58 (0.51)* 0.69 (0.73)* 0.32 (0.45) 0.21 (0.28) 
Choline 0.99 (0.29) 1.20 (0.26)  0.83 (0.09) 1.08 (0.15) 
 
Table 7.2: Mean MRS derived brain metabolite concentrations in propionic acidaemia and 
normal MRI comparator group. Mann Whitney U test (2 tailed exact significance) for 
difference in metabolite concentrations between stable and encephalopathic propionic 
acidaemia cohort, $ p<0.05, # p<0.01. 
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Figure 7.6: Bar charts of mean metabolite concentrations for basal ganglia (upper panel) and 
white matter (lower panel) for stable and encephalopathic propionic acidaemia patients and 
comparator group. Error bars indicate standard deviation. † p<0.01, * p<0.05. 
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Chemical shift (ppm) 
 
Figure 7.7: Mean MR spectra from propionic acidaemia cohort during metabolic stability 
(blue) and acute encephalopathy (red) and comparator cohort (black dash) from basal ganglia 
(upper panel) and white matter (lower panel).  ppm, parts per million. 
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7.7.4. Quantitative amino acids 
105 plasma quantitative amino acid analyses from the PA cohort were available. 88 of these 
had a concurrent (<24hours) ammonia estimation available. Correlation with ammonia 
concentration was calculated for each amino acid (Pearson correlation coefficient, r, see table 
7.3). Significant correlations between amino acids were also evaluated (table 7.4).  
 
Compared to standard control quantitative amino acid concentrations, amino acids elevated in 
PA patients included alanine, glycine and lysine; glutamine was often low as were the branch 
chain amino acids (see table 7.3 and figure 7.8). The only significant correlations with 
ammonia were between lysine (r=0.45) and tyrosine (r=0.42). Glutamine+glutamate (r=0.04) 
and glutamine alone (r=0.08) did not display a correlation with ammonia (figure 7.9).  
 
Glutamine displayed moderate degree of correlation with each of the urea cycle-related amino 
acids (figure 7.10 and table 7.4). 
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 Mean 
(standard 
deviation) 
Control values 
Median (2.5th-
97.5th centile) 
Ammonia 
Pearson 
correlation (r) 
Alanine 423 (171) 300 (112-592) -0.199 
Arginine 55 (24) 51 (14-102) -0.065 
Aspartate 15 (7)   -0.124 
Citrulline 17 (10)   0.074 
Cysteine 15 (13)   0.028 
Glutamine 388 (176) 539 (326-800) 0.080 
Glutamate 95 (53) 88 (31-219) -0.154 
Gln+Glu 483 (172)   0.036 
Glycine 580 (304) 246 (120-436) -0.019 
Histidine 71 (25) 74 (43-111) -0.151 
Isoleucine 29 (15) 50 (20-91) 0.031 
Leucine 70 (35) 97 (44-169) 0.046 
Lysine 186 (70) 130 (66-242) 0.447† 
Methionine 20 (8) 20 (10-41) -0.065 
Ornithine 43 (23) 59 (24-154) -0.052 
Phenylalanine 48 (16) 48 (30-76) -0.127 
Proline 200 (70) 154 (66-330) -0.104 
Serine 145 (56) 127 (69-206) -0.142 
Taurine 71 (31) 70 (26-169) -0.178 
Threonine 141 (102) 104 (43-218) -0.120 
Tyrosine 53 (23) 51 (29-92) 0.419† 
Valine 90 (39) 178 (79-313) 0.207 
 
Table 7.3: Plasma quantitative amino acid concentrations (μmol/L) in propionic acidaemia 
patients and correlation of amino acids with concurrent ammonia estimate. Control values: 
plasma amino acid reference intervals calculated from 271 subjects from 8 different 
laboratories, courtesy Mrs MA Preece. † p<0.0001 for correlation. 
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Figure 7.8: Box plots of plasma amino acid concentrations for propionic acidaemia cohort. 
Solid line (median) and dotted lines (2.5th and 97.5th centile) from normal control data. GLN, 
glutamine; GLUT, glutamate; GLY, glycine; ALA, alanine; VALI, valine; ILE, isoleucine; 
LEU, leucine. 
 
 
Figure 7.9: Plot of plasma glutamine and glutamate against concurrent ammonia level in 
propionic acidaemia patients. Lines: linear regression fits. 
 
 181
 
  ARG ASP CIT CYST GLN GLUT GLY HIS ILE LEU LYSI MET ORN PHE PROL SER TAU THR TYR VALI Gln+Glu
ALA 0.472 0.361 0.491 0.175 0.302 0.258 0.126 0.185 0.332 0.135 0.266 0.373 0.194 -0.128 0.680 0.580 0.309 0.227 0.268 0.170 0.387 
ARG   0.319 0.549 0.004 0.320 0.226 0.181 0.211 0.367 0.297 0.448 0.338 0.268 0.023 0.432 0.365 0.082 -0.024 0.332 0.255 0.396 
ASP     0.260 0.088 0.105 0.356 -0.016 0.285 0.232 0.004 0.115 0.405 0.279 0.010 0.220 0.611 0.217 0.389 0.131 0.175 0.216 
CIT       0.135 0.460 0.009 0.302 0.054 0.308 0.151 0.324 0.199 0.317 -0.184 0.475 0.387 0.102 -0.029 0.402 0.245 0.473 
CYST           -0.133 0.051 -0.066 0.082 0.049 0.010 0.233 -0.036 0.073 0.269 0.055 0.061 0.109 -0.028 0.212 0.063 
GLN           -0.224 0.418 0.041 0.181 0.334 0.431 0.005 0.228 -0.063 0.422 0.228 0.016 -0.140 0.450 0.128 0.955 
GLUT             -0.393 0.165 0.337 0.135 0.021 0.114 0.086 -0.051 0.241 0.109 0.114 0.230 -0.052 0.247 0.077 
GLY               -0.271 -0.035 0.132 0.257 0.026 0.022 -0.021 0.098 0.119 -0.041 -0.419 0.232 -0.117 0.308 
HIS                 0.033 0.049 0.156 0.164 0.150 0.192 0.304 0.285 0.082 0.209 0.204 0.227 0.093 
ILE                   0.544 0.081 0.570 0.209 0.068 0.388 0.216 0.014 0.306 0.103 0.709 0.288 
LEU                     0.364 0.128 0.239 0.480 0.338 -0.103 -0.180 -0.159 0.304 0.565 0.383 
LYSI                       0.052 0.192 0.109 0.333 0.153 -0.003 -0.095 0.674 0.202 0.447 
MET                         0.156 0.163 0.269 0.503 0.025 0.591 0.119 0.412 0.040 
ORN                           0.100 0.171 0.281 -0.014 0.223 0.208 0.138 0.392 
PHE                             0.129 -0.071 -0.262 -0.045 0.282 0.297 -0.080 
PROL                               0.299 0.030 0.113 0.328 0.388 0.506 
SER                                 0.326 0.468 0.301 0.012 0.267 
TAU                                   0.148 -0.119 -0.292 0.051 
THR                                     -0.170 0.164 -0.073 
TYR                                       0.210 0.444 
VAL                     0.206 
 
 
Table 7.4: Pearson correlation coefficient, r, calculated for associations between amino acids in propionic acidaemia patients (n=105 
samples). Bold: significant p<0.05. Red, r >0.5 
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Figure 7.10: Scatter plots of plasma glutamine+glutamate versus urea cycle amino acids in propionic acidaemia cohort. Line – linear 
regression line. Ornithine (upper left), citrulline (upper right), arginine (bottom left) and aspartate (bottom right) 
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7.7.5. Urine NMR Results 
Seven random urine samples from six patients with PA were available, including one sample 
from a child who had previously had a liver transplant for PA. Samples were compared to 
data from healthy controls (n=8). Urine samples from all PA patients demonstrated the 
presence of several metabolites substantially elevated compared to, or not detected, in 
controls. In particular glycine, propionylcarnitine and betaine were elevated in PA patients 
compared to controls (see figures 7.11 and 7.12). Tiglylglycine was also observed, and peaks 
consistent with propionylglycine. Methylcitrate was not convincingly observed.  
 
Principal component analysis of spectra generated separate clusters of control and PA 
patients, although two sub-groups within the PA patients were identified (figure 7.12). 
Review of the loading plots of the first and second principal components found similar 
profiles with elevated peaks of glycine, propionylcarnitine and betaine identifying the PA 
patients, although the relative ratios between these main discriminators differed such that in 
PC1 dominant peaks were betaine > glycine > propionylglycine, while in PC2 
propionylcarnitine > glycine > betaine, corresponding to the patterns seen in the spectra from 
those children.  
 
A urine sample from a PA patient who had previously received liver transplantation had 
notably lower glycine than the other PA patients, although this was still at a higher 
concentration than seen in the control samples. Furthermore elevated betaine, carnitine and 
propionylcarnitine were observed in the urine of this child indicating that liver transplantation 
had not completely normalised systemic propionate metabolism. 
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Figure 7.11: Example one dimensional proton NMR spectrum of urine from propionic 
acidaemia patient.  
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Figure 7.12: Principal component analysis of one dimensional proton NMR spectra of urine 
from propionic acidaemia and control patients. (A) Scores plot (PC1 and PC2) and loadings 
plots for (B) PC1 and (C) PC2. Diamonds, control patients; squares, PA patients. 
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7.8. Discussion 
The data presented represent the largest series of children with the severe neonatal form of 
propionic acidaemia to be investigated with brain MRS, and is to the author’s knowledge the 
first to study children during severe acute encephalopathic episodes. The selective 
vulnerability of the basal ganglia in PA is well established, and this data has provided further 
insight in to processes occurring within the basal ganglia.  
 
7.8.1. Clinical and Biochemical Features 
The clinical and biochemical features of the cohort are consistent with those previously 
reported for children with the severe neonatal onset form of PA. In particular the plasma 
quantitative amino acid profiles and urinary metabolite profiles (as determined by NMR 
spectroscopy) show alterations consistent with the diagnosis.  
7.8.2. Quantitative amino acid analysis 
The plasma quantitative amino acid profiles seen in the PA cohort here are consistent with 
some of the key observations made elsewhere [166]. Thus concentrations of alanine and 
glycine are elevated in the PA group, while glutamine and the branch chain amino acids were 
found to be frequently lower than standard reference ranges. Analysis of the cohort dataset did 
not confirm previous findings of the correlation between plasma amino acids and ammonia 
concentrations [188], and in particular the current data were not consistent with an inverse 
relationship between glutamine and ammonia. The only significant correlations with ammonia 
were for lysine and tyrosine, both of which increased with increasing ammonia.  
 
Similarly, it has been reported that glutamine+glutamate levels were strongly correlated with 
the urea cycle amino acids ornithine and arginine but not citrulline or aspartate. In the current 
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dataset, glutamine+glutamate had moderate correlations with each of ornithine, arginine, 
citrulline and aspartate (r=0.392, 0.396, 0.473 and 0.216 respectively).  
 
7.8.3. Urine NMR metabolite profiling 
The data presented from the one dimensional proton NMR examination of random urines 
demonstrated in all PA children, including one post-liver transplantation, the excretion of 
elevated glycine, betaine, tiglylglycine, propionylglycine and 3-hydroxypropionate, as 
described previously [204]. In addition, high levels of propionylcarnitine and carnitine were 
observed, consistent with the now routine use of carnitine supplementation in PA [205]. The 
high concentration of betaine observed in the urine of PA patients is also of interest; the 
reasons for its excretion and possible effects are not well documented [206]. The urinary 
profile provides insight in to the highest concentration metabolites accumulating in PA, but 
these may not be present in the CNS in the same concentrations. 
 
7.8.4. MR imaging findings 
The MRI findings in this cohort are consistent with those previously reported in PA, with 
many of the children displaying cerebral volume loss, ventricular enlargement and/or 
disturbed myelination. The observation of hippocampal abnormalities has not previously been 
reported in PA and warrants further investigation. In particular, formal analysis of 
hippocampal volumetric alterations using 3D T1 volume acquisitions would help substantiate 
this qualitative observation, and if confirmed would provide an interest neuroanatomical 
correlate for some of the reported memory and learning difficulties encountered in PA 
patients. 
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Basal ganglia abnormalities were observed in four children in the cohort, but only at the time 
of, or following, acute severe encephalopathic episodes occurring outside of the neonatal 
period. Indeed, the basal ganglia appeared normal on conventional MRI in all children who 
had not had a severe acute encephalopathic episode beyond the neonatal period. The 
quantitative analysis of T2 and ADC signal in the basal ganglia also confirmed that prior to 
acute severe episodes the signal from the basal ganglia was within the normal range.  
 
Given that all of the patients presented acutely ill during the neonatal period, it therefore 
appears that the basal ganglia are uniquely protected at this early stage in development, as has 
been similarly reported in glutaric aciduria [11]. One possible explanation could be the 
differential expression of receptor types that mediate later neurotoxicity. For example it is 
known that the expression of different constituent subunits of the NMDA receptor alters 
during the neonatal and post-neonatal period [207] and thus if NMDA-mediated excitotoxicity 
is part of the pathogenesis of the basal ganglia insult this might only occur at a later 
developmental stage when the NMDA receptor is fully expressed. 
 
The abnormal basal ganglia MR imaging features observed in the children with basal ganglia 
damage demonstrated variable involvement of the different basal ganglia structures, but 
including caudate, putamen and globus pallidus. MR imaging in the acute phase often 
demonstrated swelling of these structures with associated restricted ADC patterns consistent 
with cytotoxic oedema. In follow up imaging, basal ganglia features either partially resolved 
or progressed to atrophy and cystic degeneration. 
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7.8.5. MR Spectroscopic findings 
Evaluation of in vivo brain metabolite alterations presented here during metabolic stability 
and acute encephalopathy could help evaluate the various hypotheses explaining the brain 
pathology seen, notably the vulnerability of the basal ganglia. Some of the metabolite 
alterations described are a reflection or result of the insult that has occurred, and are not 
causative of the insult. For example decreased tNAA is seen in many pathologies, and is 
thought to reflect loss of viable neurons [50] including following acute ischemic stroke [208].  
 
Other metabolite alterations shed light on disease-specific mechanisms. Elevated lactate 
suggests a switch to anaerobic respiration, and may secondarily reflect local ischaemia, but 
the finding of elevated brain lactate in two children during metabolic stability suggests that 
brain tissue metabolism is not normal even when metabolism is well controlled. This may, for 
example, suggest sub-critical tissue ischaemia, or mitochondrial dysfunction pre-existing in 
the vulnerable brain regions. 
 
The alterations seen in glutamine and glutamate in basal ganglia are of particular note. 
Gln+Glu was significantly decreased in basal ganglia during severe acute episodes, with a 
smaller decrease noted in basal ganglia in studies acquired during metabolic stability.  In 
white matter there was a non-significant trend to decreased Gln+Glu during encephalopathy. 
 
Although the spectral signals from glutamine and glutamate overlap, there is increasing 
evidence that they can be differentiated in the analysis of cohorts even at 1.5Tesla using 
software such as LCModel. Such evidence includes Montecarlo simulations of normal brain 
spectra fitted with LCModel [209], comparisons of experimental and simulated basis sets 
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[210], and the finding of a significant correlation between in vivo and in vitro results for both 
glutamate and glutamine detected in brain tumours [29, 211].  
 
Bearing this caveat in mind, the separate alterations in glutamine and glutamate seen in the 
MRS studies are of interest. It appears that glutamine in the basal ganglia is depleted even 
during metabolic stability, and remains low when acute basal ganglia events occur. In 
contrast, glutamate was normal during metabolic stability, and fell significantly in both basal 
ganglia and white matter in the acute encephalopathy acquisitions. The decreased glutamine 
detected by brain MRS is consistent with the plasma glutamine reduction previously reported 
in PA [166], also seen in plasma glutamine levels in the current cohort.  
 
There are several possible explanations for the low glutamine and glutamate levels seen. 
Firstly, this may simply reflect neuronal loss as suggested by the lower NAA levels. However, 
the ratio of Gln+Glu/tNAA was lower in the propionic acidaemia cohort than in cohorts of 
children with other defined inherited metabolic disorders including a cohort with confirmed 
respiratory chain disorders, while the Gln+Glu/NAA ratio was elevated in a cohort with the 
urea cycle disorder argininosuccinic aciduria. This suggests that the alterations seen in 
Gln+Glu here were not simply a reflection of neuronal loss represented by lower tNAA. 
 
Secondly, the administration of the alternative pathway drugs (phenylbutyrate and benzoate) 
used to control hyperammonaemia depletes plasma glutamine and glycine and may contribute 
to the decreased brain Gln+Glu seen. Thirdly, furthermore, children were often haemofiltered 
during severe acute episodes which may further deplete glutamine due to its high sieving 
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coefficient [212]. However CVVH was instigated after the MRI/MRS in 80% of cases 
suggesting that glutamine levels were already low before CVVH was commenced.  
 
Fourthly, the finding of decreased Gln+Glu in basal ganglia during metabolic stability and 
subsequent acute decreases seen during encephalopathy, supports the hypothesis that 
glutamine and glutamate are consumed to replenish a depleted Krebs cycle [188], and that this 
decrease is a marker of compromised aerobic cellular respiration within brain tissue. As 
discussed above, anaplerosis could be compromised in PA at several steps. The low brain 
Gln+Glu levels seen here could suggest that glutamine and glutamine are being consumed to 
support a deplete Krebs cycle, or alternatively if they are being depleted by another route, that 
the potential for anaplerosis from glutamate conversion to α-ketoglutarate is limited. It 
remains to be determined whether the decreased Gln+Glu is directly detrimental or simply a 
secondary marker of compromised metabolic status. Interestingly the decrease in Gln+Glu 
was greater in the basal ganglia than in white matter, correlating with the more vulnerable 
brain region.  
 
These findings are in disagreement with the one previous MRS study of basal ganglia 
metabolism using MRS. This study reported elevated basal ganglia Gln+Glu in three 
metabolically stable propionic acidaemia patients who had normal plasma ammonia and near-
normal glutamine and glutamate in plasma and cerebrospinal fluid, leading the authors to 
suggest that differential mechanisms regulated brain parenchymal metabolism [201]. That 
study relied on peak area estimation, manual baseline fitting and metabolite ratio to creatine, 
whereas the current study provides more robust quantification. However several factors may 
explain a real biological difference in the results seen. Patients in the previous study reported 
 191
in 1996 were not receiving sodium phenylbutyrate therapy, whereas the majority of patients in 
the current study were on this glutamine-depleting therapy at the time of MRS. Furthermore, 
the patients reported in the earlier study were not reported to be receiving carnitine therapy, 
and so it is plausible that the discrepant results in basal ganglia Gln+Glu are due to alterations 
in the metabolic status of the two cohorts of patients secondary to medication and therapy 
factors. Elevated Gln+Glu in the urea cycle disorders is thought to reflect conversion of 
ammonia to glutamine, and since hyperammonaemia is encountered in PA this has been 
proposed as one possible cause of the neuropathology. However, as with the previous study 
described, significant and persistent hyperammonaemia was not seen in this cohort. 
 
The previous reports of elevated CSF glutamine in some PA patients also appear to be at odds 
with the findings reported here. However, both patients previously reported to have elevated 
CSF glutamine and low plasma glutamine had evidence of significant hyperammonaemia 
either concurrently or within a day of the CSF sampling [179, 200]. It is possible that in these 
patients hyperammonaemia stimulated compensatory generation of glutamine within the 
brain, subsequently excreted in to the CSF. Importantly, these patients in whom MRS of the 
basal ganglia was performed had normal CSF glutamine levels.  
 
Unfortunately CSF samples of amino acid analysis were not routinely collected in the patients 
reported here. It would be interesting prospectively to directly compare plasma, CSF and 
brain glutamine and glutamate levels in association with determination of ammonia and other 
propionate metabolites. In particular, differences between brain tissue and CSF metabolites 
could shed light on protective/excretory mechanisms within the CNS. 
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The accumulation of other neurotoxic metabolites may contribute to the pathology, 
particularly via NMDA receptor mediation. The current MRS technique did not detect 
substantial elevations in brain glycine, particularly this was not seen in any of the acute 
encephalopathy studies, and in two cases where possible glycine peaks were seen the 
concentration was substantially lower than seen in a child with non-ketotic hyperglycinaemia 
(see Chapter 5). The urine NMR studies did demonstrate high glycine excretion in to the urine 
(up to around 10mmol/L); it would be interesting to quantitate CSF glycine levels to 
investigate further whether there is evidence of persistent glycine elevations in the CNS. 
Furthermore no “unfitted” peaks were identified that could be consistent with other PA-
related toxic metabolites. It is probable, however, that any such toxic metabolites would be 
present at concentrations below the threshold for detection with MRS, so this negative finding 
does not exclude the neurotoxin hypothesis. 
 
Basal ganglia strokes are not limited to PA, but seen in other organic acidurias including 
glutaric aciduria type I and in methylmalonic aciduria, where the “neonatal period protection 
effect” is also seen. It is possible that common mechanisms operate in these different 
disorders, either accumulation of toxic metabolites common to all three conditions, or 
common secondary effects. MRS studies in these disorders have demonstrated low NAA 
levels in basal ganglia, with the detection of lactate in some instances, but none of the studies 
evaluated alterations in glutamine and glutamate [213-216]. One study evaluated the effects of 
carnitine therapy in methylmalonic aciduria on the basal ganglia MRS profile, finding 
normalisation of NAA and lactate levels [217]. Evaluation of brain energy metabolites using 
phosphorous spectroscopy has also been attempted in glutaric aciduria type I, although no 
significant results were reported [218]. 
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7.8.6. Effects of Liver Transplantation 
The two children who had liver transplant have had no severe acute encephalopathic episodes 
beyond the neonatal period, and have normal appearing basal ganglia on MRI. MRS 
demonstrated normal/high tNAA reflecting the absence of major neuronal loss and correlating 
with their good neurocognitive status, and no reliably detected lactate. The small numbers 
preclude statistical significance, but Gln+Glu was slightly increased in white matter but 
decreased in basal ganglia compared to the comparator group. These results support the 
hypothesis that liver transplantation provides systemic metabolic stability by providing a 
hepatic pool of functional propionyl CoA carboxylase, thus preventing further acute 
metabolic decompensations which are associated with the risk of brain infarction. The 
observation of persistent PA-related abnormalities in the urine NMR analysis of the child 
post-liver transplantation highlights the fact that liver transplantation does not correct the 
“total body” metabolic defect in PA. 
 
7.9. Limitations & future investigations 
The data presented here have yielded some interesting initial observations. There are, 
however, a number of technical and sample-size related limitations to the work that would 
need to be addressed to confirm or refute the hypotheses made. 
 
From a technical perspective, more robust differentiation of the metabolites of interest, 
notably glutamine and glutamate, is required. At 1.5T the resonances of glutamine and 
glutamate overlap significantly. At higher field strengths with narrower line-widths and better 
spectral resolution these metabolites can be differentiated with a greater degree of certainty. 
The use of the single voxel technique has targeted the investigation to two distinct brain 
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regions, but even so at 1.5T the spatial resolution is limited to 2cm x 2cm x 2cm cubes, 
representing a substantial volume of brain. Across this volume there could be significant 
regional differences in the metabolite profile, and the data presented here give an average 
effect for the volume. Thus alterations in glutamate, for example, are a bulk effect on the total 
metabolite concentration and do not provide information about the neuronal/synaptic/glial 
compartmentalisation of metabolite concentrations. 
 
The second major limitation to the current work relates to the sample size, both in terms of 
numbers of patients (albeit the world’s largest cohort of neonatal onset PA) and in terms of 
the number of time points sampled for each patient. The metabolite alterations reported for 
metabolic stability and encephalopathy represent the mean effects in the cohort. It would be 
desirable to be able to describe and evaluate metabolite alterations in single subjects before, 
during and after encephalopathic episodes. As has already been noted, only two of the patients 
had liver transplantation, and further data is required to help evaluate the proposed neuro-
protective effect of this therapy. 
 
That said, there is a need for brain protective strategies during acute metabolic 
decompensations, with potential methods including brain cooling, optimising energy 
provision, and anaplerotic therapies. MRS could provide a tool to monitor the effect of dietary 
supplements aimed at increasing glutamine levels, specifically monitoring metabolite levels 
within the target-organ of interest, namely the brain.  
 
While direct observation in vivo of brain metabolite profiles in patients with PA has yielded 
some useful and interesting data, there is limited capacity for experimental manipulations in 
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human subjects. An animal model of disease would provide a useful platform for further 
investigations, allowing the use of both non-invasive techniques such as MRS and direct 
tissue evaluation. A PCCA -/- knockout mouse has been generated, with rapid mortality in the 
early neonatal period The phenotype can be rescued by postnatal liver specific expression of 
PCC using a transgene technique [219], and also by gene therapy approaches using an AAV8 
vector [220, 221] with survival up to and beyond 6 months of age. No neuropathological 
studies have yet been reported in these animal model systems, but could provide an important 
means of exploring the hypotheses discussed here if the brain insults seen in human patients 
can be recapitulated in the animal model. 
 
7.10. Conclusions 
The data presented demonstrate that quantitative MRS is able to offer insight in to in vivo 
brain metabolic derangements, and can feasibly be employed in children with acute 
encephalopathy. In propionic acidaemia the use of MRS in conjunction with MRI has 
confirmed the basal ganglia as a particularly vulnerable target and has demonstrated novel 
insights in to alterations in neurotransmitter metabolites. Evaluation of patients in long-term 
follow up after liver transplantation demonstrates the potential for good neurological outcome 
and near-normal brain metabolism. MRS provides a tool to directly evaluate the tissue-level 
effects of novel treatment strategies including anaplerotic therapies. 
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Chapter Eight 
 
8. Argininosuccinic Aciduria 
 
In this chapter data are presented illustrating the investigation of the urea cycle disorder 
argininosuccinic aciduria, which has unique neurological characteristics. Novel MR imaging 
features are reported and the MR spectroscopy method is used to evaluate specific hypotheses 
pertaining to the neurological features of this disorder. 
8.1. The Urea cycle and disorders of the urea cycle 
The disposal of excess nitrogen in mammals is achieved by the hepatic urea cycle (figure 8.1). 
The six enzymes that constitute the cycle convert ammonia synthesised from the amino acid 
nitrogen pool to urea, which is subsequently excreted in the urine [222]. The cycle operates 
across both mitochondrial and cytosolic compartments, but the total complement of enzymes 
is only fully expressed in liver cells; outside the liver argininosuccinate synthase (ASS, EC 
6.3.4.5) and argininosuccinate lyase (ASL, E.C. 4.3.2.1) are ubiquitously expressed and form 
the citrulline-nitric oxide (NO) cycle which recycles citrulline generated by nitric oxide 
synthase (NOS, EC 1.14.13.39) during NO production back to arginine (figure 8.2) [223].  
 
Deficiencies of all of the urea cycle enzymes have been described, and result in malfunction 
of the cycle, specifically with accumulation of toxic ammonia and disordered amino acid 
metabolism [222]. The clinical presentation of the urea cycle defects (UCD) is heterogeneous, 
with severe forms presenting in the early neonatal period with significant hyperammonaemia 
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resulting in lethargy, poor feeding and progressing to seizures, neurological depression and 
death if untreated. Proximal defects (carbamoyl phosphate synthase 1 (CPS, EC 6.3.4.16, 
OMIM #237300) and ornithine transcarbamoylase (OTC, EC 2.1.3.3, OMIM #311250) 
deficiency) in particular tend to present with an early fulminant neonatal phenotype [224]. 
Partial or distal cycle defects can present with a milder phenotype at a later stage either during 
infancy, or even present in adulthood with episodic neuro/psychiatric symptoms [222], but are 
still associated with significant neurological damage [224]. 
 
A large cross-sectional multi-centre study of 183 UCD patients in the USA reported 
substantial rates of intellectual disabilities (39%), learning disabilities (35%) and psychiatric 
disorders including mood disorders (8%), while up to 15% had seizure disorders [225]. 
Furthermore, around 50% had objectively abnormal neurological examination. There were, 
however, substantial differences in the rates of these abnormalities between the different types 
of UCD. In particular, patients with argininosuccinic aciduria (ASA) had significantly higher 
rates of intellectual disabilities (70%, p<0.05), and also had higher rates of seizure disorders 
(32%, p<0.05) and abnormal neurological examination findings such as abnormal deep 
tendon reflexes (30%) or altered tone (50%). 
 
Acute hyperammonaemia is responsible for many of the neurological features of the UCD, 
with the survival and neurological outcome related to the ammonia levels (peak and duration) 
during the initial presentation [224, 226]. Ammonia enters the CNS by diffusion through the 
blood-brain barrier, where it is converted to glutamine by astrocytic glutamine synthase [224]. 
The accumulation of glutamine exerts an osmotic pressure resulting in astrocytic-mediated 
cerebral oedema, responsible for much of the neuro-pathology. Other mechanisms, however, 
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are also important components of the neurological disease in UCD, including energy 
deficiency due to secondary enzyme inhibition, alterations in neurotransmitters and their 
receptors, and secondary effects of chronic “mild” hyperammonaemia. 
 
 
Figure 8.1: Outline of the urea cycle. CPS1, carbamoyl phosphate synthase 1; OTC, ornithine 
transcarbamoylase; ASS, argininosuccinate synthetase; ASL, argininosuccinate lyase. NAGS, 
N-Acetylglutamate synthase. 
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Figure 8.2: Citrulline-Nitric Oxide cycle. Abbreviations as figure 8.1. 
8.2. Argininosuccinic aciduria 
Argininosuccinic aciduria (ASA, OMIM #207900) is an autosomal recessive urea cycle 
disorder (UCD) caused by inherited mutation in the ASL gene (7cen-q11.2) resulting in 
deficiency of argininosuccinate lyase (ASL, E.C. 4.3.2.1). ASL catalyses the cleavage of 
argininosuccinate to fumarate and arginine in the hepatic urea cycle, and as noted already is 
also widely expressed in cells outside of the liver, forming part of the citrulline-NO cycle. 
 
Two forms of ASA are clinically distinguished depending on severity and age of onset. The 
early neonatal onset severe form is similar to the other UCDs presenting in the neonatal 
period, with associated hyperammonaemia in the first days of life, while the late onset form 
presents with either episodic hyperammonaemia, or neurocognitive deficits [227, 228]. 
However, as described above, significant developmental delay, epilepsy and other 
neurological features occur in ASA even when metabolic control is generally good, and in the 
absence of significant hyperammonaemic encephalopathic episodes [229]. Anecdotal 
evidence suggests that seizure disorders and intellectual impairment are a particular problem 
in ASA patients despite good ammonia control. These clinical features suggest that disease-
specific mechanisms have a role in the neurological damage sustained in ASA. 
 
ASA is also associated with high rates of liver disease, including hepatomegaly, liver enzyme 
derangements and liver fibrosis, and as with the neurological disease this may occur despite 
Citrulline Arginine Argininosuccinic 
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NO 
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the absence of persistent or severe hyperammonaemia [228, 230]. Trichorrhexis nodosa 
(brittle hair) is another common feature in untreated patients with ASA, resulting from the 
deficiency of arginine that constitutes some 10% of the normal hair shaft [228]. Systemic 
hypertension has also been described in ASA [231, 232], potentially due to decreased nitric 
oxide synthesis. 
 
Typical biochemical findings in ASA are the presence of hyperammonaemia with elevated 
argininosuccinic acid in plasma and urine, with elevated citrulline, alanine, glutamine and 
glycine, and arginine deficiency. Orotic aciduria may be detected due to impaired ornithine 
recycling [228]. Deficiency of ASL activity is assayed in erythrocytes or skin fibroblasts by 
indirect (radio-labelled citrulline incorporation) or direct (arginine or fumarate synthesis) 
assays [233]. These assays do not however correlate with the disease severity, and in a model 
of bacterially expressed enzymes similarly there was not a good enzyme activity-phenotype 
correlation [233]. 
 
Neuroimaging features in ASA are not well documented. In a large 27 year follow up study of 
23 patients identified by newborn screening classified with the mild phenotype, cognitive 
function was generally good, although four patients had electroencephalogram (EEG) 
abnormalities in the absence of seizures, but no MR imaging was reported [234]. Similarly in 
a study of 13 patients (12 with mild phenotype) again identified by newborn screening, CNS 
dysfunction was evident as four had learning difficulties, six had EEG abnormalities and three 
had clinical seizure disorders [235]. None had MRI studies reported. Of note a separate cohort 
of late onset (mild phenotype) patients diagnosed symptomatically rather than by screening 
had significantly worse mental retardation, seizures and ataxia.  
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In other UCDs imaging features include significant cerebral oedema resembling hypoxic-
ischaemic damage during severe hyperammonaemia [236], visible with both computed 
tomography (CT) and MRI scanning. MRI delineates specific regions of the cortex and gray 
matter with specific vulnerabilities, including insular cortex, perirolandic cortex and globus 
pallidi, and notably not sparing the subcortical U fibres [237].  
 
8.3. Neuro-pathogenesis theories 
Patients with ASA have, therefore, a unique neurological phenotype amongst the UCD, which 
is not fully explained by hyperammonaemia alone. A number of hypotheses regarding the 
pathogenesis of the neurological features in ASA have been proposed in addition to the 
common effects of hyperammonaemia.  
8.3.1. Argininosuccinic acid toxicity 
Argininosuccinic acid is excreted at high concentrations in the urine of patients with ASA and 
is also present at relatively high concentrations in plasma and substantially higher levels in 
CSF [235]. Although it is the abundant metabolite present in ASA, direct toxicity from 
argininosuccinic acid has not been convincingly demonstrated. One potential mechanism is 
via formation of guanidinosuccinic acid from the combination of argininosuccinic acid and 
free radicals; guanidinosuccinate can mimic NO and also activate NMDA receptors [238]. 
Similarly argininosuccinate has been suggested to cause hepatotoxicity but direct evidence is 
scarce. 
8.3.2. Effects of arginine deficiency 
ASL is the key enzyme for arginine synthesis. In the liver most arginine synthesised is 
consumed in the urea cycle, but net arginine synthesis is achieved by the kidney which 
expresses high levels of ASL and specifically takes up citrulline for this purpose. In ASA 
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arginine is therefore an essential amino acid that must be supplied from the diet. Arginine is a 
precursor for many metabolic pathways (figure 8.3), which could be affected if arginine is 
deficient, exemplified by the clinical occurrence of trichorrhexis nodosa due to deficient 
arginine for hair shaft synthesis. 
 
In utero it is likely that sufficient arginine will be supplied by trans-placental active transport, 
since the placenta expresses specific transporters for amino acids including arginine [239]. 
Following diagnosis with ASA patients are quickly supplemented with high doses of arginine 
and may have supra-normal plasma levels. Prior to diagnosis it is possible that arginine 
deficiency may contribute to the clinical phenotype, particularly in relation to creatine 
synthesis. 
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Figure 8.3: Key metabolic pathways supplied by arginine. ASA, argininosuccinic acid; NO, 
nitric oxide; NOS, nitric oxide synthase; Gua, guanidinoacetate; Gly, glycine; ADC, arginine 
decarboxylase; AGAT arginine:glycine amidinotransferase; GAMT, guanidinoacetate 
methyltransferase; OTC, ornithine transcarbamoylase. (Adapted from [228]). 
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8.3.3. Creatine deficiency 
Creatine is formed from arginine by two enzymes, arginine:glycine amidinotransferase 
(AGAT) and guanidinoacetate methyltransferase (GAMT). Creatine plays a central role in 
energy metabolism providing a means for high energy phosphate shuttling [240] (see Chapter 
2). Although available from dietary sources, de novo synthesis is also important since the 
turnover of the substantial creatine pool to renally excreted creatinine is rapid (1.7% per day) 
[241]. AGAT activity is greatest in kidney, while GAMT activity is highest in liver 
suggesting a “renal-hepatic axis” for creatine synthesis. Creatine is transported into tissues 
(particularly muscle) by the specific transporter SLC6A8 [64, 240].		
 
Within the brain AGAT, GAMT and SLC6A8 are all expressed but in different cell 
populations. The blood brain barrier has restricted permeability to creatine, and so the CNS 
must synthesise much of its creatine requirements endogenously	 [64]. The specific creatine 
deficiency syndromes due to absence of AGAT, GAMT or SLC6A8 are all associated with 
severe neurodevelopmental delay, and in GAMT seizures are particular problem [64, 242].  
 
Secondary creatine deficiency is reported in the UCD, with decreased plasma and urine 
guanidinoacetate and creatine [243]. MRS was used to document brain creatine deficiency in 
a patient with late onset ASA prior to treatment, with improved brain creatine levels after 
arginine supplementation [244]. This patient also had low plasma concentrations of creatine 
and guanidinoacetate that corrected with treatment. 
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In addition to arginine deficiency causing a secondary creatine deficiency, ammonia is known 
to produce creatine deficiency, potentially via the inhibition of AGAT and by altering the 
expression of AGAT, GAMT and SLC6A8 genes [245].		
	
8.3.4. Guanidinoacetate toxicity 
It has also been proposed that the propensity to epilepsy in ASA may be due in part to 
excessive brain levels of guanidinoacetate, due to excessive supplementation with arginine. In 
GAMT deficiency where there are very high levels of guanidinoacetate seizures are a 
particular problem, possibly due to toxic effects of the accumulated guanidinoacetate [246]. 
The detection of possibly raised brain guanidinoacetate levels in two patients with ASA 
support this hypothesis, although urinary guanidinoacetate was high in only one of the 
patients [247, 248]. If excessive guanidinoacetate in ASA is iatrogenic, i.e. due to arginine 
supplementation, it could not explain neuropathological features occurring prior to the onset 
of therapy.  
 
8.3.5. Nitric Oxide Synthase Dysfunction 
Recent evidence suggests that the role ASL plays in the nitric oxide system results in many of 
the specific pathological features of ASA. NO has many diverse functions, including control 
of vasodilatation, as well as in platelet function, neurotransmission and is important in normal 
and pathological conditions within the CNS [223, 228, 249-252]. If NOS function is disrupted 
or uncoupled, free radical generation increases with subsequent pathological effects [253].  
 
The “arginine paradox” describes the phenomenon whereby exogenous arginine can increase 
NO production despite high and saturating levels of arginine within cells, suggesting that 
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arginine supply at the specific sites of NO synthesis are rate limiting. Thus there may be 
“intracellular compartmentalisation” of arginine [228]. 
 
In some elegant experimental work with a conditional Asl hypomorphic mouse, Erez et al 
demonstrated evidence for pathological features that recapitulate many of the phenotypic 
features of patients with ASA, including similar biochemical derangement, multiorgan 
dysfunction, and systemic hypertension [223]. They showed that the mice had a global NO 
deficiency, and that fibroblasts from patients also had deficiency of NOS-dependent NO 
production. Furthermore they demonstrated that patients with ASA have decreased NO 
generation from extracellular arginine. It is likely that NO dysfunction contributes to many of 
the features of ASA, but as yet this has not been applied to the CNS pathology, and no 
neuropathological features in the mouse model have yet been reported.  
 
8.3.6. Previous MRS studies in ASA 
Many of the hypotheses relating to brain disease in ASA could be explored using MRS, since 
many of the relevant metabolites are readily identified. No large systematic study of brain 
metabolite profiles in ASA patients has been undertaken using MRS. However several case 
studies have been reported. As mentioned previously, creatine deficiency was demonstrated in 
an adult with late onset disease that corrected with treatment [244]. This patient also had low 
guanidinoacetate levels in brain that increased with treatment. Other cases reported had 
normal choline, creatine, inositol, glutamate/glutamine, and N-acetylaspartate levels but 
potentially high levels of guanidinoacetate, using a long echo time chemical shift imaging 
technique [247, 248]. A 24 year old male who received a liver transplant for recurrent 
metabolic decompensations in ASA was studied and found to have elevated basal ganglia 
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glutamine+glutamate prior to transplant, which decreased following transplantation. In this 
patient creatine was high in basal ganglia before and after transplant, while guanidinoacetate 
increased following transplant. This paper reported metabolite ratio data, and did not present 
the original spectra, and so firm conclusions are difficult to draw given the potential 
alterations in creatine making ratio data hard to interpret [254].  
 
8.4. Aims & Objectives 
This section of the study aimed to explore the various hypotheses relating to causes of brain 
disease in ASA by applying the MRI/MRS technique. Specific objectives were to generate a 
detailed phenotypic description of the cohort clinically and biochemically, and to test the 
following hypotheses: (a) Brain guanidinoacetate is elevated in ASA patients and may 
contribute to generation of epilepsy;  (b) Brain creatine is deficient in ASA patients;  (c) Brain 
glutamine+glutamate is elevated in ASA patients  
 
8.5. Methods 
8.5.1. Patient characteristics 
Patients were recruited from a single tertiary paediatric IMD unit. Clinical data were extracted 
from medical records including age at diagnosis, mode of presentation, therapeutic modalities 
and history of subsequent neurological events. Available blood quantitative amino acid and 
ammonia determinations were also collated from the medical record. 
8.5.2. Conventional MRI: qualitative analysis 
MR imaging and MR spectroscopy were performed electively in conjunction with clinically 
indicated studies. All available brain MRI studies were retrospectively reviewed, including 
review of the qualitative radiology reports by the consultant paediatric radiologist.  
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8.5.3. MR Spectroscopy 
MRS studies were performed concurrently with clinically indicated MRI scans at 1.5 Tesla 
facilitated by general anaesthesia as needed. Comparison was made with MRS metabolite data 
from the standard cohort of children with normal appearing MRI (white matter, n=53, median 
(range) age 4.7(0.5-16.7) years; basal ganglia n=63, 4.1(0.5-16.7) years). Comparison was 
also made between MRS data acquired from mild and severe phenotype ASA patients. 
8.5.4. CSF NMR Spectroscopy 
A CSF sample from one ASA patient was available for analysis. This was submitted to 1D 1H 
NMR spectroscopy as described (Chapter 3).  
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8.6. Results 
8.6.1. Patients 
Eleven patients (4 female) with biochemically confirmed ASA were included (table 8.1). 
Patients were classified as severe phenotype if they presented with neonatal 
hyperammonaemia, or were prospectively diagnosed as a later sibling of another child with 
severe ASA phenotype. Patients were classified as partial/mild phenotype if they presented 
beyond the neonatal period (late presentation) or were prospectively diagnosed as a later 
sibling of another child with partial/mild ASA. Five severe ASA and 6 partial/mild ASA 
patients were thus identified. Three children were diagnosed by sibling screening. 
 
ASA enzyme activity assay (citrulline incorporation assay) was available in three patients 
directly (table 8.1). In most cases the residual activity corresponded to the phenotypic 
classification, such that very low residual activity (<1%) was associated with the severe 
phenotype, and higher residuals usually but not exclusively associated with partial/mild 
phenotype. 
 
All patients were treated with protein restricted diet and oral arginine supplementation. Six 
received sodium benzoate and one phenylbutyrate alternative pathway medications.  
 
8.6.2. Seizure disorders 
Seizure disorders were present in 2/6 patients with the mild phenotype and 5/5 patients with 
the severe phenotype. A range of different anticonvulsant medications were used.
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  Presenting 
mode 
Age 
diagnosis 
(yrs) 
Enzyme 
defect Class 
Neonatal 
high NH3
Later 
high 
NH3
Diet Drugs ALT raise 
Hepato-
megaly 
Liver 
USS 
Seizure 
disorder 
Neurocog 
outcome 
Motor 
function 
1 F Sib screen 5.5 nd Partial N N PR Arg N N - N Moderate LD Ambulant 
2 M Dev delay 4 nd Partial N N PR Arg, Risp N N - N 
Severe LD 
& 
behavioural 
Ambulant 
3 M Neonatal 0 28.7% Severe ++ + PR Arg, SB AC Y Y Abnl Y Global delay Ambulant 
4 F Dev delay 2 nd Partial N N PR Arg, AC N N - Y Mild LD Ambulant 
5 M Dev delay/ enceph 0.3 0.45% Severe (++) ++ PR Arg, SB Y Y Abnl Y 
Significant 
delay 
Motor 
delay 
6 F Dev delay 1.5 20% Partial N N PR Arg, AC N N - Y Severe LD Severe scoliosis 
7 M Sib screen 0 nd, sib 0.78% Severe + ++ PR Arg, SB Y Y Abnl Y 
Mainstream 
school but 
delayed 
Ambulant 
8 F Dev delay 6 nd Partial N N PR Arg N N - N 
Mild LD, 
independent 
adult 
Ambulant 
9 M Sib screen 0 nd, sib 20% Partial N N PR 
Arg, SB 
until 4yrs N N Norm N 
Mild Delay, 
statemented Ambulant 
10 M Sib screen Prenatal nd, sib 0.78% Severe N ++ PR 
Arg, SB, 
PB Y Y Abnl Y 
Significant 
delay Ambulant 
11 M Neonatal 0 nd Severe +++ + PR Arg, SB Y Y Abnl Y 
Severe 
learning and 
language 
difficulties 
Ambulant; 
Dystonia 
Table 8.1: Summary of clinical characteristics of argininosuccinic aciduria patients. Enzyme defect by citrulline incorporation assay, 
reported as percentage residual compared to parallel control values. nd, not done. Sib, value derived in sibling of case. N, no/not present. Y, 
yes/present. Abnl, abnormal. Norm, normal. PR, protein restriction. Arg, arginine; SB, sodium benzoate; PB, phenylbutyrate; risp, 
risperidone; AC, anti convulsants; LD, learning difficulties. Shaded rows indicate mild/partial phenotype patients. 
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8.6.3. Cognitive and motor impairments 
Formal neurocognitive assessments were not available. However, all patients had reported 
learning difficulties, developmental delay and behavioural difficulties to varying degrees. 
There did not appear to be a close correlation with phenotypic class, with some patients in the 
mild/partial cohort having significant cognitive impairment. The only child in the severe 
cohort with mild impairment had been diagnosed and treated prospectively from birth (sibling 
screening). 
 
Most patients were ambulant. One had a dystonic movement disorder correlating to abnormal 
basal ganglia on MRI.  
 
8.6.4. Hepatic Phenotype 
All patients in the severe phenotype cohort had evidence of liver disease, evidenced by the 
presence of hepatomegaly (5/5), ultrasound abnormalities (5/5) and elevated ALT (5/5). The 
elevated ALT was seen from the earliest ages (figure 8.4). By contrast, none of the mild 
phenotype cohort had hepatomegaly and ALT was normal in this cohort. 
 
Serum creatinine values were also examined (figure 8.4). Patients with partial/mild phenotype 
had higher blood creatinine levels than patients with the severe phenotype, though these 
values were not corrected for body or muscle mass or degree of dietary protein restriction. 
 211
0
100
200
300
400
500
600
700
800
0 5 10 15 20 25 30
Age (yrs)
A
LT
Partial/Mild
Severe
0
10
20
30
40
50
60
70
80
90
0 5 10 15 20 25 30
Age (yrs )
Se
ru
m
 C
re
at
in
in
e 
(m
m
ol
/L
)
Partial
Severe
 
Figure 8.4: Serum alanine aminotransferase (ALT) (upper panel) and serum creatinine (lower 
panel) values plotted against age for partial and severe argininosuccinic aciduria cohorts. 
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8.6.5. Plasma amino acid profiles 
172 plasma quantitative amino acid determinations were available from the clinical records of 
the 11 patients (figure 8.5 and table 8.2). Arginine was substantially elevated compared to 
normal values, while the branch chain amino acids (leucine, isoleucine, valine) were often 
lower than normal values. Citrulline levels were also substantially elevated (although formal 
normal values were not available). 
 
Severe cohort patients had significantly higher arginine, citrulline, glutamine and glutamate, 
and significantly lower branch chain amino acids compared to the partial/mild cohort.  
 
Applying a principal component analysis (unsupervised method) to the quantitative amino 
acid profiles clearly differentiated two groups corresponding to the mild and severe cohorts 
(figure 8.6), confirming that there is a substantial biochemical phenotypic basis for these two 
cohorts. 
 
One CSF sample was available for further analysis by NMR spectroscopy (figure 8.7). 
Qualitative interpretation of metabolites present identified many of the normal CSF 
metabolites expected, and spectral peaks consistent with argininosuccinic acid were also 
identified confirming previous reports of high levels of argininosuccinic acid in CSF. 
Quantification of metabolites was not undertaken. 
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 Normal Values Argininosuccinic aciduria patients:  
Mean (standard deviation), μmol/L 
Severe v 
partial t-test 
 Median (2.5th-
97.5th centile) 
All cases Severe cohort Partial cohort p-value 
Alanine 300 (112-592) 325.6 (106.9) 318.5 (93.4) 336.0 (123.7) 0.227 
Arginine 51 (14-102) 160.6 (121.5) 179.7 (137.0) 132.8 (88.1) 0.004 
Aspartate   13.1 (6.8) 13.8 (7.1) 12.1 (6.2) 0.060 
Citrulline   213.1 (147.7) 296.8 (132.2) 92.5 (58.6) 0.000 
Cysteine   20.4 (17.8) 21.6 (16.2) 18.6 (12.3) 0.147 
Glutamine 539 (326-800) 569.0 (157.1) 602.7 (176.3) 520.0 (107.5) 0.000 
Glutamate 88 (31-219) 91.1 (51.0) 109.9 (52.0) 63.9 (34.8) 0.000 
Gln+Glu   660.1 (180.0) 712.5 (200.6) 583.9 (107.1) 0.000 
Glycine 246 (120-436) 269.4 (94.1) 239.6 (78.1) 312.5 (98.8) 0.000 
Histidine 74 (43-111) 80.8 (15.3) 85.4 (15.6) 74.1 (11.9) 0.000 
Isoleucine 50 (20-91) 37.9 (20.5) 30.9 (19.3) 48.2 (17.9) 0.000 
Leucine 97 (44-169) 62.5 (34.2) 51.3 (31.1) 82.4 (30.5) 0.000 
Lysine 130 (66-242) 116.2 (47.7) 117.3 (50.1) 114.8 (44.2) 0.700 
Methionine 20 (10-41) 26.3 (10.4) 30.5 (10.7) 20.2 (6.3) 0.000 
Ornithine 59 (24-154) 91.6 (58.6) 95.1 (64.8) 86.5 (48.0) 0.279 
Phenylalanine 48 (30-76) 49.0 (16.5) 44.4 (15.4) 55.5 (16.0) 0.000 
Proline 154 (66-330) 186.4 (58.5) 187.1 (56.0) 185.4 (62.3) 0.831 
Serine 127 (69-206) 113.9 (37.0) 104.2 (30.8) 127.9 (41.0) 0.000 
Taurine 70 (26-169) 53.5 (30.7) 54.1 (36.7) 52.7 (19.0) 0.745 
Threonine 104 (43-218) 71.8 (34.0) 64.3 (32.9) 82.7 (32.9) 0.000 
Tyrosine 51 (29-92) 49.6 (19.3) 46.9 (18.9) 53.5 (19.1) 0.010 
Valine 178 (79-313) 130.3 (52.2) 111.8 (49.7) 157.1 (43.6) 0.000 
 
Table 8.2: Plasma amino acid concentrations in argininosuccinic aciduria cohorts. Control 
normal values: plasma amino acid reference intervals calculated from 271 subjects from 8 
different laboratories, courtesy Mrs MA Preece. 
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Figure 8.5: Bar chart of mean plasma amino acid concentrations in severe and partial 
argininosuccinic aciduria cohorts. Error bars: standard deviation. (See table 8.2 for t-test 
significances). 
 
 
Figure 8.6: Principal component analysis scores plot (left) of plasma amino acids profile in 
argininosuccinic aciduria cohorts and (right) receiver-operator characteristic (ROC) curve for 
second principal component. Filled circles, results from partial ASA cohort; open circles, 
results from severe ASA cohort. Area under the curve 0.975; p=0.000. 
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Figure 8.7: One dimensional proton NMR spectrum of cerebrospinal fluid from 
argininosuccinic aciduria patient 3. Prominent peaks identified. ASA, argininosuccinic acid.  
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8.6.6. Conventional MR Imaging 
MRI examinations were available for 10 patients (table 8.3 and figure 8.8). The majority had 
generally normal MR imaging. All had normal myelination, and all bar one had normal basal 
ganglia. Two (siblings) had small areas of gray matter heterotopia (gray matter in 
periventricular location). Two had small subcortical or cortical infarcts, while another two had 
peritrigonal white matter abnormalities that may represent small infarcts or dysmyelination. 
One patient (11) had marked volume loss and ventricular dilatation as well as abnormalities 
within the caudate nuclei and putamina consistent with his dystonic movement disorder. 
 
 
Figure 8.8: T2 weighted (A-C) and T1 weighted (D-E) MR images from argininosuccinic 
aciduria patients. (A) Axial, coronal and sagittal plane views from patient 1 demonstrating 
small right inferior frontal lobe infarct (arrow heads) but otherwise normal brain. (B) Axial 
view patient 3 showing peritrigonal white matter abnormalities (arrow). (C) Axial views 
patient 11 showing (left) ex-vacuo dilatation of ventricles and (right) high T2 signal in 
bilateral caudate heads and posterior putamina (arrows). (D) and (E) Coronal views patients 7 
and 10 showing periventricular gray matter heterotopia (arrowheads). 
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 Class White matter Myelination Basal ganglia Other 
1 Partial Normal Normal Normal Small right inferior frontal lobe infarct 
2 Partial Normal Normal Normal Small subcortical white infarct matter medial right frontal pole 
3 Severe Small foci of abnormal signal in peritrigonal white matter, ? infarcts 
 Normal  Normal   
4 Partial Normal Normal Normal Normal 
5 Severe Normal Normal Normal Normal 
6 Partial Normal Normal Normal Brain/ head generally small 
7 Severe Normal Normal  Normal  Small areas of nodular heterotopia adjacent to frontal horns 
8 Partial No imaging available    
9 Partial Normal Normal Normal Normal 
10 
Severe Foci of abnormal T2 signal in 
peritrigonal white matter.  Abnormal 
foci  in subcortical white matter 
 Normal Normal Small gray matter heterotopia adjacent to 
ventricles 
11 Severe Perirolanidc gliosis; volume loss, ex-vacuo dilatation of ventricles 
 Normal Abnormal T2 signal caudate 
head and posterior putamen 
 
 
Table 8.3: MR imaging features in argininosuccinic aciduria patient cohort.  
Shaded rows indicate mild/partial phenotype patients. 
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8.6.7. MR Spectroscopy 
Eight MRS studies (from 7 patients) acquired from basal ganglia were available. Five were 
from patients in the mild cohort and 3 from the severe cohort. Four MRS studies (one mild 
and three from severe cohort) were available from white matter. 
 
8.6.7.1.Basal ganglia results  
ASA patients had significantly lower tNAA than the comparator group; this was most marked 
in the severe cohort (ANOVA p<0.05, figures 8.9, 8.10 and 8.11, table 8.4). Creatine was also 
lower in ASA patients compared to controls, with lowest levels in the severe cohort (ANOVA 
ns). Glutamine+glutamate was non-significantly elevated in ASA patients with contributions 
from both glutamine and glutamate elevations. 
 
To account for the effect of bulk neuronal loss on glutamine and glutamate levels, ratio to 
NAA and Cr were calculated. Examination of metabolite ratios (figure 8.10) found that there 
was no difference between ASA and controls in the Cr/NAA ratio. 
Glutamine+glutamate/NAA and glutamine+glutamate/Cr ratios were also significantly higher 
in ASA patients. For each of these alterations, the highest ratios were in the severe ASA 
cohort, and lowest in the comparator group (ANOVA p<0.05 for Gln+Glu/NAA).   
 
No elevations in guanidinoacetate were detected in the basal ganglia in any group.  
Inositol was decreased in the basal ganglia in the severe ASA cohort. 
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8.6.7.2.White matter results 
Data were examined for the four studies together, with no differentiation between severe 
(n=3) and mild (n=1) cases (figures 8.9 and 8.12, table 8.4). In white matter, Cr was 
significantly lower in ASA patients, but Cr/NAA was not significantly lower. There was no 
increase in the mean glutamine+glutamate in the ASA cohort. The standard deviation for 
white matter glutamine was very large due to one case having very high levels of glutamine 
identified (figure 8.13). On initial inspection the spectrum from this case appeared to have an 
increased guanidinoacetate peak at 3.8ppm, however on further analysis it was evident that 
much of this peak was due to the high glutamine level that also has a peak at ~3.8ppm. 
 
Inositol was significantly lower in ASA patients in the white matter. There was also a slightly 
increased level of guanidinoacetate in ASA patients. 
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Basal ganglia metabolites (mM, mean (standard deviation)) 
 
  
 
Argininosuccinic aciduria 
Normal MRI 
comparator 
group 
All patients (n=8) 
Partial/ mild 
cohort (n=5) 
Severe cohort 
(n=3) 
 
 
(63 studies) 
 
Median age  
(years, (range)) 
9.9 (1.2-14.3)    4.1 (0.5-16.7) 
N-Acetylaspartate 4.61 (0.89) † 4.82 (1.02) 4.27 (0.65) 5.21 (0.51) $ 
Creatine 4.07 (0.76) * 4.16 (0.85) 3.92 (0.73) 4.55 (0.59) 
Glutamine 2.36 (0.92) 2.22 (0.82) 2.59 (1.21) 1.98 (0.79) 
Glutamate 4.63 (0.83) 4.89 (0.71) 4.19 (0.98) 4.45 (0.78) 
Glutamine+Glutamate 6.98 (1.39) 7.10 (1.07) 6.78 (1.27) 6.43 (1.39) 
myo-Inositol 2.31 (0.72) 2.54 (0.59) 1.93 (0.85) 2.49 (0.43) 
Choline 0.94 (0.22) * 1.00 (0.27) 0.85 (0.09) 1.11 (0.18) $ 
Guanidinoacetate 0.99 (0.39) 1.09 (0.33) 0.81 (0.48) 1.01 (0.32) 
 
White matter metabolites (mM, mean (standard deviation)) 
 
 
Argininosuccinic aciduria 
Normal MRI 
comparator 
group 
All patients (n=4, 3 severe and 1 partial) 
 
 
(53 studies) 
 
Median age  
(years, (range)) 
 
12.3 (1.2-14.2) 
   
4.7 (0.5-16.7) 
N-Acetylaspartate 4.48 (0.37)   5.11 (0.73) 
Creatine 2.45 (0.20) †   3.18 (0.47) 
Glutamine 1.79 (2.54)   1.32 (0.62) 
Glutamate 2.82 (0.27)   3.51 (0.78) 
Glutamine+Glutamate 4.61 (2.32)   4.84 (1.18) 
myo-Inositol 1.65 (0.81) †   2.57 (0.39) 
Choline 0.88 (0.09) *   1.08 (0.15) 
Guanidinoacetate 1.05 (0.41) *   0.75 (0.21) 
 
Table 8.4: Mean MRS derived brain metabolite concentrations in argininosuccinic aciduria 
cohort and normal MRI comparator group. Student’s t-test all ASA patients vs control, * 
p<0.05; † p<0.01. ANOVA between severe, partial and control groups, $ p<0.05 
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Chemical shift (ppm) 
 
 
Figure 8.9: Mean MR spectra for argininosuccinic aciduria cohort (red line) and standard 
normal MRI comparator cohort (black line, shaded area indicates standard deviation). Top 
panel: basal ganglia. Bottom panel: white matter. 
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Figure 8.10: Bar charts of mean MRS derived metabolite concentrations in comparator and 
argininosuccinic aciduria cohorts in basal ganglia. Upper panel: absolute metabolite values. 
Lower panel: metabolite ratios for glutamine, glutamate and guanidinoacetate. Student t-test, 
* p<0.05, † p<0.01. Error bars indicate standard deviation. 
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Figure 8.11: Bar charts of mean MRS derived metabolite concentrations in comparator, mild 
and severe argininosuccinic aciduria cohorts in basal ganglia Upper panel: absolute metabolite 
values. Lower panel: metabolite ratios for glutamine, glutamate and guanidinoacetate. 
ANOVA between groups, * p<0.05, † p<0.01. Error bars indicate standard deviation. 
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Figure 8.12: Bar charts of mean metabolite concentrations in comparator and 
argininosuccinic aciduria cohorts in white matter. Upper panel: absolute metabolite values. 
Lower panel: metabolite ratios for glutamine, glutamate and guanidinoacetate. Student t-test, 
* p<0.05, † p<0.01. Error bars indicate standard deviation. 
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Chemical shift (ppm) 
 
 
Figure 8.13: MRS spectrum from white matter from argininosuccinic aciduria patient 7 
showing LCModel fitted line (sum) and individual metabolite components. Components 
shown for creatine (Cr), glutamine (Gln), glutamate (Glu), guanidinoacetate (Gua), N-
acetylaspartate (NAA) and glycerophosphocholine (GPC). Upper panel: 0-4ppm. Lower 
panel: 2-4ppm only. Note guanidinoacetate and glutamine peaks overlap significantly at 
3.8ppm. 
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8.7. Discussion 
The data presented here includes the first substantial systematic report of neuroimaging and 
MRS data in a cohort of patients with ASA. The two phenotypic categories classically 
described in ASA were evident, and some interesting observations about differences and 
similarities between these groups have been made.  
 
The mild/partial phenotype cohort is classified by later presentation while the severe 
phenotype cohort present in the early neonatal period usually with significant 
hyperammonaemia. The hepatic phenotype showed a striking segregation between these two 
cohorts, with the entire mild cohort having normal ALT levels, and no hepatomegaly, while 
the entire severe cohort (including one diagnosed prospectively by sibling screening) had 
elevated ALT, hepatomegaly and abnormalities detectable by liver ultrasound scanning. 
Furthermore the elevated ALT was evident from a young age. 
 
The amino acid profile also effectively distinguishes the two cohorts, demonstrated by the 
unsupervised principal component analysis (PC2 generating a receiver operator characteristic 
(ROC) curve (i.e. plot of 1-specificity versus sensitivity) with area under the curve of 98%). 
Many amino acids were significantly different between the two groups, with the severe cohort 
having significantly higher arginine, citrulline, glutamine and glutamate and significantly 
lower branch chain amino acids and glycine. This may be in part due to differences in 
therapy: use of alternative pathway therapies (particularly sodium benzoate that conjugates 
glycine) can explain the lower glycine in the severe cohort, while these medications are also 
implicated in causing low branch chain amino acid levels [255]. Higher doses of arginine 
therapy in the severe cohort may be an explanation for the higher arginine levels in that group. 
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Tighter protein restriction may also have an effect on the differential amino acid profiles. The 
amino acid differences between the two cohorts may, however, also reflect a real biological 
difference in the metabolic disorder between the two groups. Thus the severe cohort had 
higher levels of glutamine, glutamate and citrulline.  
 
The two cohorts are less distinct in terms of the neurocognitive effects and seizure disorders. 
Seizure disorders were more prevalent in the severe cohort (5/5) but were still present in 
patients (2/6) in the mild phenotype cohort. Similarly, the presence of cognitive impairment, 
learning difficulties and behavioural problems crossed over both groups. One child (number 
7) was educated in main stream school but still had delayed development despite prospective 
diagnosis and therapy following sibling screening. Formal cognitive assessment and scoring 
was not available in this cohort, but the use of such scoring could provide an objective 
assessment and evaluation of any differences between the two cohorts. 
 
One possible explanation for why both groups seem to have significant neurocognitive 
deficits could relate to the timing of disease diagnosis. Patients within the severe cohort often 
have marked hyperammonaemia at presentation with presumably a significant detrimental 
effect, but these patients present earlier and are then treated from an earlier age. Patients in the 
mild cohort are usually diagnosed later, and so although the biochemical derangements or 
other pathological processes are presumably “milder” they will have been ongoing over an 
extended period of time, potentially accruing pathological effects during this lag time. The 
case of the adult reported to have creatine deficiency at time of diagnosis illustrates this point 
[244]. The early reports that mild phenotype patients identified by newborn screening (rather 
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than symptomatically) have better neurocognitive outcome also supports this “lag time” 
hypothesis [235]. 
 
The MR imaging features described here provide the first systematic study of ASA patient 
neuroimaging. In contrast to other UCD and IMD, the MRI features seen are generally very 
mild. Two patients had small cortical/subcortical infarcts, and another two had peritrigonal 
white matter abnormalities that could be consistent with ischaemic damage. Patient 11 had 
bilateral high signal change in the caudate and putamina, a similar pattern to that seen in some 
mitochondrial disorders. Thus there appears to be a propensity to possible vascular insults 
(infarcts), which could be related to dysfunction of normal intracranial vasoregulation. This is 
of interest given the likely central role of cellular-level NO deficiency in ASA [223, 228]. It 
would be interesting to further evaluate this in the context of the murine model of disease that 
has been generated. Alterations in the normal vascular functional response of the CNS in ASA 
could also be further validated by other functional imaging modalities such as fMRI that relies 
on normal vasoregulatory alterations, or perfusion MR imaging. 
 
Two patients who are siblings had periventricular gray matter heterotopia, i.e. accumulation 
of neurons adjacent to the ventricles that have failed to migrate correctly to the cerebral 
cortex. Children with heterotopia have a high rate of epilepsy [256]. There is usually a genetic 
basis for such heterotopias with chromosomes X, 20 and 5 often implicated, and so it is likely 
that in these siblings this is an incidental occurrence. However, heterotopias have been 
reported in other metabolic disorders including Zellweger and neonatal adrenoleukodystrophy 
[256].  
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Nitric oxide has an important function in normal neuronal migration, demonstrated in both 
animal models [257] and human cell lines [258]. It is possible, therefore, that NO system 
dysfunction in ASA could interfere with normal patterns of neuronal migration. Although 
only two of the patients here had evident heterotopia, it is possible that other patients in the 
cohort have small lesions not detected by the conventional MRI. High resolution volumetric 
MRI or other functional modalities may be able to detect higher rates of neuronal migration 
defects in these patients, which could provide an anatomical substrate for the high rates of 
seizure disorders and cognitive impairments in ASA patients, and warrants further 
investigation.  
 
8.7.1. MR spectroscopy findings 
In parallel with the relatively normal MR imaging findings, the MRS profiles in ASA in this 
cohort were also relatively normal. That said, some statistically significant differences with 
the standard comparator groups were found, and also graduated differences from control to 
mild-cohort to severe-cohort. The slight decrease in tNAA seen in both brain regions studied 
is not specific to ASA but does imply there is some neuronal loss or loss of neuronal viability 
despite the relatively normal MRI appearances. 
8.7.1.1.Creatine deficiency 
Creatine levels were significantly decreased in both white matter and basal ganglia, however 
the creatine peaks were clearly present and substantially higher than the (absent) levels 
detected in the formal creatine deficiency syndromes. Thus the clinical significance of the 
creatine “deficiency” is uncertain. Furthermore, the creatine/NAA ratio was normal in both 
brain regions, which could imply that the lower absolute creatine levels seen were a reflection 
of the loss of neurons and not a specific metabolic alteration or deficiency per se at the 
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neuronal level. Thus there is not good evidence in this cohort for creatine deficiency in the 
brain. The previous report of creatine deficiency in ASA demonstrated this in a late-onset 
adult patient prior to treatment, with brain creatine levels normalising with oral arginine 
therapy [244]. This observation in conjunction with the relatively normal creatine levels seen 
in the current cohort who were all receiving arginine supplements at the time of MRS 
examination would suggest that the current treatment regimen with arginine supplementation 
is effective in treating any significant brain creatine deficiency.  
 
It remains possible that creatine deficiency existing prior to treatment during the diagnostic 
“lag time” could have a detrimental effect. In the creatine deficiency syndromes creatine 
supplementation effectively raises brain creatine as ascertained by MRS, but does not 
completely ameliorate the clinical phenotype implying there may be irreversible damage 
sustained prior to treatment [259]. The same could be true in ASA, and could be one factor in 
explaining the potentially better outcome for children identified by newborn screening and 
treated prospectively, thereby avoiding sustained arginine and secondary creatine deficiencies. 
It would not be justifiable to stop arginine therapy in diagnosed patients to assess brain 
creatine deficiency, but potentially this could be screened for at diagnosis for example in 
patients identified by a newborn screening programme.  
 
8.7.1.2.Guanidinoacetate toxicity 
It has been suggested that elevated guanidinoacetate concentrations, potentially due to 
arginine supplementation, could be responsible for the high rates of seizures seen in ASA 
patients [247, 248]. The data in this study do not provide strong evidence in favour of 
elevated guanidinoacetate in the brain of the ASA cohort.  
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In the data from the basal ganglia, there was no difference in the guanidinoacetate 
concentration between controls and patients, and indeed there was trend to lower 
guanidinoacetate (non-significant) in the severe ASA cohort who had higher rates of seizure 
disorders. By contrast, in the smaller dataset from the white matter region, a small but 
significant elevation in guanidinoacetate was detected. Of note the white matter data was 
predominantly from severe ASA patients, but only two had seizure disorders.  
 
In the physiological pH range, the expected spectral peak of guanidinoacetate is a singlet at 
3.8ppm. Glutamine also has peaks at this chemical shift, and in vivo these (and other 
metabolites) contribute to the peak seen at circa 3.8ppm (see figure 8.13). Since glutamine 
also has other peaks between 2.4-2.5ppm it is theoretically possible to calculate the relative 
contributions of glutamine and guanidinoacetate to the peak seen at 3.8ppm. However, there 
remains some uncertainty as to the accuracy of the metabolite linear combination fitting to 
this peak. Of note in the current dataset the highest guanidinoacetate concentrations were 
associated with the highest glutamine concentrations, suggesting that the contribution of 
glutamine to the in vivo 3.8ppm peak may have been underestimated and that of 
guanidinoacetate overestimated.  
 
Given that the proposed mechanism for generating elevated guanidinoacetate is excess 
arginine supplementation, it might be expected that any elevation would be seen in all brain 
areas analysed since AGAT and GAMT are expressed throughout the brain. The absence of 
elevated guanidinoacetate in the basal ganglia data therefore does not support this hypothesis. 
Furthermore guanidinoacetate should not be elevated prior to treatment with arginine, and so 
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cannot explain the development of seizures occurring prior to diagnosis in the late onset/ mild 
phenotype. 
 
It should also be noted that in the report of two ASA patients with elevated brain 
guanidinoacetate that guanidinoacetate levels in controls were reported as “none detected” 
[248], whereas in the present data the comparator group did have apparently detectable levels. 
In GAMT deficiency, the guanidinoacetate detected was substantially higher in gray matter 
compared to white matter [246] in contrast to the pattern observed in the ASA patients here. 
For these various reasons, therefore, the data presented do not confirm the suggestion that 
guanidinoacetate toxicity plays a role in generating epilepsy in ASA. Analysis of a larger 
cohort with higher field MRI scanners may help elucidate this hypothesis further. 
 
8.7.1.3.Elevated brain glutamine and glutamate 
In the UCD generally hyperammonaemia is thought to result in elevated brain glutamine 
synthesis, since astrocytic glutamine synthase activity is a key protective mechanism against 
ammonia-induced neurotoxicity. In the acute phase, rapid increases in brain glutamine results 
in intracellular osmotic pressure causing cellular swelling and consequently brain oedema.  
 
On analysis of absolute metabolite concentrations across the cohorts, there was no significant 
elevation of glutamine+glutamate detected in ASA patients in either white matter or basal 
ganglia, though there was a trend to increased concentration in basal ganglia in ASA. 
Importantly all children were clinically well at the time of MRS, and so ammonia levels 
would not be substantially elevated at the time of study.  
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It has been noted already that there was a significant decrease in tNAA in ASA patients. This 
may suggest there is a reduction in neuronal cell number or density present within the volume 
of interest, and so ratios of glutamine and glutamate to NAA and to creatine were calculated 
to provide an approximate correction for any change in neuronal density or number. In basal 
ganglia there was significantly increased glutamine+glutamate/creatine and 
glutamine+glutamate/NAA, with contributions to this from both glutamine and glutamate 
separately. In the smaller white matter dataset results did not reach significance, but there was 
a trend to elevated glutamine+glutamate/creatine. 
 
One child had notably high glutamine levels observed by MRS, convincingly distinguished 
from glutamate (figure 8.13). This child also had the highest mean glutamine levels on plasma 
quantitative amino acids (mean 659 μmol/l). Interestingly, in this child the myo-inositol level 
was significantly decreased, a pattern reflected in the low mean inositol in the white matter 
ASA group. There was also a non-significant trend to lower inositol in the severe ASA cohort 
in basal ganglia. Inositol functions as an organic osmolyte, being actively transported in or out 
of cells (particularly glia) to counteract chronic alterations in osmotic pressure. Thus it is 
conceivable in these children that inositol is depleted in cells in response to chronically 
elevated glutamine, suggesting ongoing osmotic stress in the CNS that may contribute to the 
neuropathology. 
 
Alterations in glutamine and glutamate are proposed to be due to hyperammonaemia, and so 
would not be specific to ASA but generally applicable to all the UCD. It is important to note 
that elevated levels relative to cell density (NAA) were observed in the ASA patients despite 
their relatively good ammonia control.  
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8.8. Conclusions 
The MRS data presented here can answer some of the hypotheses presented to explain the 
CNS pathology in ASA. Firstly, brain creatine deficiency is not a significant issue in arginine 
treated ASA patients, but could potentially contribute to the neuropathology prior to diagnosis 
and the instigation of treatment particularly in late-onset/mild phenotype patients. Secondly, 
brain guanidinoacetate levels were not convincingly found to be elevated in the ASA patients, 
and levels did not correlate well with the occurrence of seizure disorders. Thirdly, brain 
glutamine+glutamate levels were found to be relatively elevated in at least some of the ASA 
patients, a feature common to other UCDs. 
 
The MRI data highlighted the relatively normal imaging features, but did identify several 
patients with possible infarcts due to vascular events that raise the possibility of vascular 
dysregulation. The alterations and deficiencies in NO function in ASA could contribute to 
this, and may provide a mechanism specific to ASA to explain the neuropathological features. 
If ASA patients suffer the same ammonia/glutamine-induced osmotic stress and changes as 
other UCD patients, as evidenced by the MRS findings, it is possible that ineffective 
NO/vascular-mediated mechanisms as described by Erez et al [223] create an ASA-specific 
defect in how the CNS responds to this generic UCD insult. Furthermore, the possibility of 
NO dysfunction in ASA interfering with normal neuronal migration is suggested by the 
finding of significant gray matter heterotopia in two of the patients. These hypotheses require 
further investigation and as noted above, other functional imaging modalities could provide in 
vivo methods for evaluating vascular regulatory function and subtle evidence of neuronal 
migrational defects. Further investigation using murine models of ASA could also focus on 
the neuropathogenesis aspects of NO dysfunction. 
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Chapter Nine 
 
9. Final Discussion 
 
 
The work described in this thesis employed in vivo magnetic resonance imaging and 
spectroscopy techniques with the aims of firstly identifying potential biomarkers of disease 
that could be used in disease diagnosis and in monitoring disease progression or response to 
novel therapies, and secondly, to investigate the pathogenesis of neurologic damage in 
specific inherited metabolic disorders. The study aimed in particular to develop and use 
quantitative in vivo brain metabolite profiling by MR spectroscopy in the investigation of the 
inherited metabolic disorders, as an adjunct to standard neuroimaging and biochemical 
analyses. This thesis has set out the results of work undertaken towards meeting these aims, 
which are briefly summarised here (see table 9.1). Limitations of the techniques employed are 
discussed, and future research directions explored. 
 
9.1. Technique Development and Assessment 
Prior to applying the techniques to evaluate disease specific hypotheses, methods for the 
acquisition, processing and analysis of in vivo MRS data had to be implemented and 
evaluated. In particular it was important to assess the validity and quality of the data being 
generated, specifically the reliability and reproducibility of the metabolite quantification. 
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Non-standard metabolite 
peak detection  
(Chapter 5) 
Succinate, glycerol, glycine detected in brain of children 
demonstrated to have specific defects in metabolic pathways 
of these metabolites. 
 
Hunter Syndrome  
(Chapter 6) 
NAA decreased in patients, with trends mapping to alteration 
in clinical neurocognitive status. 
MRS profile has potential to monitor and detect early changes 
in brain. 
 
Propionic Acidaemia 
(Chapter 7) 
Patients have relatively decreased glutamine and glutamate in 
areas of brain vulnerable to stroke, and evidence of impaired 
brain energy metabolism. 
 
Argininosuccinic 
Aciduria  
(Chapter 8) 
Neither creatine deficiency nor guanidinoacetate toxicity 
confirmed as major factors in predilection to epilepsy. 
Relatively increased glutamine and decreased inositol 
supportive of ammonia-induced osmotic stress. 
Novel neuroimaging features consistent with NO dysfunction 
described in ASA patients. 
 
Table 9.1: Summary of key results from application of MRS technique to disease cohorts. 
 
A standard acquisition protocol was implemented to facilitate the collection of in vivo MRS 
data, benefitting from pioneering work undertaken in the study of childhood brain tumours. 
The use of a standard protocol with pre-determined sampling sites (voxel positions) meant 
that metabolite data from different patient cohorts was comparable since the acquisition and 
anatomical parameters were standard, removing non-biological sources of data variability. 
The standard protocol demonstrated the feasibility of implementing such a study in a routine 
clinical paediatric setting with large datasets generated, with over 300 MRS examinations 
included in the period of the study.  Although the standard MRS examination sampled only 
the basal ganglia and parietal white matter thus restricting the analysis to these regions, these 
regions are commonly involved in metabolic diseases and allowed for the generation of 
specific comparator cohorts.  
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In addition to a standard acquisition process, the use of a standard post-processing method 
employing a well-validated software tool (LCModelTM) enabled automatic user-independent 
post-processing to be undertaken, again removing a potential source of non-biological 
variation. The detailed data quality assessment described found that good quality data was 
obtained after processing in around 95% of cases. Furthermore this process provided a 
feedback loop aiming to correct specific data acquisition problems and thereby prospectively 
improving the quality of data collected. 
 
A particular focus was placed on the analysis of the effects of different post-processing steps 
and the implications of acquiring data from two different MR scanner systems. This analysis 
found systematic differences in the metabolite estimations from the two scanner systems. 
Specific algorithms were developed to allow integration of data from the two systems. This 
experience in a single centre study highlighted the importance of considering such factors in 
the design of larger multicentre studies where potentially multiple scanner systems would be 
employed. Furthermore such considerations must play a part in the design of any multicentre 
study employing local data collection and analysis hardware, be it imaging or biochemical 
bio-fluid analysis. 
 
9.2. Background data and standard comparator cohorts 
Having established the reliability of the acquisition and processing protocols, the next 
requirement was the analysis of regional and age-related metabolite variation and the 
generation of a standard comparator cohort. These were required to enable the interpretation 
of brain metabolite data derived from specific disease cohorts and individual cases. The 
regional and age variation of the metabolite data described was found to be consistent with 
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previous studies in the literature, and furthermore the standard comparator cohort metabolite 
profile was comparable with other published normal control datasets. Indeed, the approach of 
using patients with normal MR imaging features as a comparator group was found to be 
employed in numerous other studies, and given the difficulties in obtaining a truly normal 
control group from the wider paediatric population, was found to be a workable and effective 
method. The large numbers of children included meant that the effect of metabolite “outliers” 
was reduced, such that narrow standard deviation values were seen for the cohort mean 
spectra and metabolite ranges.   
 
9.3. Identification of Diagnostic Disease Biomarkers 
Non-standard brain metabolites were detected in only a small percentage of children (~2.3%). 
When present, however, such metabolites may provide an important diagnostic handle. 
During the period of this study this approach contributed to the diagnostic process for several 
children. If such an approach were to have wider clinical relevance it would be important both 
that MRS was acquired routinely as part of the clinical assessment of patients with 
undiagnosed neurodegenerative disorders, and that methods for the identification and 
recognition of such peaks were established. 
 
9.4. Development of disease and therapy monitoring biomarkers 
The methods developed were applied to a cohort of children with Hunter Syndrome, a disease 
for which novel brain-targeted therapies are in development. One of the clinical challenges is 
in determining the efficacy of such therapies, and a multimodal MR approach was taken to 
evaluate the potential contribution of brain metabolite profiling to this process. Alterations in 
brain metabolite profiles were studied in serial assessments in a cohort of patients and found 
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to reflect alterations in the clinical status of the patients. The brain metabolite profile 
alterations also mirrored the changes in some quantitative MR imaging parameters. It was 
also suggested that brain metabolite alterations may provide an earlier marker of disease 
progression than structural MR changes, although this requires further prospective evaluation 
in cohorts of children with less advanced disease than the group studied here.  
 
A robust disease biomarker requires exquisite sensitivity and reproducibility if it is to 
accurately detect early signs of disease, and as such the inherent variability and limited 
sensitivity in the MRS technique may be a limiting factor. The clinical relevance of using 
endpoints such as alterations in MR imaging or spectroscopic parameters must also be 
addressed, since in the design of the clinical trials of novel therapies it is desirable to have 
meaningful clinical endpoints. That said, objective methods of evaluating the effect of 
therapies on the brain can play an important role in such research. 
 
9.5. Investigating disease pathogenesis 
Towards meeting the second aim of the study, namely to investigate the pathogenesis of 
neurologic damage in specific IMDs, the techniques developed were applied to cohorts of 
children with two different disorders, propionic acidaemia and the urea cycle disorder 
argininosuccinic aciduria. In both instances the cohorts represent the largest groups of patients 
systematically studied using a neuroimaging and MR spectroscopy approach. 
9.5.1. Propionic acidaemia 
Children with this disorder of branch chain amino acid catabolism face a wide range of 
complications, but have a particularly poor neurological outcome with a specific propensity to 
developing strokes affecting the basal ganglia. Data were collected from this group of patients 
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both electively while the children were well, and also from a group who were acutely unwell 
requiring intensive care support. By this means it was possible to generate and compare brain 
metabolite profiles from ‘stable’ and ‘unstable’ metabolic situations, providing some 
preliminary findings that support current hypotheses relating to glutamine depletion and 
Krebs cycle impairment in this disorder. The observations made require further substantiation, 
but importantly the study demonstrated the feasibility of employing such methods in the acute 
setting, with the potential to monitor the effects of brain protective strategies. 
9.5.2. Argininosuccinic aciduria 
The methodology was then applied to the study of argininosuccinic aciduria, which has CNS 
features unique amongst the urea cycle disorders including significant cognitive impairment 
and high rates of epilepsy that suggest disease-specific mechanisms. The study provided the 
first systematic neuroimaging analysis in a cohort of patients with this disease, identifying 
several features that warrant further investigation and that may support the nitric oxide 
dysfunction hypothesis. Several other specific hypotheses to explain the CNS features were 
investigated using the MRS methods. The presence of creatine deficiency in appropriately 
arginine-supplemented patients was not found, and furthermore the role of guanidinoacetate 
toxicity was not supported from the data.  
 
9.6. Limitations 
With some notable exceptions, previous reports of the use of MR spectroscopy in the 
inherited metabolic disorders have been limited to single case qualitative descriptions or small 
case series. This study has implemented a robust and reproducible quantitative methodology, 
deriving some important results in several different disease cohorts. As such this work 
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represents a substantial advance in this field of research. That said several remaining 
limitations warrant discussion including technical and patient sampling limitations.  
 
The MRS method is limited by the inherent insensitivity of the NMR technique and the 
difficulty of detecting low metabolite concentrations against the predominant water 
background signal. MRS is restricted to the detection of brain metabolites present at or around 
0.5mmol/l, and therefore biologically significant alterations in lower concentration 
metabolites will not be detected. The work described here has benefitted from a focus on 
several diseases where alterations have occurred within the standard metabolites detected: i.e. 
the technique is best employed to address questions it is capable of answering. 
 
A second limitation is the spatial resolution of the method. The standard single voxel 
approach used here samples a volume of 8cm3, a volume containing presumably millions of 
neurons and glial cells. The metabolite signal is therefore an average across the volume, and is 
not capable of detecting alterations in the distribution of metabolites across cell types or small 
anatomical structures. This again must be borne in mind in the interpretation of the metabolite 
data. Comment has already been made to the limited spatial coverage of the single voxel 
technique, sampling only one or two selected brain regions. 
 
Thirdly the question of data reproducibility needs to be addressed, particularly as the 
alterations in metabolites in these disorders have been shown to be often subtle, and also as 
discussed above that the detection of early disease alterations requires greater sensitivity.  
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Fourthly, at low-field strength (1.5T) there is significant overlap of many of the metabolite 
peaks. This is particularly a problem for metabolites that are represented by multiplets rather 
than singlet peaks, notably glutamine and glutamate. The current methods may be able to 
provide some differentiation but further improvements in metabolite detection and 
differentiation will be possible with the use of higher field strength scanners, and also the 
application of spectral editing methodologies.   
 
Beyond the technical limitations the study was also subject to “patient sampling limitations”. 
By this is meant that the patient cohorts available for study are often small due to the limited 
incidence and prevalence of rare diseases. Furthermore the number of sampling time points is 
restricted. While functional imaging is considered non-invasive it is not necessarily feasible to 
obtain multiple acquisitions at differing time points within the natural history of the disease in 
a single patient, with the result that the data obtained even within one disease cohort is likely 
to reflect different stages of the disease. Additionally there is very limited scope for 
experimental manipulation in human subjects, particularly in the paediatric population. 
 
Despite these limitations the work in this thesis has demonstrated that in vivo MR 
spectroscopy can generate valuable information, and has been successfully obtained in many 
children with different IMDs. The value of the information can be maximised by the use of a 
systematic quantitative approach to data acquisition and analysis as implemented here. The 
use of a large comparator cohort has also provided a strong baseline for comparison of 
individual cases and cohorts of patients with specific disorders; the use of a large comparator 
group was found to be particularly valuable when dealing with the small numbers of cases 
encountered in the rare diseases.  
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9.7. Future Perspectives 
The current study has made progress towards meeting the initial aims and has also generated 
several further hypotheses. The study has, however, highlighted several limitations that will 
be addressed in future work. 
 
Some of the technical limitations will be improved upon with the use of higher field MR 
systems that are becoming more widely available, including in clinical paediatric settings such 
as the recently opened NIHR-funded 3T MRI Research Centre at the Birmingham Children’s 
Hospital. The use of such systems will go some way to improving the limitations of 
sensitivity and metabolite separation. Thus, for example, the initial findings reported in this 
thesis pertaining to the distinction of glutamine from glutamate in disorders such as propionic 
acidaemia and urea cycle disorders will be validated and tested in prospective MRS studies at 
higher field strength. Specific spectral editing routines will also be useful in detection of 
specific metabolites of interest, e.g. as mentioned previously for the detection of GABA. 
 
Higher field scanners will also allow improvements in spatial resolution, since smaller voxel 
size regions of interest can be employed with a reasonable acquisition time. This will allow 
more specific anatomical regions of interest to be investigated, for example potentially 
studying different nuclei within the basal ganglia. Even with high field scanners, however, the 
single voxel approach still samples volumes in the order of cubic centimetres. 
 
Spatial coverage with MRS can be enhanced substantially by the use of magnetic resonance 
spectroscopic imaging (MRSI, or chemical shift imaging (CSI)) techniques, allowing 
evaluation of metabolite profiles across larger regions of the tissue being examined. These 
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methods do present additional challenges in terms of data processing, reproducibility and 
inter-voxel cross-contamination, but in some circumstances may be a useful way of studying 
spatial metabolite variation. (An example of a CSI study is given in Appendix C). This will be 
of particular value in studying disorders where there is likely to be regional variation in 
metabolite profiles, and in studying differences between normal appearing and abnormal 
appearing brain regions. 
 
Other functional imaging modalities have been alluded to in this thesis, notably those based 
on diffusion weighted imaging, which can provide information about tissue micro-structural 
changes. The combination of different modes of functional imaging data could be synergistic, 
allowing for example investigation of metabolite profile alterations in regions with altered 
tissue microstructural properties (as identified by DWI or DTI). Such an approach may be of 
value in identifying biomarkers of disease progression. The work described in Chapter Six 
relating to Hunter Syndrome provided an initial approach to combining quantitative structural 
imaging parameters with metabolite profile data, and work on-going will evaluate the 
potential to incorporate DTI parameters within such a model, particularly focussing on the 
detection of early changes that would not be identified with conventional MRI.  
 
The second major challenge faced in the investigation of rare diseases such as the IMDs is the 
“patient sampling limitation”, caused by the inherently small sample size available for study 
and the heterogeneous sampling time point in the disease course. As with other rare diseases 
such as the paediatric brain tumours, this necessitates multi-centre studies in order to acquire 
sufficient data to obtain statistically significant results. Future studies, particularly where 
functional imaging forms part of an interventional/therapeutic trial, will require the 
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acquisition of data from multiple centres. The work in this thesis highlights the importance in 
this context of prospectively considering the impact of acquiring data from multiple sources, 
and taking into account inter-scanner variability. 
 
Key clinical problems remain unresolved, notably the issue of the large cohort of children 
with undiagnosed neurodegenerative disorders. This study has found that the majority of these 
children do not have novel metabolite peaks within their brain metabolite profile. It is possible 
that the use of higher field scanners will enable detection of lower concentration non-standard 
metabolites. An alternative approach is to apply pattern recognition methods to the standard 
metabolites present to classify and diagnose disorders. Multivariate analysis methods such as 
principal component analysis have been applied in this thesis to in vitro metabolite data 
including plasma amino acids, and urinary NMR spectral profiles. Similar methods can also 
be applied to the metabolite profiles derived from in vivo MRS, as demonstrated previously in 
the classification of paediatric brain tumours [260]. A multivariate approach to identifying 
children with mitochondrial diseases is also being explored (see Appendix D where 
preliminary results are presented), and the incorporation of multiple metabolite parameters 
may improve the diagnostic power of MRS. A similar pattern recognition approach has been 
demonstrated by others in the study of the leukodystrophies (inherited white matter disorders) 
using well defined cohorts of children with confirmed diseases [118], and that model is now 
being applied to the current cohort of children with undiagnosed white matter disorders.  
 
Finally, as already noted there is a limited scope for experimental manipulation in paediatric 
subjects, and this combined with the issues of patient sampling limitations highlights the 
importance of the development of disease model systems. Importantly, the research methods 
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of in vivo metabolite profiling developed and described in this thesis can be used in the 
evaluation of such systems, both cell-based and animal disease models. As such the functional 
imaging techniques are truly translational and will continue to play an important role. Several 
potential hypotheses suggested in the study of propionic acidaemia and the urea cycle 
disorders could be further evaluated and tested in appropriate model systems; furthermore 
these could be adapted to provide means of screening potential novel therapies. 
 
This thesis aimed to contribute to improved clinical outcomes for children affected by 
neurodegeneration in the context of inherited metabolic disorders, and the work described 
here provides evidence of progress made towards this end. 
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Appendix A 
 
Comments on Diffusion Weighted Imaging 
A brief description of diffusion weighted imaging of the brain is given here, including the 
underlying principles of the technique, discussion of the pathophysiological correlates of 
alterations in diffusion parameters, and specific examples of its use in the IMDs.  
 
A1. Paediatric Diffusion Weighted Imaging of Brain 
Diffusion weighted imaging sequences are routinely available in paediatric clinical practice 
[261], with a short acquisition time (typically around 1-2mins [262]) meaning they can be 
feasibly appended to other imaging sequences. Conventional MR imaging is based on the 
detection of hydrogen nuclei predominantly from water molecules, and at the simplest level 
contrast is seen due to the variation in water concentration (proton density) in different 
tissues, e.g. between gray and white matter.  
A2. Principles of DWI 
Diffusion weighted imaging determines how easily water is able to diffuse by Brownian 
motion in different tissues, and alterations in the apparent diffusion are seen in different 
pathologies. “Diffusivity” is a property of water, depending on temperature. Alterations in 
“diffusion” seen in DWI are due to other tissue and cellular factors that affect how easily 
water can diffuse, and is referred to as the apparent diffusion coefficient. Diffusion increases 
when water is able to diffuse more readily, while diffusion decreases (is restricted) when 
water is less able to diffuse. DWI takes account of the magnitude of diffusion. Diffusion that 
can occur equally in all directions in space is isotropic, while diffusion that can occur more 
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easily in one direction or other (e.g. along an axon) is anisotropic. Diffusion tensor imaging 
(DTI) takes account of this directionality of diffusion. 
 
The DWI sequence uses diffusion-sensitising gradients added to a basic spin-echo sequence. 
An initial 90o pulse results in proton spin coherence, i.e. all proton spins are in phase with 
each other. A first magnetic gradient de-phases the spins, while a second magnetic gradient 
after the 180o inversion pulse re-phases the spins, providing spatial encoding. In the situation 
that no water molecules have moved with respect to the gradient direction (i.e. no diffusion at 
all), all the proton spins will be re-phased and high signal will be returned. When water 
molecules have moved (diffused) during the acquisition, they will sit at a different place with 
respect to the gradient and will be incompletely re-phased by the second gradient, resulting in 
loss of signal. Thus in DWI, lower signal reflects more diffusion.  
 
Typically two sequences are obtained, the first b zero image without additional gradients, and 
the second (high b) with the diffusion-sensitising gradient. The data from these two sequences 
are combined to give the Apparent Diffusion Coefficient (ADC) by  
 
Equation (A1)    S=S0e-2bADC  
 
where S is high b signal, S0 is the b zero signal. 
 
Two series of images are generated. On the DWI image, areas of high (bright) signal are due 
to reduced (restricted) diffusion (and hence less dephasing). Areas with reduced signal (dark) 
represent increased diffusion, thus CSF in ventricles appear dark. Conversely on an ADC 
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map, bright areas indicate increased diffusion values, while dark areas indicate restricted 
(decreased) diffusion. 
  
DWI sequences are heavily T2-weighted and sensitive to increased T2 signal. The 
phenomenon of T2 shine through describes a high T2 signal lesion that will appear bright on 
T2-weighted images and also bright on DWI. Increased DWI suggests decreased diffusion, but 
if the lesion also appears bright on ADC then diffusion is actually increased, and the 
brightness on DWI is caused by T2-shine through and not decreased diffusion. 
 
The diffusion of water molecules is unrestricted in a glass of water, but in brain water is 
compartmentalised and comes across barriers to diffusion. Typically intracellular water is less 
able to diffuse than extracellular water. Furthermore water is more able to diffuse along axons 
and brain tracts than perpendicular to the axon and the tracts, thus white matter has a typical 
“direction” to diffusion. Because axons and tracts in the brain do not all lie in the same 
direction, diffusion in different brain regions is not the same in all directions. DWI sequences 
typically therefore acquire signal using at least 3 gradients in different directions. An average 
DW image is then generated. This counteracts the effect of diffusion anisotropy, providing a 
measure of the magnitude of diffusion in that region but ignoring the directionality of the 
diffusion. Diffusion tensor imaging takes account of this diffusion directionality to yield 
further information. 
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A3. Diffusion Pathophysiological Correlate 
In general it is accepted that intracellular water is less able to diffuse freely than extracellular 
water, therefore in situations of increased intracellular water diffusivity will decrease, whereas 
increased extracellular water will lead to a rise in the apparent diffusion [263].  
 
Restricted diffusion is seen following an acute ischaemic insult; hypoxia-ischaemia results in 
energy failure and acute failure of the Na-K ATPase, resulting in acute cellular oedema, with 
increased intracellular water and decreased extracellular volume due to cell swelling. 
Diffusion is thus decreased (restricted). In the early stages after an acute ischaemic episode 
diffusion is restricted in affected areas, and there is robust evidence from adult ischaemic 
stroke that DWI will delineate affected areas in stroke earlier than conventional MRI. 
Decreased diffusion can also be seen in a range of other disorders, including hypercellular 
tumours, in areas containing viscous fluid such as pyogenic abscess, and also in Canavan 
disease. The “prognosis” of restricted diffusion is not straightforward, as diffusion 
abnormalities may normalise without tissue loss. 
 
Increased diffusion is thought to occur when there is increased extracellular water i.e. 
vasogenic or interstitial oedema, which may be an acute or chronic process (e.g. development 
of cystic encephalomalacia). Acute episodes may be associated with loss of blood brain 
barrier integrity causing vasogenic oedema, or acute hydrocephalus causing interstitial 
oedema.  
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A4. Reports of DWI in Inherited Metabolic Disorders 
DWI has been employed in the evaluation of foetal ischaemic infarction, acute hypoxia-
ischaemia-reperfusion injury in infants/children, arterial stroke, sinovenous thrombosis, 
vasculitis, tumours and infections [263]. Within the inherited metabolic disorders a wide 
range of diffusion alterations are reported, some disorders associated with increased diffusion 
(ALD, Alexander, Wilson), others with restricted (MLD, Canavan) or mixed picture (PKU, 
MSUD, Leigh) depending on disease stage [263]. With regard to disorders considered further 
within this dissertation, no reports were found in the literature of diffusion imaging data for 
Hunter Syndrome, with one report of diffusion changes in the wider mucopolysaccharidosis 
group [264]. Several case descriptions of propionic acidaemia reported diffusion changes in 
cortex and basal ganglia in acute episodes of metabolic derangements [10, 179], and DWI and 
DTI have been reported in methylmalonic acidaemia [265-269]. Mitochondrial disorders have 
also been explored using these modalities [262, 270-301]. 
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Appendix B 
Published articles arising from the current study. 
 
Facsimile copies of the following published articles arising from the work undertaken during 
the current period of study are included in the following pages. 
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mucopolysaccharidosis type II (Hunter Syndrome). J Inherit Metab Dis 2010, 33:819. 
 
Davison JE, Davies NP, Wilson M, Sun Y, Chakrapani A, McKiernan PJ, Walter JH, Gissen 
P, Peet AC: MR spectroscopy-based brain metabolite profiling in propionic acidaemia: 
metabolic changes in the basal ganglia during acute decompensation and effect of liver 
transplantation. Orphanet J Rare Dis 2011, 6:19. 
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Magnetic resonance spectroscopy in the diagnostic evaluation of brainstem lesions in 
alexander disease. J Child Neurol 2011, 26:356-360. 
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Abstract Neurological involvement in X-linked mucopo-
lysaccharidosis type II (Hunter syndrome) is indicative of
more severe disease, but is not attenuated by current enzyme
replacement therapy which does not significantly pene-
trate the blood–brain barrier. Magnetic resonance spec-
troscopy is an objective method of determining brain
metabolites and has the potential to identify disease
biomarkers with utility in evaluating current and novel
therapies. MRS studies from seven patients with MPSII
all receiving enzyme replacement therapy were com-
pared with a large cohort of children with various
neurocognitive disorders with normal MR imaging. All
studies were completed on 1.5Tesla clinical MR scan-
ners. Brain metabolite concentrations were determined
from basal ganglia and parieto-occipital white matter using
LCModel quantification. Serial trends in brain metabolites
were analysed. Examination of mean spectra and quantitative
metabolite concentrations demonstrated significantly de-
creased white matter N-acetylaspartate (a neuronal marker),
total choline and glutamate, and elevated myo-inositol (glial
marker) in MPSII patients. Analysis of serial determinations of
white matter N-acetylaspartate demonstrated no change in two
patients with stable MR imaging features but decreasing N-
acetylaspartate in two patients more severely affected or
deteriorating. These data demonstrate the utility of MRS to
monitor serial alterations in brain metabolites including N-
acetylaspartate which could be used as biomarkers of
progressive neurological disease in MPSII. Integrated as an
adjunct to MRI, such an approach could aid the evaluation of
the efficacy of current ERT and also novel CNS-targeted
therapies in MPSII.
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MR spectroscopy-based brain metabolite profiling
in propionic acidaemia: metabolic changes in the
basal ganglia during acute decompensation and
effect of liver transplantation
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Abstract
Background: Propionic acidaemia (PA) results from deficiency of Propionyl CoA carboxylase, the commonest form
presenting in the neonatal period. Despite best current management, PA is associated with severe neurological
sequelae, in particular movement disorders resulting from basal ganglia infarction, although the pathogenesis
remains poorly understood. The role of liver transplantation remains controversial but may confer some neuro-
protection. The present study utilises quantitative magnetic resonance spectroscopy (MRS) to investigate brain
metabolite alterations in propionic acidaemia during metabolic stability and acute encephalopathic episodes.
Methods: Quantitative MRS was used to evaluate brain metabolites in eight children with neonatal onset
propionic acidaemia, with six elective studies acquired during metabolic stability and five studies during acute
encephalopathic episodes. MRS studies were acquired concurrently with clinically indicated MR imaging studies at
1.5 Tesla. LCModel software was used to provide metabolite quantification. Comparison was made with a dataset
of MRS metabolite concentrations from a cohort of children with normal appearing MR imaging.
Results: MRI findings confirm the vulnerability of basal ganglia to infarction during acute encephalopathy. We
identified statistically significant decreases in basal ganglia glutamate+glutamine and N-Acetylaspartate, and
increase in lactate, during encephalopathic episodes. In white matter lactate was significantly elevated but other
metabolites not significantly altered. Metabolite data from two children who had received liver transplantation
were not significantly different from the comparator group.
Conclusions: The metabolite alterations seen in propionic acidaemia in the basal ganglia during acute
encephalopathy reflect loss of viable neurons, and a switch to anaerobic respiration. The decrease in glutamine +
glutamate supports the hypothesis that they are consumed to replenish a compromised Krebs cycle and that this
is a marker of compromised aerobic respiration within brain tissue. Thus there is a need for improved brain
protective strategies during acute metabolic decompensations. MRS provides a non-invasive tool for which could
be employed to evaluate novel treatments aimed at restoring basal ganglia homeostasis. The results from the liver
transplantation sub-group supports the hypothesis that liver transplantation provides systemic metabolic stability
by providing a hepatic pool of functional propionyl CoA carboxylase, thus preventing further acute
decompensations which are associated with the risk of brain infarction.
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Background
Propionic acidaemia (PA, OMIM #606054) results from
deficiency of the biotin-dependent mitochondrial
enzyme propionyl CoA carboxylase. The commonest
and most severe form of PA presents in the neonatal
period with acute metabolic acidosis, hyperammonaemia
and progressive encephalopathy. Despite optimal man-
agement, later neurologic sequelae are a major cause of
morbidity, and include neurodevelopmental delay, episo-
dic acute encephalopathy, and movement disorders due
to a propensity to basal ganglia infarction [1]. The main-
stays of current treatment are dietary protein restriction,
carnitine supplementation, and aggressive management
of acute metabolic derangements. Some centres utilise
alternative pathway drugs including sodium benzoate to
minimise the consequences of hyperammonaemia.
Orthotopic liver transplantation may prevent neurocog-
nitive decline [2] but its role remains controversial.
The pathogenesis of the neurological insult remains
poorly understood. Neurological damage may occur sec-
ondary to hyperammonaemia; alternatively inhibition of
the mitochondrial Krebs cycle and electron transfer chain
by accumulating metabolites may lead to a “bioenergetic
stroke” [3]. Based on alterations in plasma amino acids
associated with hyperammonaemia it has been hypothe-
sised that the use of dietary supplements including gluta-
mine that can replenish the Krebs cycle (anaplerotic
therapy) may support aerobic cellular energy metabolism
and hence improve clinical outcome [4]. Conflicting
changes in cerebrospinal fluid glutamine concentrations
have been reported in PA [5,6].
Magnetic resonance spectroscopy (MRS) is a non-inva-
sive technique capable of probing in vivo changes in
regional metabolites within the brain, and could be speci-
fically employed to monitor directly alterations in brain
energy metabolites including glutamine, glutamate and
lactate. Previous MRS reports have demonstrated ele-
vated glutamine+glutamate (Glx) in the basal ganglia of
metabolically stable PA patients [6], while lactate has
been detected in periventricular white matter [7].
The present study utilises quantitative MRS to investi-
gate brain metabolite alterations both during metabolic
stability and acute encephalopathic episodes, confirming
the basal ganglia as a particular target and demonstrating
novel insights in to alterations in neurotransmitter meta-
bolites in particular glutamine and glutamate.
Methods
Patients
Eight children (two female) with propionic acidaemia
were studied (median age (range) at first MRS, 36 (7-190)
months) (see table 1). Research Ethics Committee
approval and informed consent were obtained. All were
diagnosed in the neonatal period, four requiring neonatal
haemofiltration due to severe hyperammonaemia and
metabolic acidosis. Two children had received elective
orthotopic liver transplantation during early childhood.
The remaining six children all received regular oral carni-
tine and sodium benzoate, and three received sodium
phenylbutyrate, in addition to dietary protein control
under management of a specialist dietetic team.
Three children had one or more severe acute epi-
sodes with encephalopathy beyond the neonatal period
requiring intensive care support ("severe acute episode”
hereafter). During these episodes all children required
ventilatory support and continuous veno-venous hae-
mofiltration (CVVH), and only one episode was asso-
ciated with significant persistent hyperammonaemia.
During these episodes three children received intrave-
nous sodium benzoate and two received sodium
phenylbutyrate.
Magnetic Resonance Spectroscopy
MRS studies were performed concurrently with clinically
indicated MRI scans at 1.5 Tesla (Siemens Symphony
Magnetom, NUM4 or GE Signa Excite & HDx) facili-
tated by general anaesthesia as needed. Five studies
from three children were acquired during severe acute
episodes requiring intensive care support. Six studies
from six children were acquired with elective outpatient
MRI studies undertaken during metabolic stability and
before any severe acute episode had occurred.
MRS was acquired using point resolved spectroscopy
(PRESS) technique (echo time 30 ms and 135 ms, repeti-
tion time 1500 ms, 128 repetitions) with 2 cm-sided vox-
els located in the left basal ganglia and right parieto-
occipital white matter. Voxels were placed in standard
positions guided by T1 and T2 weighted image sequences
in coronal, sagittal and axial planes. Spectra were quality-
assessed to ensure appropriate voxel localisation, shim-
ming and water suppression. Raw data were processed
using LCModel [8] to generate quantitative metabolite
concentrations scaled to the water signal.
Comparison was made with MRS metabolite data
from a cohort of children with normal appearing MRI
and similar age profile who had undergone MRI/MRS
for investigation of various suspected neurodegenerative
and neurocognitive conditions (white matter, n = 53,
median (range) age 4.7(0.5-16.7) years; basal ganglia n =
63, 4.1(0.5-16.7) years).
Statistical Analysis
Mean spectra were generated for each cohort for basal
ganglia and white matter from LCModel fitted spectra
after baseline subtraction. Spectra were compared by
qualitative visual inspection.
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Table 1 Clinical features of propionic acidaemia cohort and MR Imaging findings
Neonatal
CVVH?
Liver
Transplant
(age, years)
Other diagnoses Age at
MRS
(years)
Status at
time of
MRS
Metabolic Drugs & Dietary
Restrictions
Acute encephalopathic
episodes: complications
MRI findings
Maintenance Acute Basal ganglia Other features
1 Yes 1.5 Stable LC, SB, PR Normal
2 Yes Hypo-throidism 1 Enceph. SP, SB, LC, T,
M, PR
SP, SB, NC Sepsis & hyper-
ammonaemia,
Acutely swelling
caudate, dentate
1.2 Stable SB, LC, T, PR Resolving swelling Delayed myelination, enlarged
ventricles
3 Enceph. SB, LC, T, PR Cardiomyopathy,
pneumonia
Acute swelling
caudate, putamen,
dentate
Delayed myelination, enlarged
ventricles, hippocampal atrophy
3 No Epilepsy 9.5 Enceph. SB, LC, PR SB LC Rhabdomyolysis Cystic
encephalomalacia
Enlarged ventricles/cerebral
volume loss
4 Yes Hypo-thyroidism 4 Stable SB, SP, LC, PR Normal
6 Enceph. SB, SP, LC, PR SP, SB, LC Pneumonia Acute swelling
caudate + putamen
Cerebral volume loss, small
hippocampi
5 Yes 0.6 Stable SB, LC, PR Normal Mild ventricular dilation
6 No 3 Stable SB, SP, LC, PR Normal Hippocampal sclerosis
7 No Yes (1.3) 15 Stable Anti-rejection Normal
8 No Yes (2.5) Myoclonic
epilepsy
13 Stable Anti-rejection
LC
Normal Mild ventricular enlargement.
Unilateral mesial temporal
sclerosis
MRS, magnetic resonance spectroscopy; CVVH, Continuous veno-venous haemofiltration; LC, L-carnitine; SP, Sodium Phenylbutyrate; SB, Sodium Benzoate; M, metronidazole; T, thyroxine; NC, N-Carbamylglutamate;
PR, dietary protein restriction; Enceph., denotes acute encephalopathic episode
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Metabolite concentrations for each region were com-
pared between groups by Mann Whitney nonparametric
U test (SPSS Statistics 17.0), with the p-value deter-
mined by the exact 2-tailed significance, with signifi-
cance level set at p < 0.05.
Results
Magnetic Resonance Imaging
The basal ganglia appeared normal in all children (n =
6) prior to any severe acute episode beyond the neonatal
period. MRI obtained during severe acute episodes
demonstrated abnormal signal in the basal ganglia vari-
ably including the caudate heads, putamen and globus
pallidi and in some cases there was also evidence of
acute changes in the dentate nuclei and cerebral cortex.
One child demonstrated evidence of previous basal
ganglia infarction relating to a previous acute encephalo-
pathic episode, with cystic degeneration of caudate,
putamen and globus pallidus. Interestingly the hippo-
campi appeared atrophic in seven cases. Cerebral
volume loss was most marked in children with preced-
ing severe acute episodes. The two children who had
liver transplantation had normal appearing basal ganglia,
cortex and white matter on MRI undertaken more than
10 years post-transplant, with one showing probable
temporal mesial sclerosis.
Magnetic Resonance Spectroscopy
Analysis of mean spectra (figure 1) and mean metabolite
concentrations (table 2) demonstrate metabolite altera-
tions in basal ganglia and parieto-occipital white matter,
in particular during severe acute episodes.
MRS studies undertaken during metabolic stability
before any severe acute episodes beyond the neonatal
period demonstrated decreased Glx in basal ganglia
compared to the normal MRI comparator group but a
trend to increase in white matter. Glutamine alone was
significantly decreased in basal ganglia during metabolic
stability. Mean lactate was not elevated, although two
cases had reliably detected lactate in basal ganglia.
There was no significant decrease in the total N-acety-
laspartate and N-acetylaspartylglutamate (tNAA) in this
group.
MRS studies acquired during severe acute episodes
demonstrated significantly decreased tNAA, Glx and
creatine, and significantly elevated lactate, in the basal
ganglia compared to both the normal MRI comparator
group and to the metabolically stable propionic acidae-
mia cohort. In white matter lactate was significantly ele-
vated but other metabolites were not significantly
altered. (Data shown are for all severe acute episodes;
analysis of first severe acute episode only demonstrated
similar findings). There were no significant differences
between groups in brain myo-inositol, and no propionic
acid was detected in the propionic acidaemia cohort.
Separate analysis of brain metabolites from the two
children post-liver transplant demonstrated normal basal
ganglia tNAA and slightly decreased Glx. tNAA was ele-
vated in white matter and total choline decreased.
Discussion
The data presented represent the largest series of chil-
dren with the severe neonatal form of propionic acidae-
mia to be investigated with MRS, and is to our
Figure 1 Mean MR spectra from basal ganglia during metabolic stability and acute encephalopathy in propionic acidaemia. (A)
Metabolically stable and (B) acutely encephalopathic propionic acidaemia patients compared to normal imaging comparator cohort. ppm, parts
per million; a.u., arbitrary units. Major metabolite peaks identified (labelled arrows), significant differences indicated by *. Glx, glutamine +
glutamate; Ins, myo-inositol; Cre, Creatine; NAA, N-acetylaspartate; Lac, lactic acid.
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knowledge the first to study children during severe
acute encephalopathic episodes. The selective vulnerabil-
ity of the basal ganglia in PA is well established, and our
data provide further insight in to processes occurring
within the basal ganglia. MRI results found that basal
ganglia appeared normal in children who had not had a
severe acute encephalopathic episode beyond the neona-
tal period, as similarly reported in glutaric aciduria [9],
but were acutely damaged during episodes of acute ill-
ness. Similarly brain metabolite alterations were more
marked during severe acute episodes.
Decreased tNAA is seen in many pathologies, and is
thought to reflect loss of viable neurons [10] including
following acute ischemic stroke [11]. Elevated lactate
suggests a switch to anaerobic respiration, reflecting
local ischaemia or mitochondrial dysfunction. As pre-
viously reported, elevated lactate was seen in two of the
cases during metabolic stability, suggesting that brain
tissue metabolism is not normal even when metabolism
is well controlled.
The alterations seen in glutamine and glutamate in
basal ganglia are of particular note. Glx was significantly
decreased during severe acute episodes, with a smaller
(non-significant) decrease noted in basal ganglia in stu-
dies acquired during metabolic stability. The ratio of
Glx/tNAA was lower in the propionic acidaemia cohort
than in cohorts of children with other defined inherited
metabolic disorders including a cohort with confirmed
respiratory chain disorders, while the Glx/NAA ratio
was elevated in a cohort with the urea cycle disorder
argininosuccinic aciduria (JED, unpublished data). This
suggests that the alterations seen in Glx here were not
simply a reflection of neuronal loss represented by
lower tNAA.
Table 2 Metabolite concentrations in basal ganglia and parieto-occipital white matter
Basal ganglia metabolites (mM, mean (standard deviation))
Propionic Acidaemia Normal MRI
comparator group
Metabolic stability (6 studies
from 6 patients)
Acute encephalopathy (5 studies
from 3 patients)
Post-liver transplant (2 studies
from 2 patients)
(63 studies)
Median age (years,
(range))
3.6 (0.6-15.9) 6.13 (1.0-9.4) 14.4 (12.9-15.9) 4.1 (0.5-16.7)
N-Acetylaspartate 5.03 (0.53) 3.89 (0.20)†# 5.35 (0.28) 5.21 (0.51)
Creatine 4.57 (0.47) 3.71 (0.58)† $ 4.42 (0.14) 4.55 (0.59)
Glutamine 1.29 (0.30) * 1.00 (1.00)* 1.27 (0.25) 1.98 (0.79)
Glutamate 4.28 (0.25) 3.07 (0.60)†# 4.30 (0.39) 4.45 (0.78)
Glutamine
+Glutamate
5.57 (0.41) * 4.07 (1.19)† $ 5.57 (0.28) 6.43 (1.39)
myo-Inositol 2.58 (0.26) 2.79 (0.90) 2.39 (0.0) 2.49 (0.43)
Lactate 0.21 (0.25) 0.93 (0.34)†# 0.00 (0.32) 0.11 (0.20)
Choline 1.10 (0.18) 1.16 (0.29) 0.90 (0.63) 1.11 (0.18)
White matter metabolites (mM, mean (standard deviation))
Propionic Acidaemia Normal MRI
comparator group
Metabolic stability (5 studies
from 5 patients)
Acute encephalopathy (4 studies
from 3 patients)
Post-liver transplant (2 studies
from 2 patients)
(53 studies)
Median age (years,
(range))
3.1 (0.6-15.9) 7.74 (3.0 -9.4) 14.4 (12.9-15.9) 4.7 (0.5-16.7)
N-Acetylaspartate 5.28 (0.80) 4.50 (0.47) 6.11 (0.39) 5.11 (0.73)
Creatine 3.55 (0.19) * 3.33 (0.53) 3.70 (0.00) 3.18 (0.47)
Glutamine 1.43 (0.54) 1.34 (1.30) 1.62 (0.49) 1.32 (0.62)
Glutamate 3.83 (0.45) 2.65 (0.44)*$ 4.27 (0.31) 3.51 (0.78)
Glutamine
+Glutamate
5.26 (0.89) 3.98 (1.54) 5.89 (0.80) 4.84 (1.18)
myo-Inositol 2.73 (0.31) 2.57 (0.39) 2.79 (0.02) 2.57 (0.39)
Lactate 0.40 (0.30) 0.81 (0.74)* 0.32 (0.45) 0.21 (0.28)
Choline 0.93 (0.15)* 1.12 (0.37) 0.83 (0.09) 1.08 (0.15)
Comparison between propionic acidaemia cohorts and normal MRI comparator group.
Mann Whitney U test (2 tailed exact significance) for difference in metabolite concentrations between Normal MRI Comparator group and propionic acidaemia
cohorts,*p < 0.05, † p < 0.01. Mann Whitney U test (2 tailed exact significance) for difference in metabolite concentrations between stable and encephalopathic
propionic acidaemia cohort, $ p < 0.05, # p < 0.01
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Although the spectral signals from glutamine and glu-
tamate overlap, there is increasing evidence that they
can be differentiated in the analysis of cohorts even at
1.5Tesla using software such as LCModel. Such evidence
includes Montecarlo simulations of normal brain spectra
fitted with LCModel [12], comparisons of experimental
and simulated basis sets [13], and the finding of a signif-
icant correlation between in vivo and in vitro results for
both glutamate and glutamine detected in brain tumours
[14,15].
A previous MRS study reported elevated basal ganglia
Glx in three metabolically stable propionic acidaemia
patients who had normal ammonia and near-normal
glutamine and glutamate in plasma and cerebrospinal
fluid leading the authors to suggest differential mechan-
isms regulating brain parenchymal metabolism [6].
However this study relied on peak area estimation and
ratio to creatine, whereas the current study provides
more robust quantification. Moreover the reduced gluta-
mine detected by brain MRS is consistent with the
plasma glutamine reduction previously reported in PA
[16], also seen in plasma glutamine levels in our cohort
(data not shown).
The administration of the alternative pathway drugs
used to control hyperammonaemia depletes plasma glu-
tamine and glycine and may contribute to the decreased
brain Glx seen. Furthermore, all children were haemofil-
tered during severe acute episodes which may further
deplete glutamine due to its high sieving coefficient
[17]. However CVVH was instigated after the MRI/MRS
in 80% of cases suggesting that glutamine levels were
already low before CVVH was commenced.
The acute decrease seen in Glx supports the hypothesis
that they are consumed to replenish a depleted Krebs
cycle [4], and that this decrease is a marker of compro-
mised aerobic cellular respiration within brain tissue. It
remains to be determined whether the decreased Glx is
directly detrimental or simply a secondary marker of
compromised metabolic status. Interestingly the decrease
in Glx was greater in the basal ganglia than in white mat-
ter, correlating with the more vulnerable brain region.
There is a need for brain protective strategies during
acute metabolic decompensations, with potential methods
including brain cooling, adequate energy provision, and
anaplerotic therapies. MRS could provide a tool to moni-
tor the effect of dietary supplements aimed at increasing
glutamine levels, specifically monitoring metabolite levels
within the target-organ of interest, namely the brain.
The two children who had liver transplant have had
no severe acute encephalopathic episodes beyond the
neonatal period, and have normal appearing basal gang-
lia on MRI. MRS demonstrated normal/high tNAA
reflecting the absence of major neuronal loss and
correlating with their good neurocognitive status, and
no reliably detected lactate. The small numbers preclude
statistical significance, but Glx was slightly increased in
white matter but decreased in basal ganglia compared to
the comparator group. These results support the
hypothesis that liver transplantation provides systemic
metabolic stability by providing a hepatic pool of func-
tional propionyl CoA carboxylase, thus preventing
further acute metabolic decompensations which are
associated with the risk of brain infarction.
The data presented here have yielded some interesting
observations, however further prospective data collection
and analysis could overcome some of the specific limita-
tions of the present work. In particular, use of higher
field strength MRI scanners (3Tesla and above) would
provide more robust differentiation of the metabolites of
interest, notably glutamine and glutamate. Serial data
collection in specific patients could also confirm the
alterations in brain metabolites seen before, during and
after metabolic decompensations. Finally analysis of a
larger cohort of post-liver transplant patients as well as
longer follow up with serial studies will provide stronger
evidence for the therapeutic value of liver transplanta-
tion in PA.
Conclusions
We have demonstrated that quantitative MRS is able to
offer insight in to in vivo brain metabolic derangements,
and can feasibly be employed in children with acute
encephalopathy. In propionic acidaemia the use of MRS
in conjunction with MRI has confirmed the basal ganglia
as a particularly vulnerable target and has demonstrated
novel insights in to alterations in neurotransmitter meta-
bolites. Evaluation of patients in long-term follow up
after liver transplantation demonstrates the potential for
good neurological outcome and near-normal brain meta-
bolism. MRS provides a tool to directly evaluate the tis-
sue-level effects of novel treatment strategies including
anaplerotic therapies.
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Brief Communication
Magnetic Resonance Spectroscopy in
the Diagnostic Evaluation of Brainstem
Lesions in Alexander Disease
James E. Davison, MRCPCH1,2, Nigel P. Davies, PhD1,3,
Martin W. English, MD1, Sunny Philip, MD1,
Lesley K.R. MacPherson, FRCR1, Paul Gissen, PhD1,2, and
Andrew C. Peet, PhD1,4
Abstract
Alexander disease is a progressive neurodegenerative disease, which can present with brainstem lesions with imaging
characteristics similar to multifocal low-grade glioma, thus presenting a diagnostic dilemma. The authors report a 6-year-old child
presenting with multifocal brainstem lesions subsequently diagnosed to have Alexander disease. In vivo magnetic resonance spec-
troscopy generated a metabolite profile of the lesion allowing differentiation from low-grade glioma. Magnetic resonance spectro-
scopy is a powerful tool in the assessment of brainstem lesions and is a useful adjunct to conventional magnetic resonance imaging
in the assessment and diagnosis of atypical brain lesions.
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brain tumors, radiology, gliomas, brainstem, Alexander disease, magnetic resonance spectroscopy
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Alexander disease (MIM203450) is a rare, progressive
neurodegenerative disease associated with the formation of
brainstem lesions that can have appearances on conventional
magnetic resonance imaging (MRI) of brainstem tumors.1,2 The
natural history comprises continued neurological deterioration
associated with megalencephaly, seizures, and progressive bul-
bar and pseudobulbar signs. Alexander disease is caused by
gain-of-function mutations in the GFAP gene, which encodes
glial-fibrillary acidic protein (GFAP).3 This results in the accu-
mulation of Rosenthal fibers in astrocytic foot processes and
perikarya, with astrocytic hypertrophy, glial dysfunction, and
abnormal myelination.4 Since Alexander disease can be diag-
nosed by detecting the genetic mutation in blood, biopsy of the
lesion can be averted if characteristic imaging appearances are
present.
The use of MRI in the diagnosis of Alexander disease is well
established with specific diagnostic imaging criteria proposed.5
Magnetic resonance spectroscopy is a noninvasive method that
determines brain tissue metabolite concentrations and has been
employed in studies of Alexander disease.6-8 Recently, serial
changes in MRI and spectroscopy in 5 Alexander disease
patients were reported.9 While white matter imaging appear-
ances were stable over time, there were progressive changes
in magnetic resonance spectroscopy determined metabolites
consistent with progressive demyelination or astrocytic
hypertrophy and increased membrane density, leading the
authors to speculate that gliomas and Alexander disease ‘‘have
something in common.’’ Indeed the distinction between Alex-
ander disease and malignant processes is not always clear.
Rosenthal fibers are present in astrocytomas and mass lesions
occur in Alexander disease, including in the optic chiasm, cer-
ebellum, and brainstem,1,10,11 regions in which low grade glio-
mas are common. Astrocytic proliferation that occurs in
Alexander disease may generate these tumor-like lesions.10
Alexander disease-related brainstem lesions resemble low-
grade glioma and may cause diagnostic dilemmas, particularly
in the absence of typical frontal predominant white matter
changes.12
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Intellectual and neurological functioning in Morquio
syndrome (MPS IVa)
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Abstract Mucopolysaccharidosis type IVa (MPS IVa,
Morquio syndrome OMIM #253000) is a lysosomal storage
disease caused by deficiency in N-acetylgalactosamine-6-
sulfatase (GALNS, EC 3.1.6.4; encoded by GALNS gene at
16q24.3). Unlike other MPS disorders involving excessive
heparan and dermatan sulfate, Morquio syndrome has not
been associated with neurological involvement nor with
intellectual impairment as this disorder of keratan sulfate
has been described as a purely visceral and skeletal disorder.
Neurocognitive assessment was undertaken of MPS IVa
patients with age appropriate intellectual tests as well as a
Child Behaviour Checklist as part of clinical follow up.
Available neuroimaging studies (MRI and MR spectros-
copy) were reviewed. Whilst more than half of the
overall IQ scores fell in the average range, scores for
3/8 children fell below average. A number of behaviou-
ral problems were highlighted, including anxiety/
depression, attention and somatic complaints. Subtle
neuroimaging abnormalities were demonstrated in over
half of the children. These findings present a challenge
to existing assumptions about the nature of Morquio A
syndrome. A hypothesis regarding the potential role of
calcium signalling is explored.
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Figure C.1: Magnetic resonance spectroscopic imaging of frontal white matter in child with 
Alexander disease. Note high inositol and visible scyllo inositol peaks. High lactate detected 
from voxels overlying ventricles. 
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Appendix D 
 
Towards Multivariate Analysis of Brain Metabolite 
Profiles 
 
D1. Introduction 
One of the common clinical indications for performing MR spectroscopy in children is in the 
investigation of possible mitochondrial disease, since it is thought that elevated brain lactate 
may be a useful marker of mitochondrial disease. As documented in this thesis (section 
4.3.7.1) the sensitivity of lactate as a stand alone test is, however, low with only 27-30% of 
mitochondrial disease cases identified in the current cohort. One possible approach to 
improving the diagnostic power of MRS is to incorporate information from the other 
metabolites detected in a multivariate analysis. In this Appendix, initial preliminary work 
towards developing a multivariate analysis tool for identifying mitochondrial disease cases is 
described. 
 
D2. Methods 
MRS derived brain metabolite profiles from 15 studies acquired using the standard protocol 
from children with confirmed mitochondrial disease were compared to profiles from 186 
other children with either other known IMD or unknown diagnosis. All studies included 
passed the quality assessment, and all had short echo time (TE 30ms) MRS data available 
from both basal ganglia and white matter voxels.  
 
Differences in individual metabolites between the mitochondrial and comparison cohorts were 
analysed first on a univariate basis using Student’s t-test and by calculation of the area under 
the curve (AUC) of the receiver operator characteristic (ROC) curves. A multivariate model 
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was then constructed using SPSS Statistics (v17.0). This first employed an unsupervised 
principal component analysis (PCA) to reduce the dimensionality of the metabolite dataset, 
incorporating metabolite concentrations from both basal ganglia and white matter voxels 
including lactate, creatine, tNAA, tCho, glutamine+glutamate, inositol and the composite 
lipid/macromolecular signals at 0.9, 1.3 and 2.0ppm. A supervised linear discriminant 
analysis (LDA) was then employed to construct a binary diagnostic model, taking the first 14 
principal components from the PCA as its input (since the smallest group size was n=15, and 
to avoid “over-fitting” n-1 variables can be put in to a linear discriminant analysis). The LDA 
is supervised in that information about which category each case falls into is entered as the 
model is constructed.  
 
An automated cross-validation of the multivariate model was then performed whereby each 
case was classified by the functions derived from all cases other than that case. Model 
loadings plots were generated by the matrix multiplication of the PCA and LDA coefficients. 
The linear discriminant score for each case was used to construct a ROC curve for the test. 
Significance of difference between the ROC curve for lactate and for the multivariate model 
was tested using a non-parametric test for the difference of AUC that accounts for the 
correlation of the ROC curves [303]. 
 
 
D3. Results 
 
 D3.1 Univariate analysis 
Mean basal ganglia tNAA and white matter lactate were the only metabolites significantly 
different between the mitochondrial and comparison cohorts evaluated by Student’s t-test. 
Assessed by ROC curve AUC, only lactate in basal ganglia or white matter generated an AUC 
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significantly different from 0.5. (AUC of 0.5 indicates a test is equivalent to “flipping a coin” 
in determining case classification). 
 
 D3.2 Multivariate model analysis 
The multivariate model generated correctly classified 80.1% of all cases (76.6% in cross-
validation); the ROC curve AUC of the multivariate LDA score was 0.84, significantly higher 
(p<0.05) than either basal ganglia or white matter lactate alone.  
 
36 false positive classifications were made, of which 20 had a known diagnosis of another 
IMD, 4 were being evaluated as potential mitochondrial diseases, and 16 had an 
unknown/unclassified diagnosis. Four false negative classifications were made. 
 
Loadings plots for the model showed that the greatest contributions to mitochondrial class 
were from high basal ganglia lactate and macromolecular-lipid signal (2.0ppm), and low 
inositol and macromolecular-lipid signal (1.4ppm) in both basal ganglia and white matter. 
 
 
Metabolite concentration (mean (SD), mmol/l). 
 Basal ganglia  White matter  
   t-test ROC    t-test ROC  
 Mito. Comp. p1 AUC p2 Mito. Comp. p1 AUC p2
n 15 186    15 186    
Age (yr) 4.40 (4.64) 5.42 (4.50) ns   4.40 (4.64) 5.42 (4.50) ns   
Cr 4.17 (0.89) 4.50 (0.71) ns 0.62 ns 2.98 (0.64) 3.08 (0.54) ns 0.55 ns 
tNAA 4.26 (1.17) 4.81 (0.81) <0.05 0.65 ns 4.13 (1.39) 4.42 (1.12) ns 0.54 ns 
tCho 1.11 (0.29) 1.12 (0.23) ns 0.53 ns 1.06 (0.29) 1.04 (0.21) ns 0.53 ns 
Gln+Glu 5.87 (1.68) 6.26 (1.63) ns 0.57 ns 4.17 (1.61) 4.86 (1.54) ns 0.61 ns 
Ins 2.60 (0.77) 2.75 (0.83) ns 0.55 ns 2.59 (0.66) 2.85 (0.84) ns 0.58 ns 
Lac 0.42 (0.57) 0.24 (0.48) ns 0.65 <0.05 0.68 (0.67) 0.33 (0.46) <0.01 0.69 <0.05
Table D1: Mean metabolite concentrations in mitochondrial (Mito.) and mixed comparison 
(Comp.) cohorts. ROC, receiver operator characteristic curve; AUC, area under the curve. p1, 
t-test for difference between mitochondrial and comparison cohorts. p2 significance of 
difference of AUC from 0.5. 
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 Predicted Group Membership 
Comp Mito 
Original group 
membership 
Comp 150 36 
Mito 4 11 
Cross-validation Comp 148 38 
Mito 9 6 
Table D2: Multivariate model classification outcome 
 
 
 
Figure D1: ROC Curves for basal ganglia lactate (green), white matter lactate (yellow) and 
multivariate model score (red) for identification of mitochondrial disease cases. 
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WM Lac
WM MMLIP 0.9
WM MMLIP1.4
WM MMLIP2.0  
Figure D2: Loadings plot for multivariate model. Negative values indicate metabolites 
contributing to mitochondrial class. BG, basal ganglia; WM, white matter.  
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D4. Discussion 
A multivariate model constructed incorporating multiple metabolite variables from two brain 
regions performs significantly better than lactate alone in distinguishing a cohort of 
mitochondrial cases from a mixed cohort of other children with known and unknown 
diagnoses. Assessment of apparent false positive classifications may identify patients with 
other IMD with brain metabolite profiles similar to the mitochondrial diseases, and potentially 
others with as yet undiagnosed mitochondrial disease. However, the model has a significant 
false negative rate (cases missed) suggesting that MRS may not be able to identify all cases. 
The loadings plots may provide useful information about typical brain metabolite changes 
occurring in the mitochondrial diseases. 
 
This concept requires further prospective validation, and in particular the potential of over-
fitting needs to be further evaluated to determine whether the model is genuinely able to 
identify mitochondrial disease cases. 
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